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ABSTRACT 
 The manipulation of biological targets using synthetic compounds has been the 
focal point of medicinal chemistry. The work described herein centers on the synthesis of 
organic small molecules that act either as probes for studying protein conformational 
changes or DNA–protein interaction, or as multifunctional radical quenchers.  
            Fluorescent labeling is of paramount importance to biological studies of proteins. 
For the development of new extrinsic small fluorophores, a series of tryptophan 
analogues has been designed and synthesized. Their pdCpA derivatives have been 
synthesized for tRNA activation and in vitro protein synthesis. The photophysical 
properties of the tryptophan (Trp) analogues have been examined, some of which can be 
selectively monitored even in the presence of multiple native tryptophan residues. 
Further, some of the Trp analogues form efficient FRET pairs with acceptors such as 
acridon-2-ylalanine (Acd) or L-(7-hydroxycoumarin-4-yl)ethylglycine (HCO) for the 
selective study of conformational changes in proteins. 
            Molecules which can bind with high sequence selectivity to a chosen target in a 
gene sequence are of interest for the development of gene therapy, diagnostic devices for 
genetic analysis, and as molecular tools for nucleic acid manipulations. Stereoselective 
synthesis of different alanyl nucleobase amino acids is described. Their pdCpA 
derivatives have been synthesized for tRNA activation and site-specific incorporation 
into the DNA-binding protein RRM1 of hnRNP LL. It is proposed that the nucleobase 
moieties in the protein may specifically recognize base sequence in the i-motif DNA 
through H-bonding and base-stacking interactions. 
 ii 
 
The mitochondrial respiratory chain accumulates more oxidative damage than any 
other organelle within the cell. Dysfunction of this organelle is believed to drive the 
progression of many diseases, thus mitochondria are an important potential drug target. 
Reactive oxygen species (ROS) are generated when electrons from the respiratory chain 
escape and interact with oxygen. ROS can react with proteins, lipids or DNA causing cell 
death. For the development of effective neuroprotective drugs, a series of N-hydroxy-4-
pyridones have been designed and synthesized as CoQ10 analogues. All the analogues 
synthesized were evaluated for their ability to quench lipid peroxidation and reactive 
oxygen species (ROS). 
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CHAPTER 1 
INTRODUCTION 
1.1. Protein Biosynthesis 
Proteins are macromolecules comprised of amino acid residues that perform 
important biological functions. Proteins differ from one another most fundamentally in 
the sequences of their amino acids, which are dictated by the nucleotide sequences of 
their genes, and which usually result in a preferred specific three-dimensional structure. 
The folded protein structure determines the nature of the catalytic activity or structural 
function of the protein. Protein biosynthesis involves several events, including 
transcription of nuclear DNA to mRNA, and translation of mRNA with the stepwise 
incorporation of amino acids to afford proteins. Protein translation is mediated by the 
ribosome, which link amino acids together in the order specified by the messenger RNA 
(mRNA).
1
 Ribosomes are comprised of two major components of unequal size (30S and 
50S in E. coli). The small subunit decodes the RNA, while the large subunit mediates 
peptide bond formation.
2
 Each subunit, composed of an array of ribosomal RNAs 
(rRNAs) and proteins, has three sites for binding tRNA, designated as the A-site 
(aminoacyl-tRNA site), P-site (peptidyl-tRNA site) and E-site (exit site for deacylated 
tRNA).
3
 The 30S subunit contains a 16S rRNA and 21 different proteins, and 50S subunit 
consists of a 5S, 23S rRNA and 31 different proteins.
4
 
Each tRNA recognizes an mRNA codon (contiguous set of three nucleotides), 
complementary to the tRNA anticodon, and carries an activated, cognate amino acid at its 
opposite end. Every cell contains at least 20 tRNA molecules, one for each naturally 
occurring amino acid, and each tRNA recognizes at least one codon (triplet sequence) in 
 2 
 
the genetic code. There are 64 codons; 61 of them decode natural amino acids, while the 
other three are “nonsense” or stop codons which define the C-terminus of the growing 
polypeptide chain. mRNA translation proceeds through three distinct steps, namely 
initiation, elongation and termination. The process begins with activation of tRNA with 
its cognate amino acid by its aminoacyl-tRNA synthetase. Translation initiation involves 
the binding of the 30S ribosomal subunit to the mRNA and aminoacylated tRNA, with 
the 16S ribosomal RNA having base pairs complementary to the Shine–Dalgarno 
sequence in the bound mRNA.
4
 Formation of the initiation complex requires initiation 
factors that are not permanently associated with the ribosome; these are designated as 
IF1, IF2 and IF3. Generally, the initiation codon translated is AUG, such that polypeptide 
synthesis starts with amino acid residue methionine (Met). In prokaryotes, the tRNA that 
starts translation is a methionine tRNA in which the Met residue is formylated 
(tRNAf
Met
). Only this tRNA is able to form the initiation complex and occupies the 
ribosomal P-site. Ribosomes elongate the polypeptide chains at a rate of 10 to 20 amino 
acids per second
4
 with the help of nonribosomal proteins elongation factors (EF-Tu, EF-
Ts and EF-G).
4 
The elongation process starts with decoding where the ribosome selects 
and binds an aminoacyl-tRNA (bound to EF-Tu.GTP) whose anticodon is 
complementary to the mRNA codon in the A site.
5
 The amino group of the aminoacyl-
tRNA present in the A-site mediates a nucleophilic attack at the activated peptide of the 
peptidyl-tRNA ester in P-site, thereby forming a new peptide bond and transferring the 
nascent polypeptide to the tRNA in the A site (Figure 1.1). This event is followed by 
translocation of the tRNAs in the A- and P-sites to the P- and E-sites, respectively 
followed by dissociation of the deacylated tRNA from the E-site. Elongation factor EF-G 
 3 
 
promotes translocation through GTP binding and hydrolysis. The next aminoacylated-
tRNA, having an anticodon complementary to the next codon in the mRNA, is then 
bound to the vacant A-site. Elongation proceeds until termination is signaled by the 
presence of any one of the three mRNA stop codons namely UAG, UAA or UGA. In E. 
coli, protein release factors RF-1(recognizes UAA and UAG) or RF-2 (recognizes UAA 
and UGA) bind to the stop codon in the A-site and induce the transfer of the peptidyl 
group from the peptidyl-tRNA to water triggering the release of the nascent polypeptide 
and dissociation of ribosomal complex into 50S and 30S subunits.
5
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Figure 1.1. Peptide bond formation during protein translation
 
where R1, R2 and R3 are the 
side chain substituents of the amino acids. 
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1.2. Site-specific Incorporation of Unnatural Amino Acids into Proteins 
The site-specific incorporation of noncanonical amino acids into proteins using 
misacylated suppressor tRNAs
6-9
 has drawn significant attention due to its potential 
applications in studies of protein structure, function, dynamics and intermolecular 
interactions. This strategy, which involves site-directed mutagenesis of DNA to replace 
the codon for a specific amino acid of interest with a nonsense codon (Figure 1.2) has 
been developed into a very powerful tool to introduce a variety of new functionalities 
other than those found in the 20 proteinogenic amino acids. 
mutant protein
(2) deprotection
in vitro 
translation
COH
unnatural amino acid
A
C
C
unnatural amino acid
AUC
CUA
pET28b(+)-protein(TAG)
T7promoter
in 
vit
ro
tra
ns
cri
pti
on UAGmRNATA
G
(1) pdCpA-
  unnatural amino acid,
T4 RNA ligase
abbreviated suppressor tRNA
plasmid bearing a stop codon  
Figure 1.2. Strategy for the site-specific incorporation of unnatural amino acids into 
proteins in vitro. 
 
A suppression event refers to suppressing a stop codon with a misacylated 
suppressor tRNA, thereby circumventing the effect of release factors that signal the 
termination of protein synthesis in the ribosome. The natural nonsense codons used for 
this purpose are UAG (amber),
6
 UGA (opal)
10
 and UAA (ochre)
11
. Hecht and co-workers 
 5 
 
first developed this methodology by aminoacylating a dinucleotide, pCpA, with an N-
protected amino acid and ligating the aminoacylated dinucleotide to a 74 nucleotide 
abbreviated tRNA (tRNA-COH) lacking the 3ʹ-terminal cytidine and adenosine moieties, 
with the help of T4 RNA ligase.
12-14
 Later, Schultz and co-workers modified the strategy 
by replacing the aminoacylated dinucleotide pCpA with dinucleotide pdCpA
15,16 
which 
simplified the synthesis of the dinucleotide. This technology is now widely used for 
misacylation of tRNA, enabling the incorporation of a broad variety of unnatural amino 
acids into proteins. 
More recently, Hecht and co-workers demonstrated that the modification of the 
23S rRNA in bacteria can dramatically alter the architecture of the ribosomal 
peptidyltransferase center and allow the incorporation of D-amino acids, β-L-amino acids 
and dipeptidomimetics.
17-21
 The selection of ribosomes having modifications in some 
regions of the 23S rRNA was done using puromycin derivatives. Puromycin
22,23
 is an 
aminonucleoside antibiotic produced by Streptomyces alboniger (Figure 1.3). Puromycin 
is considered an aminoacyl-tRNA mimic and acts as a universal translation inhibitor. It  
binds to the A-site of the PTC and readily accepts the growing peptide chain from the 
peptidyl-tRNA in the P-site, which leads to premature chain release. Puromycin, and its 
derivatives having various amino acid side chains, show different chain termination  
efficiencies.
24,25
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Figure 1.3. Structure of the antibiotic puromycin. 
 
1.3 Förster Resonance Energy Transfer (FRET) in Proteins 
Fluorescence spectroscopy has become a crucial tool in biochemical research by 
virtue of its robustness and high sensitivity.
26
 Fluorophores absorb light of a specific 
wavelength (λex), and after a finite time (τ) (typically 1–10 nanoseconds), energy is 
emitted at a longer wavelength (λem). The fluorescence quantum yield, which is the ratio 
of the number of fluorescence photons emitted to the number of photons absorbed, is a 
measure of the efficiency with which fluorescence processes occur. A broad variety of 
fluorescent molecules are currently available, which include protein fluorophores (e.g., 
green fluorescent protein), organic fluorophores (e.g., fluorescein, coumarins, cyanines, 
bodipy dyes) and even inorganic fluorescent nanoparticles (e.g., quantum dots).
26,27
 The 
diversity in molecular and electronic structures has resulted in wide range of 
photophysical properties including molar absorptivity, Stokes shift, quantum yield, 
lifetime and also the ability to respond to their environment. The selection of a 
fluorophore mainly depends on the specific photophysical properties required, and the 
extent to which it can be integrated into a specific macromolecule without perturbing its 
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function. Green fluorescent protein (GFP) and its derivatives have found broad 
application in biochemistry and cell biology.
27
 GFP was first isolated from jellyfish 
Aequorea victoria and can be encoded genetically as a fusion protein to specific proteins 
of interest. The use of GFP has some limitations due to its relatively large size (238 
amino acids). Therefore, alternative chemoselective labeling techniques using low 
molecular weight compounds have been developed.
27
 Fluorescent protein labeling by 
site-specific incorporation of unnatural amino acids is a useful alternative.
28-32
  
Monitoring changes in the fluorescence spectrum of a protein is commonly used 
to detect conformational and electrostatic transitions due to ligand binding, protein–
protein associations, or chemical transformations. The fluorescence signal can result from 
naturally occurring amino acids (e.g., tryptophan and tyrosine) or conjugated dyes.
33 
Distance dependent phenomena, such as Förster resonance energy transfer (FRET), have 
facilitated the study of protein conformation and function by measuring changes in 
energy transfer efficiency between a donor and an acceptor.
34,35
 The acceptor may be a 
fluorescent molecule, leading to longer wavelength emission, or a quencher.
35-39
 The 
transfer process is effective when the donor and acceptor are separated by less than 10 
nanometers. Size is important in FRET donor/acceptor pairs, as are their rotational 
degrees of freedom and propensity to interact with water. Typically, a FRET system in a 
protein may include two different variants of green fluorescent protein (GFP)
34,40-42
 or 
two large polycyclic aromatic molecules.
43,44
 The fluorophores/quenchers are often 
chemically tethered to proteins via flexible linkers.
43,44
 The large size of a fluorophore 
can significantly perturb protein structure and function. This is particularly of concern 
when trying to monitor conformational changes in an enzyme active site. Moreover, the 
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flexible tethers provide the reporter molecules with still more conformational freedom, 
independent of actual protein conformational changes. Thus, to measure subtle 
conformational changes in proteins, it is important to develop smaller fluorophores 
/quenchers that can be efficiently incorporated into the normal peptide backbone. 
A few studies have incorporated donor and acceptor amino acids into a protein, 
through decoding a four-base codon CGGG and a nonsense codon UAG in the presence 
of an an aminoacyl tRNACCCG and an aminoacyl-tRNACUA,
45-48
 to monitor protein 
backbone cleavage
45
 and protein structural changes.
46-48 
Dihydrofolate reductase (DHFR) 
bearing a fusion peptide at its N terminus was labeled with a fluorescent donor 7-
azatryptophan (1.2) and acceptor dabcyl-1,2-diaminopropionic acid (1.3) which flanked 
an HIV-1 protease cleavage site (Figure 1.4).
27,45
 Stoichiometric cleavage of the peptide 
by HIV-1 protease was monitored by FRET, with an increase in donor’s fluorescence 
emission intensity quantitatively identical to that anticipated from protein cleavage 
(Figure 1.4).
27,45
       
Hecht and co-workers used this strategy for studying conformational changes in 
DHFR. Two fluorescent amino acids, 4-biphenyl-L-phenylalanine (donor) and L-(7-
hydroxycoumarin-4-yl)ethylglycine (acceptor) were incorporated into the protein, 
enabling a study of conformational changes associated with inhibitor (trimethoprim, 
TMP) binding (Figure 1.5).
48
 The binding of TMP is known to produce only modest 
changes in DHFR structure, far smaller than those generally studied by FRET.
48
 Thus, the 
incorporation of small fluorescent amino acids is a good strategy for monitoring of small 
conformational changes, such as those that occur during the catalytic cycle.
48 
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Figure 1.4. Cleavage of DHFR fusion protein containing donor (7-azatryptophan) and 
acceptor (dabcyl-1,2-diaminopropionic acid) by HIV-1 protease, resulting in a decrease 
in FRET and an increase in fluorescence emission intensity of the donor.
45 
 
   
 
Figure 1.5. Strategy employed for incorporation of donor and acceptor amino acids into 
DHFR at positions 17 and 115, respectively.
48
  
 
1.4. DNA
_
Protein Interaction 
DNA
_
protein interaction plays an important role in the regulation of all aspects of 
DNA function including DNA replication, repair, recombination and transcription.
49
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DNA
_
binding proteins
50-52
 contain DNA binding domains and may have affinity for 
either single or double stranded DNA. DNA
_
protein complexes
53
 can be grouped into 
several classes, for example, polymerases that synthesize long chains or polymers of 
nucleic acids, nucleases which cleave DNA molecules, transcriptional factors which 
modulate the process of transcription, and structural proteins. Non-specific DNA 
interactions are formed through functional groups on the protein making ionic bonds to 
the acidic sugar-phosphate backbone of the DNA, and are largely independent of base 
sequence. In comparison, specific DNA
_
protein interactions depend largely on the base 
sequence and are stronger. Many sequence-specific DNA-binding proteins have been 
grouped into families.
54
 Major families of motifs include the helix–turn–helix (HTH), 
homeodomain, helix, zinc fingers, zinc containing steroid receptors, leucine zipper and 
helix–loop–helix (HLH).54-56 Many sequence-specific DNA-binding proteins are 
multimeric. Such multimeric interactions would be expected to increase the number of 
protein–DNA contacts, and thus to increase binding affinity.54,57 However, there are 
monomeric sequence specific proteins as well, multimerization is not required for high 
affinity.
54
 Most sequence-specific protein–DNA complexes have Kd values in the range 
of 10
-11
-10
-8
 mol L
-1
. Proteins with strict sequence specificity, generally show higher 
affinities in vitro (i.e. have lower Kd) than do proteins with a more ‘relaxed’ sequence 
specificity.
54
 
 
The interactions between protein and nucleic acid are mediated by electrostatic 
attraction, hydrogen bonding and van der Waals contacts.
58
 Electrostatic forces are long 
range, not very structure-specific, and contribute substantially to the overall free energy 
of association. Two other mechanisms (hydrogen bonding and van der Waals contacts) 
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are more sequence specific, especially hydrogen bonding interactions. This sequence 
specificity involves functional groups of the amino acids or backbone atoms of the 
protein and nucleobases in the grooves of the DNA (Figure 1.6).
54,59,60
 Sequence-specific 
DNA-binding proteins generally interact with the major groove of B-DNA, because it  
 
                  
Figure 1.6. Points of recognition in the major (M) and minor (m) grooves of DNA for 
each of the four base pairs. a, electron acceptor; d, electron donor; me, methyl group. 
Hydrogen bonding in base pairs is indicated by dashed lines. dR in circles denotes the 
deoxyribose-phosphate backbone of DNA.
54 
 
exposes more functional groups.
59
 Ninety percent of protein
_
nucleic acid hydrogen bonds  
involve a donor group on the protein and an acceptor group on the nucleic acid.
54,58
 The 
protein backbone NH groups and the charged side chains of arginine, lysine, asparagine 
and glutamine are major hydrogen–bond donors. For DNA the phosphate oxygens and 
some atoms of guanine and adenine bases (N
7
, O
6
 for guanine and N
7
, N
6
 for adenine) are 
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the common acceptors for this type of interaction.
54,58
 Adenine is mostly recognized by 
asparagine and glutamine whereas guanine is mostly recognized by lysine and arginine as 
donors (Figure 1.7).
54,58
 Sometimes the hydrogen-bonding interactions between protein 
and DNA occur through water-mediated contacts.
61
 
               
Figure 1.7. The H-bonding interaction between asparagine/glutamine and adenine, and 
between arginine and guanine.
63 
 
 
In addition to H-bonding involving the polar amino acids, nonpolar hydrophobic 
side chains such as alanine and isoleucine have been found to make van der Waals 
contact with the 5-methyl group of thymidine; the aromatic ring of phenylalanine can 
intercalate between base pairs in some complexes. Additionally, cation-π interactions62 
have also been found to be quite common at the interface between protein and DNA, and 
even more frequent than π-π stacking interactions. The majority of cation-π contacts 
involve adenines, and Arg-Ade is the most frequent cation-π pair. 
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1.5. Mitochondrial Respiratory Chain 
 
Mitochondria are membrane enclosed organelles found in eukaryotic cells; they 
are responsible for important cellular functions such as energy metabolism, cell signaling 
and programmed cell death. Mitochondria generate ATP through the mitochondrial 
electron transport chain (ETC) coupled with oxidative phosphorylation (OX-PHOS). This 
process involves an pathway with five multisubunit protein complexes: Complexes I to 
IV (which constitute the electron transport chain) and ATP synthase (Complex V), and 
two free diffusible molecules. namely ubiquionone and cytochrome c. Electrons 
originating from NADH (Complex I) and FADH2 (Complex II) pass from electron donors 
to electron acceptors via redox reactions throughout the ETC, and generate a proton (H
+
) 
gradient, enabling the conversion of ADP to ATP in Complex V.
64-66 
The Krebs cycle provides the initial electron donors, NADH (nicotinamide 
adenine dinucleotide) and succinate. In functional mitochondria, the Complex I (NADH-
ubiquinone oxidoreductase or NADH dehydrogenase) transfers two electrons from 
NADH to the lipid-soluble electron carrier ubiquinone (Q) or coenzyme Q (CoQ) (Figure 
1.8). During this reaction, Complex I transfers 4 H
+
 from the matrix to the intermembrane 
space for each two electrons received. Complex II (succinate dehydrogenase) also 
catalyzes the transfer of electrons from succinate (through FADH2), to CoQ. However, 
unlike Complex I, no protons are transported to the intermembrane space in this pathway. 
Transfer of the first electron forms the free radical (semiquinone) form of Q and transfer 
of the second electron forms the semiquinone form to the ubiquinol form, QH2. Reduced 
ubiquinol transfers two electrons to Complex III (cytochrome bc1 complex or ubiquinol-
cytochrome c oxidoreductase). Complex III transfers 2H
+
 from the matrix to  
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Figure 1.8. Mitochondrial membranes and different compartments involved in the 
electron transport chain (ETC). 
 
intermembrane space and transfers two electrons from ubiquinol to cytochrome c. 
Cytochrome c serves as an electron carrier between Complex III and Complex IV 
(cytochrome c oxidase). Complex IV accumulates electrons from cytochrome c to reduce 
oxygen (the most electronegative and terminal electron acceptor in the chain), and 
transfer 4 H
+
 protons into the intermembrane space. In summary, electrons are 
transported from the TCA cycle to oxygen, ultimately producing water along with the 
translocation of ten protons at Complex I (4H
+
), Complex III (2H
+
) and Complex IV 
(4H
+
).
67,68
Although, some recent editions of the biochemistry textbooks mention a 
4H
+
/2e, 4H
+
/2e, 2H
+
/2e stoichiometry for complex I, III, and IV, respectively,
69,70
 the 
analysis of chemical reactions occuring in ETC catalyzed by each complex, as well as 
thermodynamic considerations performed by Pardo and coworkers,
71
favors the 
stochiometry of 4, 2, 4 over 4, 4, 2 for Complexes I, III, and IV, respectively.  
The proton motive force (PMF) generated by the translocation of ten protons from 
the matrix to intermembrane space by the electron transfer chain is the driving force for 
ATP synthase to synthesize ATP from ADP and inorganic phosphate (Pi).
72,73 A small 
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percentage of electrons leak directly from Complex I and Complex III to oxygen, 
resulting in the formation of the free radical superoxide (Figure 1.9A).
74-76
 Complex I is 
the major source of superoxide in the respiratory chain. Although superoxide is not 
highly toxic,
77
 it can undergo a spontaneous or superoxide dismutase catalyzed 
disproportionation reaction to form hydrogen peroxide (H2O2). In the presence of reduced 
iron or copper, peroxide can undergo the Fenton reaction
78,79
 (Figure 1.9B) to produce 
highly toxic hydroxyl radicals, which diffuse through cells readily and are capable of 
reacting with virtually any biological molecule including DNA, proteins and lipids.
76,80
    
Reactive oxygen species (ROS) are essential in living systems because of their 
role in many vital processes such as signal transduction and as a natural defense system 
against pathogens. ROS include free radicals, such as hydroxyl and superoxide radicals, 
which are substances with one or more orbital electrons with unpaired spin states, and 
nonradicals, including hydrogen peroxide and singlet oxygen.
76
 Under normal conditions,  
  
 
Figure 1.9. Mitochondrial formation and fate of superoxide (adapted from ref. 94). 
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ROS is maintained at a basal level by a network of low molecular weight antioxidants 
such as glutathione, -tocopherol (vitamin E), L-ascorbic acid (vitamin C), and enzymes 
including glutathione peroxidase, superoxide dismutase (SOD) and catalase.
81-83
 Given 
the role of mitochondria as the powerhouse of the cell, mitochondrial dysfunction is 
strongly linked to the pathogenesis of a number of human diseases (e.g. diabetes, 
cardiovascular diseases and neurodegenerative diseases).
84-91 
Defects in any of the 
complexes in the electron transport chain can cause a mitochondrial disorder and can 
result in significant
 
oxidative stress in the mitochondria with high mutation rates of 
mitochondrial DNA.
92-95
 In neuronal degenerative diseases such as Parkinson’s disease, 
Alzheimer’s disease, and amyotrophic lateral sclerosis, the exposure to oxidative stress 
has been found to cause mutations in the mitochondrial DNA (mtDNA) causing mtDNA 
damage.
96-100
 One of the primary targets of ROS is cellular lipids.
101-103
 Abstraction of 
hydrogen atoms from lipid membranes forms a carbon centered radical. This radical can 
readily react with oxygen, forming a hydroperoxy radical (Figure 1.10). A lipid radical is 
again produced from the reaction of lipid with lipid peroxyl radical, thereby creating a 
chain reaction which can afford many lesions in the membrane lipids from a single 
hydroxyl radical.  
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Figure 1.10: Radical chain reaction mechanism of lipid peroxidation. 
 
The deleterious effects of oxidative stress are the reason that one of the major 
approaches for the treatment of mitochondrial disease involves appropriate antioxidants 
that can reduce the amount of intracellular ROS. It has been shown that a variety of 
naturally occurring antioxidants increase protection against oxidative stress in cells; 
vitamin E and CoQ10 therapy has been reported to be beneficial in patients with 
mitochondrial disease (e.g. Friedreich’s ataxia (FRDA),104-107 α-tocopherol (α-TOH) is 
among the most potent natural lipophilic antioxidants studied for quenching lipid 
peroxidation.
108-110
 α-Tocopherol is able to transfer its phenolic H atom to a carbon-
centered radical, and thereby quench the free radical chain reaction that occurs in the 
presence of O2 (Figure 1.11).
111–113
 The α-TOH radical generated is resonance stabilized, 
thus facilitating its formation associated with radical quenching.
114
 α-TOH radicals can 
be converted back to α-TOH by interacting with the other redox molecules, notably 
NADH and vitamin C. Since the addition of oxygen to lipid radical to lipid peroxy radical 
(Figure 1.10) is extremely fast with rate constants on the order of 10
9
 M
-1
s
-1
, the reaction 
of phenolic antioxidants with lipid radical is generally disregarded at their low 
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concentration.
 115,116
  
A problem in using these natural compounds as antioxidants is their low solubility 
in hydrophilic media such as extracellular and cytoplasmic fluids; this may limit their 
efficacy. One approach to obviate this problem has been to develop mitochondrially 
targeted ubiquinone analogues including the compounds MitoQ containing a lipophilic 
triphenylphosphonium cation.
117
 Another approach has been to synthesize ubiquinone  
analogues with fewer carbons in the side chain compared to CoQ10 to facilitate 
exogeneous delivery.
118
 A problem in using synthetic stoichiometric antioxidants such as 
BHT is a big excess amout would be needed to quech ROS.
119
 Thus the identification of 
small molecule antioxidants which can potentially be used catalytically has become a 
critical goal. 
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Figure 1.11. Quenching of radical-mediated lipid peroxidation by -tocopherol where R. 
is a lipid radical. 
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CHAPTER 2 
SYNTHESIS OF TRYPTOPHAN ANALOGUES FOR STUDYING PROTEIN 
CONFORMATIONAL CHANGES 
2.1. Introduction 
Tryptophan (Trp) is often important to protein function and structural integrity 
and is also the main source of intrinsic protein fluorescence.
120
 Therefore, it has long 
been used as a probe of protein structure and function.
120
 However, due to its complicated 
photophysics and multiple occurrence in some proteins of interest, Trp cannot always be 
used as a suitable optical probe.
121
 Therefore, it seemed of interest to design novel 
tryptophan analogues having more useful spectroscopic properties and which do not 
perturb the local environment of the target proteins. Azatryptophans meet the above 
described criteria, where one of the endocyclic CH group of indole moiety is substituted 
with nitrogen. This substitution comprises not only the smallest possible structural 
alteration of all known Trp analogues but can also lead to substantial changes in the 
photophysical properties of the aromatic system. Among the azaindole chromophores, 4-
azaindole has been identified as a promising candidate. It has strongly red-shifted 
fluorescence with a large Stokes shift (~130 nm). It is also biocompatible, as its 4-
azatryptophan derivative can be incorporated into target proteins. However, the 
fluorescence intensity and quantum yield of 4-azatryptophan are much lower than that of 
tryptophan itself. In addition, azatryptophans are hydrophilic, such that their presence in 
the hydrophobic core of proteins could modify protein structure and function. To 
overcome these limitations we have prepared the more hydrophobic N-Me-4-
azatryptophan and also two tricyclic 4-azatryptophan derivatives (Figure 2.1) having 
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larger Stokes shifts (~150-160 nm) and significantly higher molar absorptivities than that 
of tryptophan.  
H
NN
N
H
N
N
N
1H-pyrrolo[3,2-c]isoquinoline 1H-pyrrolo[2,3-f]quinolineNMe-4-azaindole
N
H
N
4-azaindole       
Figure 2.1. Structure of 4-azaindole and the chromophoric moieties of the tryptophan 
analogues. 1H-pyrrolo[3,2-c]isoquinoline consists of a benzene ring fused to a bicyclic 4-
azaindole ring and 1H-pyrrolo[2,3-f]quinoline is a 4-azaindole modified with a benzo 
ring spacer, separating the pyridine ring from the pyrrole ring. 
 
  7-Azatryptophan is a another promising alternative to tryptophan as a 
photophysical probe as its chromophoric moiety, 7-azaindole, has absorption and 
emission spectra red shifted by 10 and 46 nm, respectively, from those of 
tryptophan.
120,122
 N-Me-7-azaindole
122
 (Figure 2.2) has been found to have better 
fluorescence properties than 7-azaindole itself because it retains the pronounced red shift 
present in the parent 7-azaindole, but with stronger fluorescence, prompting us to study 
this analogue. 
                             
N N
NMe-7-azaindole
N
H
N
7-azaindole  
Figure 2.2. Structures of 7-azaindole and NMe-7-azaindole. 
 
We also have investigated three different cyanotryptophan (CNTrp) analogues as 
potential probes for fluorescence analysis of protein structure and function. Recently, p- 
cyanophenylalanine (CNPhe)
123
 has emerged as a useful spectroscopic probe for studying 
protein structure and dynamics. Introduction of the cyano group increased the 
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fluorescence quantum yield of CNPhe in water to about five times that of phenylalanine 
(Phe).
 
The polarity of the cyano group is intermediate between that of a methylene and an 
amide group. This intermediate polarity allows CNPhe to be accepted in both 
hydrophobic and hydrophilic environments in a protein.
124 
These interesting properties of 
CNPhe encouraged us to explore the fluorescence properties of cyanotryptophans.
 
Thus 
far, only 5-cyanotryptophan has been used as an infrared probe of the local hydration 
status of proteins or peptides but its fluorescence quantum yield is approximately one 
order of magnitude smaller than that of Trp, rendering it less useful as a fluorescence 
probe.
125
 Therefore, three cyanotryptophans were synthesized along with six 
azatryptophans (Figure 2.3). 
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Figure 2.3. Tryptophan analogues (Trp-1
 – Trp-9) which were synthesized and 
incorporated into different positions of dihydrofolate reductase (DHFR). 
 
 
            To realize the asymmetric synthesis of the Trp analogues, a stereoselective 
strategy utilizing the Schöllkopf chiral reagent
 
has been adopted.
126
 This strategy has 
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enabled the successful synthesis of non-proteinogenic S-amino acids. In order to evaluate 
the properties of the Trp analogues as constituents of DHFR, their aminoacylated pdCpA 
 (Figure 2.4) were synthesized, employed for the preparation of misacylated tRNAs, and 
then they were introduced site-specifically into DHFR. 
            DHFR is an essential and ubiquitous enzyme required for normal cellular 
metabolism in both prokaryotes and eukaryotes. The main role of DHFR is maintenance 
of the intracellular pools of 5,6,7,8-tetrahydrofolate, which is required for the 
biosynthesis of purines, pyrimidines and several amino acids.
127
 DHFR catalyzes 
formation of 5,6,7,8-tetrahydrofolate from 7,8-dihydrofolate using nicotinamide adenine 
dinucleotide phosphate (NADPH) as a cofactor (Figure 2.5).
127
  
            As discussed in Chapter 1, few studies have incorporated donor and acceptor 
amino acids into a single protein. Using misacylated suppressor tRNAs with two different 
anticodons, a Trp donor and an acceptor amino acid acridone-2-ylalanine (Acd)
128-130
 
were both incorporated into DHFR. Therefore, the aminoacylated pdCpA derivative of 
amino acid Acd was also synthesized (Figure 2.6).  
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Figure 2.4. Series of aminoacylated pdCpA derivatives synthesized for site-directed 
incorporation of modified Trps at different positions of DHFR. 
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Trp22
Trp30
Trp47
 
Figure 2.5. Structure of wild-type E. coli DHFR (PBD entry 1RX6), including Trp22, 
Trp30, and Trp47. The substrate tetrahydrofolate is shown in green and the cofactor 
NADPH is shown in red.         
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Figure 2.6. Structures of acceptor amino acid acridone-2-ylalanine (Acd) and its pdCpA 
derivative synthesized for tRNA activation and site-directed incorporation into DHFR. 
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2.2. Results 
Synthesis of Fluorescent Tryptophanyl pdCpAs Esters 
            The synthesis of the aminoacylated pdCpA derivative of amino acid Trp-1 
(Scheme 2.1) was accomplished starting from commercially available 4-azaindole. This 
compound was formylated to yield 2.11 which was N-tosylated with p-TsCl and NaH, 
affording 2.12 in 23% overall yield.
131,132 
Reduction of aldehyde 2.12 with NaBH4 in 
EtOH afforded alcohol 2.13 in 87% yield.
131 
Chlorination of 2.13 with thionyl chloride 
then provided 2.14.
133 
Asymmetric synthesis of the amino acid precursor was carried out 
using the Schöllkopf reagent ((R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine).
126 
Regioselective lithiation (n-butyllithium, THF, 
_
78°C) of the Schöllkopf reagent 
produced the lithium enolate which afforded adduct 2.15 in 62% yield with high 
diastereoselectivity.
126
 Mild hydrolysis (2 N HCl) provided α-substituted amino acid 
methyl ester 2.16 which was protected as the NVOC carbamate to yield 2.17 in 33% 
overall yield.
48
 N-detosylation of 2.17 using cesium carbonate in 2:1 THF–MeOH 
afforded ester 2.18.
134 
Hydrolysis of 2.18 then afforded the free acid, which was activated 
as cyanomethyl ester 2.19 in 52% overall yield.
 
Treatment of cyanomethyl ester 2.19 with 
the tris(tetrabutylammonium) salt of pdCpA
15
 in anhydrous DMF gave the aminoacylated 
pdCpA containing amino acid Trp-1 in 42% yield. 
            The synthesis of the aminoacylated pdCpA derivative of amino acid Trp-2 
(Scheme 2.2) was accomplished starting from commercially available 7-azaindole. 
Formylation of 7-azaindole under Duff reaction conditions
131
 yielded aldehyde 2.20, the 
latter of which was subjected to N-tosylation with p-toluenesulfonyl chloride (p-TsCl) 
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Scheme 2.1. Synthesis of Trp-1 and its Aminoacyl-pdCpA. 
 
and sodium hydride to afford 2.21 in 53% overall yield (Scheme 2.2).
 
Reduction of 
aldehyde 2.21 to alcohol 2.22 using NaBH4 in EtOH proceeded almost quantitatively.
 
Chlorination of alcohol 2.22 with thionyl chloride afforded 2.23 in 81% yield.
 
Regioselective lithiation (n-BuLi, THF, 
_
78 °C) of the chiral auxiliary
 
produced the 
lithium enolate, which afforded the adduct 2.24 from 2.23 with high diastereoselectivity. 
Mild hydrolysis (2 N HCl) provided α-substituted amino acid methyl ester 2.25 which 
was protected as the NVOC carbamate to yield 2.26 in 58% overall yield. N-Detosylation  
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Scheme 2.2. Synthesis of Trp-2 and its Aminoacyl-pdCpA. 
 
of 2.26 using cesium carbonate in 2:1 THF–MeOH afforded ester 2.27. Hydrolysis of 
2.27 then afforded the free acid, which was activated as cyanomethyl ester 2.28 in 73% 
overall yield.
 
Treatment of cyanomethyl ester 2.28 with the tris(tetrabutylammonium) salt 
of pdCpA in anhydrous DMF gave the aminoacylated pdCpA containing amino acid 
Trp-2 in 66% yield (Scheme 2.2).  
            For the synthesis of the aminoacylated pdCpA derivative of amino acid Trp-3 
(Scheme 2.3), N-detosylation of 2.15 was performed using cesium carbonate in 2:1 THF–
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MeOH to yield 2.29 in 68% yield. N-methylation of 2.29 with methyl iodide and sodium 
hydride afforded 2.30 in 74% yield.
132 
Mild hydrolysis (2 N HCl) afforded the α- 
substituted amino acid methyl ester 2.31 which was protected as the NVOC carbamate to 
yield 2.32 in 25% overall yield. Methyl ester 2.32 was then hydrolyzed to afford the free 
acid which was subsequently treated with chloroacetonitrile to afford the requisite 
cyanomethyl ester 2.33 in 52% yield.
 
Treatment of the cyanomethyl ester with a solution 
of the tris(tetrabutylammonium) salt of pdCpA in dry DMF gave the aminoacylated 
 
pdCpA containing amino acid Trp-3 in 39% yield.   
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Scheme 2.3. Synthesis of Trp-3 and its Aminoacyl-pdCpA. 
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            For the synthesis of the aminoacylated pdCpA derivative of amino acid Trp-4 
(Scheme 2.4), N-detosylation of 2.24 was performed using cesium carbonate in 2:1 THF–
MeOH to yield 2.34 in 39% yield.
 
N-methylation of 2.34 with methyl iodide and sodium 
hydride afforded 2.35 in 83% yield.
 
Mild hydrolysis (2 N HCl) of 2.35 afforded the α-
substituted amino acid methyl ester 2.36 which was protected as the NVOC carbamate to 
yield 2.37 in 62% overall yield. Methyl ester 2.37 was then hydrolyzed to afford the free 
acid which was subsequently treated with chloroacetonitrile to afford the requisite  
cyanomethyl ester 2.38 in 71% yield. Treatment of cyanomethyl ester 2.38 with the 
tris(tetrabutylammonium) salt of pdCpA in anhydrous DMF afforded pdCpA ester 2.4 in 
31% yield. 
 
N N
S
O
N
N
O
O
O
2.24
Cs2CO3
THF/MeOH 2:1
      rt, 12 h
N N
H
N
N
O
O
2.34
39% 83%
NaH, MeI
DMF, 0 oC, 30 min
N N
NH2
O
O
N N
N
N
O
O
N N
HN
O
O
O
O
NO2
O
O
 71%
2.35
2.36 2.37
62% (two steps)
2. Et3N, ClCH2CN
anh. DMF, 16 h
1. LiOH, THF/MeOH/H2O
(3:1:1), rt, 3 hNVOC-Cl
K2CO3
dioxane/water
(1:1), 14 h
2 N HCl
THF, rt, 2 h
N N
HN
O
O
O
O
NO2
O
ONC TBA-pdCpA
anh. DMF/Et3N
sonication, 6 h
31%
2.38
N N
HN
O
OpdCpA
O
O
NO2
O
O
2.4  
Scheme 2.4. Synthesis of Trp-4 and its Aminoacyl-pdCpA. 
 30 
 
 
            For the asymmetric synthesis of Trp-5, the required indole was prepared in four 
steps (Scheme 2.5) from commercially available 4-bromoisoquinoline according to the 
method of Dupas et al.
135
 with some modifications. The synthesis began with amination 
of 4-bromoisoquinoline (Scheme 2.5) using Cu/CuCl couple to afford 2.39.
136
 Iodination 
with iodine/silver sulfate system provided 4-amino-3-iodoisoquinoline (2.40) in 71% 
yield.
137
 Sonogashira coupling of trimethylsilylacetylene (TMSA) and 4-amino-3-
iodoisoquinoline (2.40) proceeded very smoothly at room temperature; the desired 
ethynyl derivative 2.41
135
 was obtained in 91% yield. The aminoethynyl derivative 2.41 
was then heated to reflux with NaNH2 in DMF to effect cyclization into key intermediate 
2.42
135 
which was formylated to yield aldehyde 2.43 (Scheme 2.6). This intermediate was 
subjected to N-tosylation with p-toluenesulfonyl chloride (pTsCl) and sodium hydride to  
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Scheme 2.5. Synthesis of Pyrroloisoquinoline 2.42. 
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Scheme 2.6. Synthesis of Trp-5 and its Aminoacyl-pdCpA. 
 
 
afford 2.44 in 46% overall yield.
 
Reduction of aldehyde 2.44 to alcohol 2.45 using 
NaBH4 in EtOH proceeded almost quantitatively.
 
Chlorination of alcohol 2.45 with 
thionyl chloride afforded 2.46 in 77% yield. Asymmetric synthesis of the amino acid 
precursor was carried out using the Schöllkopf reagent, (R)-2,5-dihydro-3,6-dimethoxy-
2- isopropylpyrazine. Regioselective lithiation (n-butyllithium, THF, 
_
78°C) of the chiral 
auxiliary produced the lithium enolate which afforded the adduct 2.47 from 2.46 with 
high diastereoselectivity (only one diastereomer was detectable in the 
1
H NMR and 
13
C 
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NMR spectra). Mild hydrolysis (2 N HCl) afforded the α-substituted amino acid methyl 
ester 2.48. Amine 2.48 was protected as the NVOC carbamate, yielding 2.49 in 90% 
yield. The NVOC group was chosen as it can be removed by UV irradiation. N-
Detosylation of 2.49 was performed using cesium carbonate in 2:1 THF–MeOH to yield 
2.50 in 73% yield.
 
Methyl ester 2.50 was then hydrolyzed to afford the free acid which 
was subsequently treated with chloroacetonitrile to afford the requisite cyanomethyl ester 
2.51 in 54% overall yield. Treatment of cyanomethyl ester 2.51 with the 
tris(tetrabutylammonium) salt of pdCpA in anhydrous DMF afforded pdCpA ester 2.5 in 
55% yield.  
The synthesis of the aminoacylated pdCpA derivative of amino acid Trp-6 
(Scheme 2.7) was accomplished starting from commercially available pyrroloquinoline 
which was formylated to yield 2.52. This compound was N-tosylated with pTsCl and 
NaH, affording 2.53 in 55% overall yield.
 
Reduction of aldehyde 2.53 with NaBH4 in 
EtOH then afforded alcohol 2.54 in 82% yield. Chlorination of 2.54 with thionyl chloride 
then provided 2.55.
 
Regioselective lithiation (n-butyllithium, THF, 
_
78°C) of the 
Schöllkopf reagent produced the lithium enolate which afforded the adduct 2.56 with 
high diastereoselectivity. Mild hydrolysis (2 N HCl) afforded the α-substituted amino 
acid methyl ester 2.57 which was protected as the NVOC carbamate to yield 2.58 in 92% 
yield. N-Detosylation of 2.58 using cesium carbonate in 2:1 THF–MeOH afforded ester 
2.59.
  
Hydrolysis of 2.59 afforded the free acid, which was activated as cyanomethyl ester 
2.60 in 40% overall yield. Treatment of cyanomethyl ester 2.60 with the 
tris(tetrabutylammonium) salt of pdCpA in anhydrous DMF gave the aminoacylated 
pdCpA containing amino acid Trp-6 in 54% yield (Scheme 2.7). 
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Scheme 2.7. Synthesis of Trp-6 and its Aminoacyl-pdCpA. 
 
         
            The synthesis of the aminoacylated pdCpA derivative of amino acid Trp-7 
(Scheme 2.8) was accomplished starting from commercially available 6-cyanoindole, 
which was formylated to yield 2.61.
138 
The latter was N-tosylated with p-TsCl and NaH, 
affording 2.62 in 68% overall yield.
 
Reduction of the aldehyde moiety with NaBH4 
afforded alcohol 2.63 in 80% yield. Chlorination of 2.63 with thionyl chloride then 
provided 2.64 as a yellowish solid. Regioselective lithiation (n-butyllithium, THF, 
_
78°C)  
of the Schöllkopf reagent produced the lithium enolate which afforded adduct 2.65 with 
high diastereoselectivity. Mild hydrolysis (2 N HCl) provided α-substituted amino acid 
methyl ester 2.66 which was protected as the NVOC carbamate to yield 2.67 in 79% 
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overall yield. N-Detosylation of 2.67 using cesium carbonate in 2:1 THF–MeOH afforded 
ester 2.68.
  
Hydrolysis of 2.68 afforded the free acid, which was activated as cyanomethyl 
ester 2.69 in 44% overall yield (Scheme 2.8). Finally, treatment of cyanomethyl ester 
2.69 with the tris(tetrabutylammonium) salt of pdCpA (TBA-pdCpA)
 
in anhydrous DMF 
afforded pdCpA ester 2.7 in 71% yield.   
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Scheme 2.8. Synthesis of Trp-7 and its Aminoacyl-pdCpA. 
 
            The synthesis of the aminoacylated pdCpA derivative of amino acid Trp-8 
employed a similar route (Scheme 2.9). Initially, commercially available 7-cyanoindole 
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Scheme 2.9. Synthesis of Trp-8 and its Aminoacyl-pdCpA. 
 
was formylated to yield 2.70, the latter of which was N-tosylated with p-TsCl and NaH, 
affording 2.71 in 66% overall yield.
 
Treatment of aldehyde 2.71 with NaBH4 afforded 
alcohol 2.72 in 77% yield. Chlorination of 2.72 with thionyl chloride then provided 2.73.
 
Regioselective lithiation of the Schöllkopf reagent produced the lithium enolate which 
afforded adduct 2.74 with high diastereoselectivity. Mild hydrolysis (2 N HCl) provided 
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α-substituted amino acid methyl ester 2.75 which was protected as the NVOC carbamate 
to yield 2.76 in 73% yield. N-Detosylation of 2.76 using cesium carbonate in 2:1 THF–
MeOH afforded ester 2.77.
 
Hydrolysis of 2.77 afforded the free acid, which was activated 
as cyanomethyl ester 2.78 in 55% overall yield. Treatment of the cyanomethyl ester with 
a solution of the TBA-pdCpA in anhydrous DMF gave the corresponding aminoacylated 
pdCpA containing amino acid Trp-8 in 65% yield (Scheme 2.9). 
            The synthesis of the aminoacylated pdCpA derivative of amino acid Trp-9 was 
accomplished starting from the intermediate 2.74 (Scheme 2.10). N-Detosylation of 2.74 
was performed using cesium carbonate in 2:1 THF–MeOH to yield 2.79 in 68% yield. N-
methylation of 2.79 with methyl iodide (MeI) in presence of sodium hydride afforded 
2.80 in 74% yield. Mild hydrolysis (2 N HCl) afforded the α-substituted amino acid 
methyl ester 2.81. Amine 2.81 was protected as the NVOC carbamate to yield 2.82 in  
65% overall yield. Methyl ester 2.82 was then hydrolyzed to afford the free acid which 
was subsequently treated with chloroacetonitrile to afford the requisite cyanomethyl ester 
2.83 in 52% overall yield. Treatment of the cyanomethyl ester with a solution of the 
TBA-pdCpA in anhydrous DMF gave the corresponding aminoacylated pdCpA 
derivative 2.9 in 69% yield (Scheme 2.10).   
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Scheme 2.10. Synthesis of Trp-9 and its aminoacyl-pdCpA. 
 
Synthesis of N-acetylated methyl esters of Trp analogues 
            The synthesis of N-acetylated methyl esters of azaTrp analogues is illustrated in 
Scheme 2.11. Compounds 2.85, 2.87, 2.91 and 2.93 were prepared from intermediates 
2.16, 2.25, 2.48 and 2.57, respectively. They were acetylated using Ac2O
139
 and then 
detosylated using cesium carbonate.
 
Compounds 2.88 and 2.89 were synthesized by 
acetylating intermediates 2.31 and 2.36 respectively. 
            The synthesis of the N-acetylated methyl esters of the cyanoTrp analogues is 
illustrated in Scheme 2.12. Compounds 2.95 and 2.97 were prepared from intermediates 
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2.66 and 2.75; these were acetylated using Ac2O and then detosylated using cesium 
carbonate. Compound 2.98 was synthesized by acetylating intermediate 2.81. 
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Scheme 2.11. Synthesis of N-acetylated Methyl Esters of Azatryptophan Analogues. 
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Scheme 2.12. Synthesis of N-acetylated Methyl Esters of Cyanotryptophan Analogues. 
 
Synthesis of Acceptor Amino Acid Acd and its Aminoacyl-pdCpA Derivative  
The synthesis of the aminoacylated pdCpA derivative of acceptor amino acid Acd 
was accomplished starting from commercially available Boc-4-aminophenylalanine 
which was first methylated with thionyl chloride in methanol to yield the methyl ester 
2.99 (Scheme 2.13). Treatment of 2.99 with 2-chlorobenzoic acid then gave 2.100 in 47% 
yield.
128 
Cyclodehydration of 2.100 to the acridinone derivative 2.101 with hot 
polyphosphoric acid (PPA) caused loss of the Boc protecting group.
128 
Accordingly, free 
amine 2.101 was protected as the NVOC carbamate, yielding 2.102 in 10% overall yield 
from 2.100. Methyl ester 2.102 was then treated with LiOH to afford the free acid, which 
was subsequently treated with chloroacetonitrile to afford the requisite cyanomethyl ester 
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2.103 in 40% yield.
  
Treatment of the cyanomethyl ester with a solution of 
tris(tetrabutylammonium) salt of pdCpA in dry DMF gave the corresponding 
aminoacylated pdCpA 2.10 in 34% yield. 
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Scheme 2.13. Synthesis of Acd and its Aminoacyl-pdCpA. 
 
Measurement of Photophysical Properties of Tryptophan Derivatives Trp-1–Trp-9 
            UV/vis absorption spectra (220-400 nm) were recorded using a Cary 60 UV/vis 
spectrophotometer. Fluorescence quantum yields (Table 2.1) of fluorescent compounds 
were determined using the gradient method.
140
 Tryptophan derivatives Trp-1–Trp-9 
were dissolved in methanol, and solutions of each compound were made such that the 
UV absorptions at the maximum wavelength were 0.02, 0.04, 0.06, 0.08 and 0.1. 
Anthracene (ΦF 0.27, ex 340 nm), was used as a reference standard to calculate the 
fluorescence quantum yields of the tryptophan analogues according to the formula Φx = 
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Φs × (Gradx × nx
2
)/(Grads × ns
2
), where Grad is gradient of the plot of integrated intensity 
versus absorbance, n is the refractive index of the solvent, s is the standard of known ΦF, 
and x is the tested sample.
140 
 
Table 2.1. Molar Absorptivities and Quantum Yields of N-Acetylated Methyl Esters of 
Trp Analogues in MeOH. 
 
 
Trp analogue λabs, max 
(nm) 
ε (M-1cm-1) λex (nm) λem (nm)  ΦF 
Tryptophan      280     6900   280    340 0.18 
    Trp-1      290     7870   290    390 0.04 
    Trp-2      289     8920   289    371 0.02 
    Trp-3      292     7740   292    404 0.06 
    Trp-4      288     8070   288    391 0.30 
    Trp-5      262   18100   262    413 0.10 
    Trp-6      272   15500   272    421 0.03 
    Trp-7      290   10300   290    370 0.53 
    Trp-8      310     8100   310    390 0.40 
    Trp-9      315     8000   315    395 0.41 
 
 
Activation of Suppressor tRNACUA and Synthesis of Modified DHFRs 
            The individual N-NVOC protected aminoacylated pdCpA derivatives were ligated 
to a suppressor tRNACUA lacking its 3′-terminal cytidine and adenosine residues 
(tRNACUA-COH)
 12-14,141
 via the agency of T4 RNA ligase. As shown in Figure 2.7, this 
assay afforded full length tRNA transcripts activated with amino acids Trp-1 – Trp-6. 
 42 
 
The NVOC protecting groups were then removed by exposure to high intensity UV light 
at 4 
o
C.
142
 The aminoacyl-tRNAs so obtained were employed in an in vitro cell free 
transcription-translation system, which was programmed with DHFR DNA plasmids 
containing TAG codons at the positions corresponding to residues Trp22, Trp30 or Trp47 
of DHFR.
143
 As shown in Figure 2.8, each of the six azatryptophanyl-tRNAs afforded 
good suppression of the UAG codons at positions 22, 30 and 47 of the DHFR mRNAs, 
with suppression yields ranging from 12 to 65% compared to wild-type DHFR. The 
enzymatic activities of the modified DHFRs were judged by their ability to consume 
NADPH (Table 2.2). Since the substrates (dihydrofolate and NADPH) were present in 
excess of the enzyme, the rate constants (kD) measured represent the enzyme turnover 
efficiency. Replacement of Trp22, which is in the Met20 loop subdomain of DHFR,
144
 
with tryptophan analogues Trp-1 – Trp-4 afforded DHFRs which consumed NADPH 22 
– 51% as well as wild-type DHFR under the assay conditions. Substitution of tricyclic 
amino acids Trp-5 and Trp-6 at position 22 resulted in DHFRs which consumed 
NADPH 6 and 7% as well as wild type, respectively. After replacement of Trp30 and 
Trp47 by the same Trp analogues, the modified DHFRs had about the same NADPH 
consuming activity as wild type (Table 2.2). 
            Similarly, the individual N-NVOC protected aminoacylated pdCpA derivatives of 
Trp-7 – Trp-9145 were ligated to a suppressor tRNACUA (tRNACUA-COH)
 
by the use of T4 
RNA ligase and the NVOC protecting groups were removed by exposure to high 
intensity UV light at 4 
o
C. The aminoacyl-tRNAs so obtained were employed in an in 
vitro cell free protein synthesizing system, which was programmed with DHFR DNA 
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1             2               3              4              5              6             7
 
 
Figure 2.7. Ligation between the tRNA-COH (truncated tRNACUA) and aminoacylated 
pdCpA derivatives 2.1-2.6 as monitored by acidic polyacrylamide gel electrophoresis. 
Lane 1, truncated tRNACUA; lane 2, ligation of truncated tRNACUA with 2.1; lane 3, 
ligation of truncated tRNACUA with 2.2; lane 4, ligation of truncated tRNACUA with 2.3; 
lane 5, ligation of truncated tRNACUA with 2.4; lane 6, ligation of truncated tRNACUA 
with 2.5; lane 7, ligation of truncated tRNACUA with 2.6. The experiment was performed 
by Dr. Shengxi Chen. 
 
 
1 2 3 4 5 6 7 8
100 2 36 34 18 26 25 12 yield (%)
22 TAG
30 TAG
47 TAG
100 2 33 55 21 25 58 27 yield (%)
100 0 50 65 20 41 47 25 yield (%)  
Figure 2.8. Autoradiogram of a 15% SDS-polyacrylamide gel (100 V, 2 h) illustrating 
the incorporation of tryptophan analogues into positions 22 (upper panel), 30 (middle 
panel) and 47 (lower panel) of DHFR. Lane 1, wild-type DHFR expression; lane 2, 
modified DHFR DNA in the presence of abbreviated suppressor tRNACUA-COH; lane 3, 
incorporation of amino acid Trp-1; lane 4, incorporation of amino acid Trp-2; lane 5, 
incorporation of amino acid Trp-3; lane 6, incorporation of amino acid Trp-4; lane 7, 
incorporation of amino acid Trp-5; lane 8, incorporation of amino acid Trp-6. 
Phosphorimager analysis was performed using an Amersham Biosciences Storm 820 
equipped with ImageQuant version 5.2 software from Molecular Dynamics. The 
experiment was performed by Dr. Shengxi Chen. 
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plasmids containing TAG codons at the positions corresponding to residues Trp22 or 
Trp74 of DHFR.
 
Modified DHFR translation was carried out in an in vitro coupled 
transcription–translation system in the presence of the tryptophanyl-tRNACUA derivatives.  
 
Table 2.2. Enzymatic Activities of DHFRs Singly Modified at Positions 22, 30 or 47. 
The experiment was performed by Dr. Shengxi Chen. 
 
 
                                   position 22 (Trp)              position 30 (Trp)             position 47 (Trp)    
DHFR                                 kD (s
-1
)                              kD (s
-1
)                               kD (s
-1
)                       
wild-type                               12                                       12                                   12 
Trp-1                                 6.1 ± 0.5
a
                            13.2 ± 0.4                     11.5 ± 0.4  
Trp-2                                 5.4 ± 0.4                             12.6 ± 0.4                     12.4 ± 0.4  
Trp-3                                 2.6 ± 0.2                             12.0 ± 0.4                     13.8 ± 0.4   
Trp-4                                 3.7 ± 0.2                             13.9 ± 0.5                     13.2 ± 0.5  
Trp-5                                 0.7 ± 0.1                             12.5 ± 0.4                     11.9 ± 0.4  
Trp-6                                 0.8 ± 0.1                             13.4 ± 0.5                     12.8 ± 0.4                
a
Standard deviation is based on data from three experiments. 
 
As shown in Table 2.3, each of the three cyanotryptophanyl-tRNAs afforded good 
suppression of the UAG codons at positions 22 and 74 of DHFR, with relative yields 
ranging from 15% to 41% compared to the cell free synthesis of wild-type DHFR. The 
enzymatic activities of the modified DHFRs were measured by their ability to consume 
NADPH (Table 2.3) under steady-state conditions. Replacement of Trp22, which is in the 
catalytically relevant Met20 loop subdomain of DHFR, with tryptophan analogues Trp-7 
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– Trp-9 resulted in substantial reduction in enzyme activity (the turnover rate constants 
were found to be 9% to 14% of that obtained for wild-type DHFR
146
 under the same 
assay conditions). We then replaced another tryptophan residue (Trp74), which is not 
located in the active site, with the same three tryptophan analogues. All of the modified 
DHFRs obtained had about the same NADPH consuming activity as wild type (Table 
2.3). 
 
Table 2.3. Expression Yields and Enzymatic Activities of DHFRs Singly Modified at 
Positions 22 and 74. The experiment was performed by Dr. Shengxi Chen. 
 
 
                                     position 22 (Trp)                                                 position 74 (Trp)                                         
 DHFR                        yield (%)      kD (s
-1
)                                   yield (%)      kD (s
-1
) 
                                        
 wild-type                          100                12                                                100               12 
 
  Trp-7                        15 ± 2        1.7 ± 0.1                                    37 ± 3      11.8 ± 0.5 
 
  Trp-8                        15 ± 2        1.1 ± 0.1                                    35 ± 3      13.3 ± 0.5 
 
  Trp-9                        19 ± 2        1.3 ± 0.1                                    41 ± 3      15.2 ± 0.6 
 
   
a 
Standard deviation is based on data from three experiments. 
 
 
Fluorescence and FRET in Modified DHFRs 
 
            We evaluated the fluorescence spectral properties of the tryptophan analogues 
when present in DHFR. The fluorescence emission spectra of the DHFRs containing the 
cyanotryptophans at position 74 are shown in Figure 2.9. The modified DHFRs were 
subjected to irradiation at 310 nm in order to minimize the fluorescence from Trp 
residues. The high quantum yield of Trp-7 allowed us to observe strong fluorescence 
emission at 370 nm after excitation at 310 nm, even though this was 20 nm from its 
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 maximum absorption wavelength. As expected, Trp-8 and Trp-9 exhibited substantially 
red-shifted emission spectra centered around 410 nm (Figure 2.9, green and blue traces 
respectively).  
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Figure 2.9. Fluorescence emission spectra of modified DHFRs containing amino acid 
Trp-7 at position 74 (red trace), Trp-8 at position 74 (green trace) and Trp-9 at position 
74 (blue trace) and wild-type DHFR (black).The spectra were recorded at pH 8.0 with ex 
310 nm. The experiment was performed by Dr. Shengxi Chen. 
 
 
To explore the capability of the azatryptophan derivatives as FRET donors, we 
selected two analogues (Trp-4 and Trp-5) and incorporated them into DHFR. As shown 
in Table 2.1, analogue Trp-4 has a higher molar absorbance (8070) and a higher quantum 
yield (0.30) than tryptophan (6900 and 0.18, respectively); and analogue Trp-5 has a 2.6-
fold greater molar absorbance than tryptophan, albeit a lower (0.10) quantum yield. Both 
of the analogues exhibit stronger fluorescence emission and should thus minimize the 
background from the tryptophans in DHFR. The emission wavelength maxima of 
tryptophan analogues Trp-4 and Trp-5 are at 391 nm and 413 nm, respectively (Table 
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2.1). To utilize the emission of these two fluorescence donors in FRET, we selected 
acridon-2-ylalanine (Acd) as the fluorescence acceptor; this fluorophore has absorption 
peaks at 388 and 407 nm in H2O and emission peaks at ~ 420 and 450 nm. Once the 
FRET pairs were selected, we calculated the Förster distance (R0) of these donors and 
acceptor, following the standard protocol.
129
 The R0 between Trp-4 and Acd is 27.4 Å; 
and the R0 between Trp-5 and Acd is 29.5 Å. We replaced Glu17 with the acceptor Acd 
to study the conformational changes in DHFR structure via FRET. For the donor 
position, we selected Asn37 to fit the calculated R0 value, as its distance to E17 is 33 Å 
(PBD entry 1RA1). As shown in Scheme 2.14, by decoding nonsense codon UAG and 
four-base codon CGGG in the presence of an aminoacyl-tRNACUA and aminoacyl-
tRNACCCG, the donors (Trp-4 or Trp-5) and the acceptor (Acd) amino acids were 
incorporated into DHFR at positions 37 and 17, respectively. The incorporation yields 
were 8.3 and 8.8%, relative to wild type (Figure 2.10). As shown in Table 2.4, even 
though the acceptor Acd at position 17 decreased the activity of DHFR to 59% of  
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energy
transfer
 
Scheme 2.14. Strategy Employed for Incorporation of a Pair of Fluorophores into DHFR 
at Positions 17 and 37 for a FRET Study.  
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wild type, the donors (Trp-4 or Trp-5) did not further perturb the activity of DHFR when 
introduced into position 37. The doubly modified DHFRs were excited at 260 nm, which 
was chosen in order to decrease the interference of the remaining tryptophans in DHFR 
(having max 280 nm). As shown (Figure 2.11), the modified DHFR containing the 
fluorescent acceptor Acd at position 17 and the donor Trp-5 at position 37 exhibited a 
FRET emission peak at 423 nm. Similarly, the modified DHFR containing the fluorescent 
acceptor Acd at position 17 and the donor Trp-4 at position 37 exhibited a stronger 
FRET emission at 423 nm. Comparatively, the four remaining tryptophans in DHFR 
displayed only very weak FRET emissions at the same wavelength (Figure 2.11, blue 
trace).   
 
   
  1             2           3               4             5
17CGGG
and 37TAG
   100              0              0                8.3              8.8 yield (%)  
Figure 2.10. Autoradiogram of a 15% SDS-polyacrylamide gel (100 V, 2 h) illustrating 
the incorporation of Acd and tryptophan analogues into positions 17 and 37 of DHFR. 
Lane 1, wild-type DHFR expression; lane 2, modified DHFR DNA (17CGGG; 37TAG) 
in the presence of abbreviated suppressor tRNACCCG-COH; lane 3, modified DHFR DNA 
in the presence of L-acridon-2-ylalanyl-tRNACCCG; lane 4, incorporation of amino acids 
Trp-4 and Acd; lane 5, incorporation of amino acids Trp-5 and Acd. The experiment 
was performed by Dr. Shengxi Chen. 
 
 
To explore the capability of cyanotryptophan derivatives as FRET donors, we 
selected 6-CNTrp (Trp-7). As shown in Table 2.1, the emission wavelength (em) of 
fluorescence donor Trp-7 was at 370 nm. As the fluorescence acceptor we selected L-(7- 
hydroxycoumarin-4-yl) ethylglycine (HCO)
48
 whose excitation and emission maxima 
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were found to be at 345 and 440 nm, respectively. For this FRET pair, we calculated the 
Förster distance (R0) as 28.3 Å by following the standard protocol. As noted (Table 2.3), 
position 74 tolerated the introduction of all the cyanotryptophans without significant loss 
 
Table 2.4. Enzymatic Activities of Modified DHFRs Containing FRET Pairs. 
 
DHFR                                                                                   kD (s
-1
)                            
wild-type                                                                                 12                             
17Acd37Trp-4                                                                  7.1 ± 0.4 
17Acd37Trp-5                                                                  6.1 ± 0.4                           
17Acd                                                                                7.1 ± 0.5                                  
a
Standard deviation based on data from three experiments. 
  
 
Figure 2.11. Fluorescence emission spectra of DHFRs containing amino acid Acd at 
position 17 (blue trace), Acd at position 17 and Trp-4 at position 37 (red trace), and Acd 
at position 17 and Trp-5 at position 37 (green trace). The spectra were recorded at pH 8.0 
following excitation at 260 nm. The experiment was performed by Dr. Shengxi Chen. 
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of enzyme function, it was chosen as the position for the donor; for the acceptor position, 
we chose position 17. Its distance to W74 is 25 Å (PBD 1RA1), which is suitable for 
studying FRET between this pair. Using the same strategy applied for azatryptophans, the 
acceptor (HCO) and donor (Trp-7) amino acids were incorporated into a single protein 
of DHFR at positions 17 and 74, respectively. The incorporation yield was 13% relative 
to wild type and the rate of NADPH consumption decreased to 9.4 ± 0.5 s
-1
 compared to 
12 s
-1
 for wild type. Then the doubly-modified DHFR was excited at 310 nm in order to 
decrease the interference from tryptophan (max 280 nm). As shown in Figure 2.12, the 
modified DHFR containing the fluorescence acceptor HCO at position 17 and donor 
Trp-7 at position 74 exhibited a substantial FRET signal at 460 nm.  
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Figure 2.12. Fluorescence emission spectra of DHFRs containing amino acid Trp-7 at 
position 74 (red trace), HCO at position 17 and Trp-7 at position 74 (green trace), and 
wild-type DHFR (black). The spectra were recorded at pH 8.0 with ex 310 nm. The 
Experiment was performed by Dr. Shengxi Chen. 
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4.3. Discussion 
            As part of ongoing efforts to develop smaller and sensitive fluorophores that can 
be readily accommodated within a protein without perturbation of conformation and 
function, we synthesized a series of azatryptophans and cyanotryptophans. Recently, N-
methylated 4- and 7-azaindoles have been found to have fluorescence properties better 
than the parent 4- and 7-azaindoles because they retain the pronounced red shift 
characteristic of the parent 4- and 7-azaindoles, but with more intense fluorescence.
120
 
Therefore, along with 4- and 7-azatryptophans, we also synthesized N-methylated 4- and 
7-azatryptophans as well as two tricyclic tryptophan derivatives (Figure 2.3). Likewise, 
along with 6-cyanotryptophan and 7-cyanotryptophan, N-methylated 7-cyanotryptophan 
was synthesized (Figure 2.3). Being more hydrophobic, the N-methylated analogues 
should also stabilize the hydrophobic core of proteins.  
            In order to synthesize the respective aminoacylated tRNAs, the pdCpA 
derivatives of tryptophan analogues were prepared from their respective amino acids. 
Enzymatic synthesis and resolution is often used for the synthesis of naturally occurring 
chiral α–amino acids. However, this strategy is frequently not useful for synthesizing 
amino acids with non-natural side chains. To realize the asymmetric synthesis of the Trp 
analogues, a stereoselective strategy utilizing the Schöllkopf chiral reagent has been 
adopted and all the syntheses started from commercially available indoles except Trp-5. 
For the asymmetric synthesis of Trp-5, the requisite indole 2.42 was prepared in four 
steps from commercially available 4-bromoisoquinoline according to the method of 
Dupas et al.
135
 with some modifications. The synthesis began with amination of 4-
bromoisoquinoline (Scheme 2.5). The reaction was carried out using Cu/CuCl couple, 
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which induced the transformation at much lower temperature
  
than the reported procedure 
(autoclave, aqueous ammonia, CuSO4, 150°–200°C).
147
 Iodination with iodine/silver 
sulfate provided 4-amino-3-iodoisoquinoline (2.40) in satisfactory yield. Sonogashira 
coupling of trimethylsilylacetylene (TMSA) and 4-amino-3-iodoisoquinoline (2.40) 
proceeded very smoothly at room temperature to afford the desired ethynyl derivative 
2.41, whereas the literature procedure involved coupling with 4-amino-3-
bromoisoquinoline at higher temperature in lower yield. The aminoethynyl derivative 
2.41 was then heated to reflux with NaNH2 in DMF to effect cyclization into key 
intermediate 2.42.
 
The formylation reaction of azaindoles were performed using Duff 
reaction conditions,
131
 whereas the cyanoindoles were formylated by Vilsmeier–Haack 
reaction
138
. Tosyl protecting group was chosen for indole NH protection because it was 
expected to survive untill the last step. Finally it was removed using cesium carbonate in 
2:1 THF–MeOH. The asymmetric synthesis of the amino acid precursor was carried out 
using the Schöllkopf reagent [(R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine] which 
is basically a valine derived bis-lactim ether. The auxiliary could be deprotonated at the 
prochiral -carbon, and the resulting enolate attacked the chloride electrophiles to yield 
adducts with high diastereoselectivity (only one diastereomer was detectable in the 
1
H 
NMR and 
13
C NMR spectra). The enolate is essentially planar, and the steric bulk of the 
isopropyl group directed the incoming electrophile to attack from the opposite face, 
yielding trans adducts. Hydrolysis, typically under mild acidic conditions, yielded the -
substituted amino acids with high enantiopurity and the free amines were protected as 
NVOC carbamates. The NVOC protecting group was chosen as it can be readily 
deprotected by treatment with UV irradiation at the tRNA level without any undesirable 
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side reaction. Protected methyl esters were hydrolyzed to form NVOC protected acids, 
the latter of which were activated as the corresponding cyanomethyl esters by treatment 
with chloroacetonitrile in dry DMF in the presence of triethylamine. The key 
cyanomethyl esters of the N-protected amino acids were coupled with pdCpA TBA salt to 
give dinucleotide esters (2.1–2.9) which were obtained as colorless solids after HPLC 
purification and lyophilization. Misacylated tryptophanyl tRNAs were produced by 
ligating abbreviated tRNA, lacking the terminal cytidine and adenosine moieties at the 3ʹ-
end, with the pdCpA derivatives 2.1–2.9 using T4 tRNA ligase. The ligase is an ATP 
dependent enzyme that catalyzes 3ʹ→5ʹ phosphodiester bond formation between single-
stranded RNAs. The activated tRNAs were then deprotected by UV irradiation to afford 
the free aminoacyl tRNAs. The activated suppressor tRNA was employed in an in vitro 
protein synthesizing system programmed with DHFR mRNA having a UAG codon at 
predetermined positions of the elaborated protein to introduce Trp analogues into specific 
positions of DHFR. 
According to the X-ray crystallographic structure of DHFR, residue Trp22 is 
involved in substrate binding through H-bonds between the residue and an ordered water 
molecule.
148 
Replacement of this residue may disorder substrate binding and affect the 
function of DHFR. This is consistent with the finding that incorporation of Trp analogues 
into position 22 reduced the activity of the modified DHFRs significantly compared to 
wild type. Replacement of the tryptophan residues Trp30, Trp47 or Trp74, which are not 
located in the active site, with the tryptophan analogues afforded modified DHFRs 
having the same NADPH consuming activity as wild type. The results demonstrated that 
these tryptophan derivatives have properties as fluorescence donors suitable for minimal 
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perturbation of protein structures, thus potentially allowing the study of conformational 
changes in DHFR.
 
            Acridon-2-ylalanine (Acd) or L-(7-hydroxycoumarin-4-yl) ethylglycine (HCO) 
has been used as a fluorescence acceptor for FRET studies. Acd has a small size (222 
Å
3
), long lifetime ( ~ 15 ns) and high quantum yield (F 0.95 in water). HCO also has a 
small size, relatively large Stokes shift, high quantum yield (F 0.63 in water) and a blue 
wavelength fluorescence emission. The Glu17 residue of E. coli DHFR is located in the 
Met 20 loop, which exhibits conformational changes upon substrate and cofactor binding 
and product release.
148 
Position 17 of DHFR tolerates small fluorescent amino acids.
47,48 
Therefore, we replaced Glu17 with the acceptor Acd/HCO to study the conformational 
changes in DHFR structure via FRET. 
            Several tryptophan analogues have been prepared and characterized with respect 
to their photophysical properties, and incorporated into different positions of 
dihydrofolate reductase. Three of the tryptophan analogues were found to support FRET 
efficiently. The results demonstrate the utility of these tryptophan analogues as 
participants in energy transfer experiments in DHFR, even in the presence of other 
unmodified tryptophans. 
 
2.4. Experimental Procedures 
 
            Materials. The chemicals used were purchased from Aldrich Chemical Co., 
Sigma Chemical Co. or Combi-Blocks and were used without further purification. 
Anhydrous methanol and DMF were used as purchased. Tetrahydrofuran and 
dichloromethane were distilled from sodium/benzophenone and calcium hydride,  
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respectively. The tris(tetrabutylammonium) salt of pdCpA was prepared by passing 
pdCpA through the activated TBA form of Dowex 50W×8 (200-400 mesh). 
            General Experimental Procedures. All experiments requiring anhydrous 
conditions were conducted in flame-dried glassware fitted with rubber septa under a 
positive pressure of dry nitrogen, unless otherwise noted. Reactions performed at room 
temperature unless indicated otherwise. Analytical thin layer chromatography was 
performed using glass plates pre-coated with silica gel (0.25 mm, 60 Å pore size, 230-
400 mesh, Silicycle) impregnated with a fluorescent indicator (254 nm). TLC plates were 
visualized by exposure to ultraviolet light (UV). Flash column chromatography was 
performed employing silica gel (60 Å pore size, 40-63 μm, standard grade, Silicycle). An 
acetone bath was cooled to the appropriate temperature by addition of small portions of 
dry ice. 
Instrumentation. 
1
H NMR and 
13
C NMR spectra were recorded on Varian 
INOVA 400 (400 MHz) and Varian INOVA 500 (500 MHz) spectrometers at 25 °C. 
Proton chemical shifts are expressed in parts per million (ppm, δ scale) and are 
referenced to residual protium in the NMR solvent (CDCl3, DMSO-d6 and CD3OD).  
Splitting patterns are designated as follows: s, singlet; br s, broad singlet; d, doublet; dd, 
doublet of doublets; t, triplet; q, quartet; m, multiplet. High resolution mass spectrometric 
data were obtained at the Arizona State University CLAS High Resolution Mass 
Spectrometry Facility or the Michigan State Mass Spectrometry Facility. HPLC 
purification was performed with a Waters 600 pump coupled with a Varian ProStar 340 
detector and a Grace Econosil C18 column (250 × 10 mm, 5 μm). The tetra-n-
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butylammonium (TBA) salt of pdCpA was prepared using Dowex 50WX8, 200–400 
mesh activated in its TBA form. 
N
N
O
S
O
O
 
1-Tosyl-1H-pyrrolo[3,2-b]pyridine-3-carbaldehyde (2.12). To a stirred  solution 
containing 1.50 g (12.7 mmol) of 1H-pyrrolo[3,2-b]pyridine in 20 mL of 1:1 AcOH–H2O 
was added 2.67 g (19.0 mmol) of hexamethylenetetramine (HMTA). The reaction 
mixture was heated at reflux under argon overnight. The reaction mixture was cooled to 0 
°C and the formed precipitate was filtered and dried under vacuum. 1H-pyrrolo[3,2-
b]pyridine-3-carbaldehyde (2.11) was obtained as a light yellow solid and was used 
directly in the next step without further purification. To a stirred solution containing 487 
mg (3.33 mmol) of 1H-pyrrolo[3,2-b]pyridine-3-carbaldehyde (2.11) in 20 mL of  
anhydrous DMF at 0 °C was added 119 mg (4.99 mmol) of NaH. The reaction mixture 
was stirred at 0 °C for 10 min under argon and then 954 mg (4.99 mmol) of p-TsCl was 
added. The reaction mixture was stirred at 0 °C under argon for 3 h, diluted with 100 mL 
of satd aq NaHCO3 and extracted with two 50-mL portions of EtOAc. The combined 
organic phase was dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (10 × 4 cm). Elution with 
4:1 hexanes–ethyl acetate gave 1-tosyl-1H-pyrrolo[3,2-b]pyridine-3-carbaldehyde (2.12) 
as an off-white solid: yield 691 mg (23% for two steps); silica gel TLC Rf 0.35 (1:1 
hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) 2.31 (s, 3H), 7.23-7.29 (m, 3H), 
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7.77 (d, 2H, J = 8.0 Hz), 8.21 (d, 1H, J = 8.0 Hz), 8.38 (s, 1H), 8.62 (d, 1H, J = 4.0 Hz) 
and 10.29 (s, 1H); 
13
C NMR (CDCl3, 100 MHz)  21.7, 120.4, 121.2, 121.4 127.3, 128.8, 
130.6, 134.1, 134.8, 144.9, 146.8, 147.8 and 184.9; mass spectrum (APCI), m/z 301.0639 
(M+H)
+
 (C15H13N2O3S requires m/z 301.0647). 
N
N
HO
S
O O
 
1-Tosyl-1H-pyrrolo[3,2-b]pyridin-3-yl)methanol (2.13). To a suspension of 880 mg 
(2.93 mmol) of 1-tosyl-1H-pyrrolo[3,2-b]pyridine-3-carbaldehyde (2.12) in 15 mL of 
EtOH was added 222 mg (5.86 mmol) of NaBH4 and the reaction mixture was stirred at 
room temperature for 2 h. The reaction mixture was diluted with 100 mL of satd aq 
NaHCO3
 
and the formed precipitate was filtered and dried under vacuum. 1-Tosyl-1H-
pyrrolo[3,2-b]pyridin-3-yl)methanol (2.13) was obtained as an off-white solid: yield 770 
mg (87%); silica gel TLC Rf 0.1 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 
MHz)  2.34 (s, 3H), 4.92 (s, 2H), 7.22-7.26 (m, 3H), 7.73-7.76 (m, 3H), 8.25 (d, 1H, J = 
8.0 Hz) and 8.46 (d, 1H, J = 4.0 Hz); 
13
C NMR (CDCl3, 100 MHz)  21.8, 56.8, 119.5, 
121.3, 122.9, 126.2, 127.0, 129.1, 130.3, 135.1, 145.7, 145.9 and 147.6; mass spectrum 
(APCI), m/z 303.0799 (M+H)
+
 (C15H15N2O3S requires m/z 303.0803).  
N
N
S
O
Cl
O
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3-(Chloromethyl)-1-tosyl-1H-pyrrolo[3,2-b]pyridine (2.14). To a cooled (
_
10 °C) 
solution containing 770 mg (2.55 mmol) of 1-tosyl-1H-pyrrolo[3,2-b]pyridin-3-
yl)methanol (2.13) in 15 mL of anhydrous CH2Cl2  and 1.42 mL (1.03 g, 10.2 mmol) of 
Et3N was added dropwise 0.37 mL (606 mg, 5.09 mmol) of SOCl2. The reaction mixture 
was left to warm slowly to room temperature and stirred for 6 h, then diluted with 50 mL 
of brine and extracted with two 50-mL portions of EtOAc. The combined organic phase 
was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with 4:1 
hexanes–ethyl acetate gave 3-(chloromethyl)-1-tosyl-1H-pyrrolo[3,2-b]pyridine (2.14) as 
a yellow oil: yield 579 mg (73%); silica gel TLC Rf 0.45 (1:1 hexanes–ethyl acetate); 
1
H 
NMR (CDCl3, 400 MHz) 2.19 (s, 3H), 4.77 (s, 2H), 7.11-7.20 (m, 3H), 7.69-7.72 (d, 
2H, J = 8.0 Hz), 7.83(s, 1H), 8.18 (dd, 1H, J = 8.4 and 1.2 Hz) and 8.48 (dd, 1H, J = 4.8 
and 1.2 Hz); 
13
C NMR (CDCl3, 100 MHz) 21.3, 35.4, 119.5, 119.8, 120.8, 126.6, 127.9, 
128.4, 129.9, 134.4, 145.6, 145.9 and 146.1; mass spectrum (APCI), m/z 321.0474 
(M+H)
+
 (C15H14N2O2SCl requires m/z 321.0465).  
N
N
S
O
N
N
O
O
O
 
3-(((2S,5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-
pyrrolo[3,2-b]pyridine (2.15). To a stirred solution containing 0.34 mL (363 mg, 1.97 
mmol) of Schöllkopf’s reagent in 5 mL of anhydrous THF at _78 °C was added 0.25 mL 
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(172 mg, 2.68 mmol) of 2.5 M BuLi. The reaction mixture was stirred at 
_
78 °C for 30 
min under argon and then a solution containing 575 mg (1.79 mmol) of 3-(chloromethyl)-
1-tosyl-1H-pyrrolo[3,2-b]pyridine (2.14) in 5 mL of  anhydrous THF was added. The 
reaction mixture was stirred at 
_
78 °C for 1 h under argon, then diluted with 50 mL of 
satd aq NH4Cl and extracted with two 50-mL portions of EtOAc. The combined organic 
phase was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with 2:1 
hexanes–ethyl acetate gave the expected product 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-
2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-pyrrolo[3,2-b]pyridine (2.15) as a yellow 
oil: yield 513 mg (62%); silica gel TLC Rf 0.35 (4:1 hexanes–ethyl acetate); 
1
H NMR 
(CDCl3, 400 MHz) 0.55 (d, 3H, J = 8.0 Hz), 0.85 (d, 3H, J = 8.0 Hz), 1.96-2.06 (m, 
1H), 2.22 (s, 3H), 3.10-3.12 (m, 1H), 3.30-3.32 (m, 2H), 3.54 (s, 3H), 3.56 (s, 3H), 3.61-
3.65 (m, 1H), 4.27-4.29 (m, 1H), 7.06-7.11 (m, 3H), 7.50 (s, 1H), 7.60 (d, 1H, J = 8.0 
Hz), 8.12 (dd, 1H, J = 8.4 and 1.2 Hz) and 8.41 (dd, 1H, J = 4.8 and 1.2 Hz); 
13
C NMR 
(CDCl3, 100 MHz) 16.5, 18.9, 21.4, 28.2, 31.5, 52.1, 52.2, 55.1, 60.4, 118.8, 119.9, 
120.5, 126.5, 127.3, 128.2, 129.9, 134.9, 145.1, 145.6, 148.5, 162.7 and 163.7; mass 
spectrum (APCI), m/z 469.1913 (M+H)
+
 (C24H29N4O4S requires m/z 469.1909).  
N
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-tosyl-1H-
pyrrolo[3,2-b]pyridin-3-yl)propionate (2.17). To a stirred  solution containing 513 mg 
(1.09 mmol) of 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-
1-tosyl-1H-pyrrolo[3,2-b]pyridine (2.15) in 16 mL of  THF at 0 °C was added 14 mL of 2 
N aq HCl. The reaction mixture was stirred at room temperature for 2 h. The reaction 
mixture was then slowly poured into 50 mL of satd aq NaHCO3 and then extracted with 
two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. Methyl (S)-2-amino-3-(1-tosyl-1H-pyrrolo[3,2-
b]pyridin-3-yl)propionate (2.16) was obtained as a yellow oil and was used directly in the 
next step without further purification. To a stirred  solution containing 165 mg (0.44 
mmol) of methyl (S)-2-amino-3-(1-tosyl-1H-pyrrolo[3,2-b]pyridin-3-yl) propionate 
(2.16) in 2 mL of  dioxane-water (1:1) was added 214 mg (1.55 mmol) of K2CO3 
followed by 123 mg (0.57 mmol) of NVOC-Cl. The reaction mixture was stirred at room 
temperature for 14 h under argon, then diluted with 50 mL of brine and extracted with 
two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)-
2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-tosyl-1H-pyrrolo[3,2-
b]pyridin-3-yl)propionate (2.17) as a yellow oil: yield 216 mg (33% for two steps); silica 
gel TLC Rf 0.50 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) 2.28 (s, 3H), 
3.26-3.28 (m, 2H), 3.53 (s, 3H), 3.72 (s, 3H), 3.86 (s, 3H), 4.60-4.62 (m, 1H), 5.36 (d, 
1H, J = 16 Hz), 5.55 (d, 1H, J = 16 Hz), 6.93 (s, 1H), 7.18-7.23 (m, 3H), 7.61-7.68 (m, 
3H), 7.78 (d, 1H, J = 7.2 Hz), 8.20 (d, 1H, J =8.0 Hz) and 8.47 (d, 1H, J = 4.4 Hz); 
13
C 
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NMR (CDCl3, 100 MHz)21.5, 26.8, 52.1, 54.6, 56.1, 56.3, 63.3, 107.9, 109.1, 118.4, 
119.5, 121.2, 126.6, 127.9, 128.7, 128.9, 130.1, 134.6, 139.1, 145.5, 145.7, 147.6, 147.7, 
153.7, 155.8 and 171.4; mass spectrum (APCI), m/z 613.1609 (M+H)
+
 (C28H29N4O10S 
requires m/z 613.1604). 
N
H
N
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[3,2-
b]pyridin-3-yl)propionate (2.18). To a stirred  solution containing 151 mg (0.25 mmol) 
of methyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-tosyl-1H-
pyrrolo[3,2-b]pyridin-3-yl)propionate (2.17) in 3 mL of  2:1 THF–methanol was added 
261 mg (0.74 mmol) of Cs2CO3. The reaction mixture was stirred at room temperature for 
2 h under argon, then diluted with 50 mL of brine and extracted with two 50-mL portions 
of EtOAc. The organic phase was dried (MgSO4) and concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (10 × 2 
cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)-2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[3,2-b]pyridin-3-yl)propionate (2.18) as a 
yellow oil: yield 42.0 mg (38%); silica gel TLC Rf 0.30 (1:1 hexanes–ethyl acetate); 
1
H 
NMR (CDCl3, 400 MHz) 3.36-3.38 (m, 2H), 3.60 (s, 3H),  3.76 (s, 3H), 3.90 (s, 3H), 
4.59-4.64 (m, 1H), 5.43 (d, 1H, J = 16 Hz), 5.65 (d, 1H, J = 16 Hz), 7.03 (s, 1H), 7.08-
7.12 (m, 1H), 7.23 (d, 1H, J = 2 Hz), 7.61-7.66 (m, 2H), 8.43 (d, 1H, J =4.4 Hz) and 8.63 
(d, 1H, J = 7.2 Hz); 
13
C NMR (CDCl3, 100 MHz) 27.1, 52.1, 55.9, 56.1, 56.3, 63.4, 
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107.8, 108.9, 110.9, 117.0, 119.1, 127.2 129.3, 129.4, 138.9, 142.2, 144.9, 147.6, 153.8, 
156.4 and 172.2; mass spectrum (APCI), m/z 459.1507 (M+H)
+
 (C21H23N4O8 requires m/z 
459.1516). 
N
H
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Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-
pyrrolo[3,2-b]pyridin-3-yl)propionate (2.19). To a stirred  solution containing 42.0 mg 
(0.09 mmol) of methyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-
pyrrolo[3,2-b]pyridin-3-yl) propionate (2.18) in 1 mL of 1:3:1 water–THF–methanol was 
added 275 µL (6.46 mg, 0.27 mmol) of 1 N LiOH. The reaction mixture was stirred at 
room temperature for 3 h, and then concentrated under diminished pressure. The residue 
was redissolved in 1 mL of anhydrous DMF under argon. To the stirred solution was 
added 38.0 µL (28.0 mg, 0.27 mmol) of Et3N followed by 17.0 L (20.0 mg, 0.27 mmol) 
of chloroacetonitrile. The reaction mixture was stirred at 23 °C for 16 h, and then diluted 
with 20 mL of EtOAc. The organic layer was washed with brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with ethyl acetate gave the expected product 
cyanomethyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-
pyrrolo[3,2-b]pyridin-3-yl)propionate (2.19) as a light yellow solid: yield 23.1 mg (52%);  
silica gel TLC Rf 0.5 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz)  3.45 (d, 
2H, J = 4.4 Hz), 3.75 (s, 3H), 3.92 (s, 3H), 4.52-4.75 (m, 3H), 5.44 (d, 1H, J = 16.0 Hz), 
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5.69 (d, 1H, J = 16.0 Hz), 7.03 (s, 1H), 7.14-7.17 (m, 1H), 7.03 (s, 1H), 7.69 (s, 2H), 8.45 
(d, 1H, J = 4.4 Hz) and 9.11 (d, 1H, J = 5.6 Hz); 
13
C NMR (CDCl3, 100 MHz) 27.4, 
48.5, 55.7, 56.3, 56.5, 63.7, 108.2, 109.1, 110.8, 114.3, 117.6, 119.2, 127.6, 129.46, 
129.49, 139.3, 142.8, 145.1, 147.9, 153.9, 156.4 and 170.4; mass spectrum (APCI), m/z 
484.1467 (M+H)
+
 (C22H22N5O8 requires m/z 484.1468).  
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 (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[3,2-
b]pyridin-3-yl)-pdCpA (2.1). To a solution containing 5.20 mg (4.0 μmol) of pdCpA 
tetrabutylammonium salt in 100 L of 9:1 anhydrous DMF–triethylamine was added 9.0 
mg (21 μmol) of cyanomethyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-
3-(1H-pyrrolo[3,2-b]pyridin-3-yl)propionate (2.19). The reaction mixture was sonicated 
for 6 h. The reaction mixture was purified by HPLC on a reversed phase column (C18, 10 
× 250 mm) using a linear gradient of 99:1 → 1:99 50 mM aq ammonium acetate (pH 
4.5)–acetonitrile. The retention time of the desired product was 21 min. The fractions 
containing the product were lyophilized to afford 2.1 as a colorless solid: yield 1.61 mg 
(42%); mass spectrum (ESI), m/z 1061.2188 (M-H)
- 
(C39H43N12O20P2 requires m/z 
1061.2192). 
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1-Tosyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (2.21). To a stirred solution 
containing 1.00 g (8.47 mmol) of 1H-pyrrolo[2,3-b]pyridine in 10 mL of 1:1 AcOH–H2O 
was added 1.78 g (12.7 mmol) of hexamethylenetetramine (HMTA). The reaction 
mixture was heated at reflux under argon overnight. The reaction mixture was cooled to 0 
°C and the formed precipitate was filtered and dried under vacuum. 1H-pyrrolo[2,3-
b]pyridine-3-carbaldehyde (2.20) was obtained as a colorless solid and was used directly 
in the next step without further purification. To a stirred solution containing 757 mg (5.17 
mmol) of 2.20 in 20 mL of anhydrous DMF at 0 °C was added 414 mg (10.4 mmol) of 
NaH. The reaction mixture was stirred at 0 °C for 10 min under argon, and then 1.48 g 
(7.76 mmol) of p-TsCl was added. The reaction mixture was stirred at 0 °C under argon 
for 3 h, diluted with 100 mL of satd aq NaHCO3 and extracted with two 50-mL portions 
of EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 4 cm). Elution with 4:1 hexanes–ethyl acetate gave 1-tosyl-1H-pyrrolo[2,3-
b]pyridine-3-carbaldehyde (2.21) as a yellow solid: yield 1.34 g (53% for two steps); 
silica gel TLC Rf 0.35 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz)  2.40 (s, 
3H), 7.27-7.34 (m, 3H), 8.16 (d, 2H, J = 8.4 Hz), 8.39 (s, 1H), 8.50 (d, 1H, J = 2.4 Hz), 
8.51 (d, 1H, J = 5.6 Hz) and 10.04 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) 21.8, 119.1, 
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119.5, 120.7, 120.8, 128.8, 130.1, 131.5, 134.4, 135.9, 146.5, 146.8 and 185.3; mass 
spectrum (APCI), m/z 301.0658 (M+H)
+
 (C15H13N2O3S requires m/z 301.0647). 
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3-Hydroxymethyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine (2.22). To a suspension of 1.34 g 
(4.46 mmol) of 1-tosyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (2.21) in 20 mL of 
EtOH was added 222 mg (8.92 mmol) of NaBH4 and the reaction mixture was stirred at 
room temperature for 2 h, then diluted with 100 mL of satd aq NaHCO3. The formed 
precipitate was filtered and dried under vacuum. 3-Hydroxymethyl-1-tosyl-1H-
pyrrolo[2,3-b]pyridine (2.22) was obtained as an off-white solid: yield 1.20 g (90%); 
silica gel TLC Rf 0.1 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz)  2.29 (s, 
3H), 4.75 (s, 2H), 7.10-7.20 (m, 3H), 7.62 (s, 1H), 7.88 (dd, 1H, J = 8.0 and 1.6 Hz), 7.99 
(d, 2H, J = 8.0 Hz) and 8.37 (dd, 1H, J = 4.4 and 1.6 Hz); 
13
C NMR (CDCl3, 100 MHz)  
21.7, 57.4, 118.8, 118.9, 122.0, 123.9 128.2, 128.7, 129.8, 135.5, 145.3, 145.4 and 147.8; 
mass spectrum (APCI), m/z 303.0805 (M+H)
+
 (C15H15N2O3S requires m/z 303.0803). 
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3-(Chloromethyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine (2.23). To a cooled (
_
10 °C) 
solution containing 1.20 g (3.9 mmol) of 3-hydroxymethyl-1-tosyl-1H-pyrrolo[2,3-
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b]pyridine (2.22) in 20 mL of anhydrous CH2Cl2  and 2.18 mL (1.58 g, 15.6 mmol) of 
Et3N was added dropwise 0.58 mL (947 mg, 7.93 mmol) of SOCl2. The reaction mixture 
was allowed to warm slowly to room temperature and was then stirred for 6 h, diluted 
with 50 mL of satd aq NaHCO3, and extracted with two 50-mL portions of EtOAc. The 
combined organic phase was dried (MgSO4) and concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution 
with 4:1 hexanes–ethyl acetate gave 3-(chloromethyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
(2.23) as a brown solid: yield 1.01 g (81%); silica gel TLC Rf 0.42 (4:1 hexanes–ethyl 
acetate); 
1
H NMR (CDCl3, 400 MHz)  2.33 (s, 3H), 4.69 (s, 2H), 7.18-7.25 (m, 3H), 
7.74 (s, 1H), 7.92 (d, 1H, J = 1.2 Hz), 7.94 (d, 1H, J = 1.6 Hz), 8.06 (d, 1H, J = 8.0 Hz) 
and 8.43 (dd, 1H, J = 4.8 and 1.2 Hz); 
13
C NMR (CDCl3, 100 MHz)  21.7, 37.5, 15.4, 
119.0, 121.5, 124.9, 128.2, 128.5, 129.8, 135.2, 145.5, 145.6 and 147.5; mass spectrum 
(APCI), m/z 321.0469 (M+H)
+
 (C15H14N2O2SCl requires m/z 321.0465). 
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3-(((2S,5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-
pyrrolo[2,3-b]pyridine (2.24). To a stirred solution containing 0.62 mL (650 mg, 3.53 
mmol) of Schöllkopf’s reagent in 10 mL of anhydrous THF at _78 °C was added 0.45 mL 
(308 mg, 4.82 mmol) of 2.5 M BuLi. The reaction mixture was stirred at 
_
78 °C for 30 
min under argon and then a solution containing 1.03 g (3.21 mmol) of  3-(chloromethyl)-
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1-tosyl-1H-pyrrolo[2,3-b]pyridine (2.23) in 10 mL of  anhydrous THF was added. The 
reaction mixture was stirred for 1 h under argon at 
_
78 °C, then diluted with 50 mL of 
satd aq NH4Cl and extracted with two 50-mL portions of EtOAc. The combined organic 
phase was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with 2:1 
hexanes–ethyl acetate gave 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-
yl)methyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine (2.24) as a yellow oil: yield 994 mg (66%); 
silica gel TLC Rf 0.15 (4:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz)  0.51(d, 
3H, J = 6.8 Hz), 0.78 (d, 3H, J = 8.0 Hz), 1.99-2.03 (m, 1H), 2.22 (s, 3H), 3.07-3.12 (m, 
3H), 3.57 (s, 3H), 3.60 (s, 3H), 4.22-4.25 (m, 1H), 7.02-7.05 (m, 1H), 7.13 (d, 1H, J = 8.0 
Hz), 7.36 (s, 1H), 7.74 (dd, 1H, J = 8.0 and 1.6 Hz), 7.87 (d, 2H, J = 8.4 Hz) and 8.29 
(dd, 1H, J = 4.8 and 1.6 Hz); 
13
C NMR (CDCl3, 100 MHz)  16.4, 18.8, 21.5, 29.1, 31.3, 
52.1, 52.3, 55.5, 60.4, 114.9, 118.3, 123.7, 124.6, 127.5, 128.2, 129.5, 135.5, 144.6, 
144.8, 147.1, 161.8 and 164.0; mass spectrum (APCI), m/z 469.1921 (M+H)
+
 
(C24H29N4O4S requires m/z 469.1909). 
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-tosyl-1H-
pyrrolo[2,3-b]pyridin-3-yl) (2.26). To a stirred solution containing 783 mg (1.67 mmol) 
of 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-
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pyrrolo[2,3-b]pyridine (2.24) in 20 mL of  THF at 0 °C was added 17.5 mL of 2 N aq 
HCl. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture 
was then slowly poured into 50 mL of satd aq NaHCO3 and then extracted with two 50-
mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. Methyl (S)-2-amino-3-(1-tosyl-1H-pyrrolo[2,3-
b]pyridin-3-yl)propionate (2.25) was obtained as a yellow oil and was used directly in the 
next step without further purification. To a stirred  solution containing 450 mg (1.20 
mmol) of methyl (S)-2-amino-3-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propionate (2.25) 
in 4 mL of  dioxane-water (1:1) was added 583 mg (4.22 mmol) of K2CO3 followed by 
336 mg (1.56 mmol) of NVOC-Cl. The reaction mixture was stirred at room temperature 
for 12 h under argon, then diluted with 50 mL of brine and extracted with two 50-mL 
portions of EtOAc. The combined organic phase was dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 4 cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)-2-((4,5-
dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-
yl)propionate (2.26) as a yellow oil: yield 588 mg (58% for two steps); silica gel TLC Rf 
0.45 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) 2.34 (s, 3H), 3.21-3.26 
(m, 2H), 3.68 (s, 3H),  3.91 (s, 3H), 3.94 (s, 3H), 4.67-4.72 (m, 1H), 5.47-5.56 (m, 2H), 
6.95 (s, 1H), 7.13-7.23 (m, 3H), 7.52 (s, 1H), 7.70 (s, 1H), 7.78 (d, 2H, J = 8.0 Hz), 8.01 
(d, 2H, J = 8.4 Hz) and 8.40 (d, 1H, J = 4.4 Hz); 
13
C NMR (CDCl3, 100 MHz) 21.7, 
28.1, 52.8, 54.1, 56.5, 56.6, 64.1, 108.3, 110.1, 113.4, 118.9, 123.0, 124.6, 127.7, 127.9, 
128.0, 128.1,129.7, 135.4, 139.7, 145.4, 147.3, 148.3, 153.8, 155.3 and 171.6; mass 
spectrum (APCI), m/z 613.1613 (M+H)
+
 (C28H29N4O10S requires m/z 613.1604).  
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[2,3-
b]pyridin-3-yl)propionate (2.27). To a stirred solution containing 331 mg (0.54 mmol) 
of methyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-tosyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)propionate (2.26) in 6 mL of  2:1 THF–methanol was added 
572 mg (1.62 mmol) of Cs2CO3. The reaction mixture was stirred at room temperature for 
3 h under argon, then diluted with 50 mL of brine and extracted with two 50-mL portions 
of EtOAc. The organic phase was dried (MgSO4) and concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (10 × 2 
cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)-2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propionate (2.27) as a 
yellow oil: 28.0 mg (15%); silica gel TLC Rf 0.2 (1:1 hexanes–ethyl acetate); 
1
H NMR 
(CDCl3, 400 MHz) 3.27-3.28 (m, 1H), 3.65-3.66 (m, 1H), 3.70 (s, 3H), 3.73 (s, 3H), 
3.88 (s, 3H), 4.76-4.80 (m, 1H), 5.44 (d, 1H, J = 15.2 Hz), 5.59 (d, 1H, J = 15.2 Hz), 
6.47-6.51 (m, 1H), 6.93-7.01 (m, 3H), 7.65 (s, 1H), 7.78-7.82 (m, 1H), 8.21 (d, 1H, J 
=3.6 Hz) and 10.70 (br s, 1H); 
13
C NMR (CDCl3, 100 MHz) 28.1, 52.5, 54.6, 56.1, 
56.3, 63.8, 108.0, 109.8, 115.5, 120.1, 123.9, 127.1 128.2, 139.5, 142.5, 142.6, 148.0, 
148.5, 153.6, 155.6 and 172.7; mass spectrum (APCI), m/z 459.1521 (M+H)
+
 
(C21H23N4O8 requires m/z 459.1516).  
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Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-
pyrrolo[2,3-b]pyridin-3-yl)propionate (2.28). To a stirred solution containing 25.0 mg 
(0.05 mmol) of 2.27 in 1 mL of 1:3:1 water–THF–methanol was added 150 µL (0.15 
mmol) of 1 N LiOH. The reaction mixture was stirred at room temperature for 3 h, and 
then concentrated under diminished pressure. The residue was redissolved into 1 mL of 
anhydrous DMF and 23.0 µL (17.0 mg, 0.15 mmol) of Et3N was added followed by 10.0 
L (11.2 mg, 0.15 mmol) of chloroacetonitrile. The reaction mixture was stirred at 23 °C 
for 16 h and then diluted with 20 mL of EtOAc. The organic layer was washed with 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with ethyl acetate 
gave cyanomethyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-
pyrrolo[2,3-b]pyridin-3-yl)propionate (2.28) as a light yellow solid: yield 19.0 mg (73%); 
silica gel TLC Rf 0.45 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) 3.33-
3.34 (m, 1H), 3.69 (s, 1H), 3.80 (s, 3H),  3.92 (s, 3H), 4.67-4.88 (m, 3H), 5.47 (d, 1H, J = 
14.8 Hz), 5.58 (d, 1H, J = 14.8 Hz), 6.25 (s, 1H), 6.93 (s, 1H), 7.00-7.03 (m, 1H), 7.15 (s, 
1H), 7.67 (s, 1H), 7.82 (d, 1H, J = 7.6 Hz), 8.22 (d, 1H, J = 4.0 Hz) and 10.70 (br s, 1H); 
13
C NMR (CDCl3, 100 MHz)28.0, 49.2, 54.7, 56.5, 64.2, 107.5, 108.3, 110.3, 114.0, 
116.0, 120.1, 124.1, 127.1, 127.7, 139.8, 143.1, 148.5, 153.7, 155.6 and 171.2; mass 
spectrum (APCI), m/z 484.1462 (M+H)
+
 (C22H22N5O8 requires m/z 484.1468).  
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(S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[2,3-
b]pyridin-3-yl)-pdCpA (2.2). To a solution containing 5.20 mg (4.0 μmol) of pdCpA 
tetrabutylammonium salt in 100 L of 9:1 anhydrous DMF–triethylamine was added 9.0 
mg (21 μmol) of cyanomethyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-
3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propionate (2.28). The reaction mixture was sonicated 
for 6 h. The reaction mixture was purified by HPLC on a reversed phase column (C18, 10 
× 250 mm) using a linear gradient of 99:1 → 1:99 50 mM aq ammonium acetate (pH 
4.5)–acetonitrile. The retention time of the desired product was 21 min. The fractions 
containing the product were lyophilized to afford 2.2 as a colorless solid: yield 2.50 mg 
(66%); mass spectrum (ESI), 1061.2185 (M-H)
- 
(C39H43N12O20P2 requires m/z 
1061.2192). 
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3-(((2S, 5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1H-
pyrrolo[3,2-b]pyridine (2.29). To a stirred  solution containing 309 mg (0.66 mmol) of  
3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-
pyrrolo[3,2-b]pyridine (2.15) in 5 mL of  2:1 THF–methanol was added 699 mg (1.98 
mmol) of Cs2CO3. The reaction mixture was stirred at room temperature for overnight 
under argon. The reaction mixture was diluted with 20 mL of brine and extracted with 
portions of two 20-mL portions of EtOAc. The organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 4 cm). Elution with ethyl acetate gave the expected product 3-
(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1H-pyrrolo[3,2-
b]pyridine (2.29) as a yellow oil: yield 141 mg (68%); silica gel TLC Rf 0.2 (1:1 
hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) 0.63 (d, 3H, J = 6.8 Hz), 0.94 (d, 
3H, J = 7.2 Hz), 2.13-2.15 (m, 1H), 3.29-3.32 (m, 1H), 3.49-3.50 (m, 1H), 3.61 (s, 3H), 
3.63 (s, 3H), 4.40-4.41 (m, 1H), 7.02-7.05 (m, 3H), 7.33 (s, 1H), 7.62 (d, 1H, J = 8.0 Hz), 
8.45 (d, 1H, J = 4.4 Hz) and 10.19 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) 16.7, 19.2, 
28.6, 31.7, 52.4, 52.5, 56.5, 60.7, 112.5, 116.6, 118.2, 126.7, 128.8, 142.6, 145.9, 163.6 
and 163.7; mass spectrum (APCI), m/z 315.1822 (M+H)
+
 (C17H23N4O2 requires m/z 
315.1821). 
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3-(((2S, 5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-methyl-
1H-pyrrolo[3,2-b]pyridine (2.30). To a stirred  solution containing 140 mg (0.45 mmol) 
of 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1H-
pyrrolo[3,2-b]pyridine (2.29) in 3 mL of  anhydrous DMF at 0 °C was added 21.4 mg 
(0.89 mmol) of NaH followed by 0.06 mL (127 mg, 0.89 mmol) of MeI. The reaction 
mixture was stirred at 0 °C under argon for 1 h. The reaction mixture was diluted with 
100 mL of satd aq NaHCO3, extracted with portions of two 20-mL portions of EtOAc and 
then dried under diminished pressure. The residue was purified by chromatography on a 
silica gel column (10 × 2 cm). Elution with ethyl acetate gave the expected product 3-
(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-methyl-1H-
pyrrolo[3,2-b]pyridine (2.30) as a yellow oil: yield 108 mg (74%); silica gel TLC Rf 0.3 
(1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) 0.62 (d, 3H, J = 6.8 Hz), 0.95 
(d, 3H, J = 6.8 Hz), 2.12-2.16 (m, 1H), 3.14-3.20 (m, 1H), 3.50-3.55 (m, 1H), 3.59-3.60 
(m, 1H), 3.61 (s, 3H), 3.66 (s, 3H), 3.68 (s, 3H), 4.31-4.33 (m, 1H), 7.01-7.04 (m, 1H), 
7.06 (s, 1H), 7.47 (d, 1H, J = 8.0 Hz) and 8.41 (d, 1H, J = 4.4 Hz); 
13
C NMR (CDCl3, 100 
MHz) 16.6, 19.1, 28.5, 31.7, 32.8, 52.3, 52.4, 56.5, 60.7, 111.7, 115.9, 116.0, 129.5, 
130.5, 142.3, 146.1, 163.5 and 163.6; mass spectrum (APCI), m/z 329.1974 (M+H)
+
 
(C18H25N4O2 requires m/z 329.1977).  
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-methyl-1H-
pyrrolo[3,2-b]pyridin-3-yl)propionate (2.32). To a stirred  solution containing 107 mg 
(0.33 mmol) of 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-
1-methyl-1H-pyrrolo[3,2-b]pyridine (2.30) in 4 mL of THF at 0 °C was added 4 mL of 2 
N aq HCl. The reaction mixture was stirred at room temperature for 2 h. The reaction 
mixture was then slowly poured into 50 mL of satd aq NaHCO3 and then extracted with 
two 50-mL portions of EtOAc. The organic phase was dried (MgSO4) and concentrated 
under diminished pressure. Methyl (S)-2-amino-3-(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-
yl)propionate (2.31) was obtained as a yellow oil and was used directly in the next step 
without further purification. To a stirred  solution containing 27.0 mg (0.12 mmol) of 
methyl (S)-2-amino-3-(1-tosyl-1H-pyrrolo[3,2-b]pyridin-3-yl)propionate (2.31) in 2 mL 
of  dioxane-water (1:1) was added 56.0 mg (0.41 mmol) of K2CO3 followed by 39.1 mg 
(0.18 mmol) of NVOC-Cl. The reaction mixture was stirred at room temperature for 14 h 
under argon then diluted with 50 mL of brine and extracted with two 50-mL portions of 
EtOAc. The organic phase was dried (MgSO4) and concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (10 × 2 
cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)- 2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonylamino)-3-(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)propionate 
(2.32) as a yellow oil: yield 33.0 mg (25% over two steps); silica gel TLC Rf 0.1 (1:1 
hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) 3.29-3.31 (m, 2H), 3.60 (s, 3H), 
3.69 (s, 3H), 3.72 (s, 3H), 3.84 (s, 3H), 4.55-4.56 (m, 1H), 5.38 (d, 1H, J = 16.0 Hz), 5.60 
(d, 1H, J = 16 Hz), 6.99 (s, 1H), 7.06-7.09 (m, 2H), 7.55 (d, 1H, J = 8.0 Hz), 7.61 (s, 1H), 
8.38 (d, 1H, J = 4.4 Hz) and 8.60 (d, 1H, J = 7.2 Hz); 
13
C NMR (CDCl3, 100 MHz)
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27.0, 32.7, 51.9, 55.7, 56.1, 56.2, 63.1, 107.8, 108.9, 110.0, 116.6, 116.9, 129.5, 130.1, 
131.2, 138.9, 141.9, 145.2, 147.5, 153.8, 156.1 and 171.9; mass spectrum (APCI), m/z 
473.1682 (M+H)
+
 (C22H25N4O8 requires m/z 473.1672).  
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Cyanomethyl (S)- 2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-methyl-
1H-pyrrolo[3,2-b]pyridin-3-yl)propionate (2.33). To a stirred  solution containing 32.0 
mg (0.07 mmol) of methyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-
methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)propionate (2.32) in 1 mL of 1:3:1 water–THF–
methanol was added 214 µL (0.21 mmol) of 1 N LiOH. The reaction mixture was stirred 
at room temperature for 3 h, and then concentrated under diminished pressure. The 
residue was redissolved into 1 mL of anhydrous DMF and 30.0 µL (22.1 mg, 0.21mmol) 
of Et3N was added followed by 13.0 L (16.2 mg, 0.21 mmol) of chloroacetonitrile. The 
reaction mixture was stirred at 23 °C for 16 h and then diluted with 20 mL of EtOAc. The 
organic layer was washed with brine, dried (MgSO4) and concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (10 × 2 
cm). Elution with ethyl acetate gave cyanomethyl (S)-2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonylamino)-3-(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)propionate 
(2.33) as a light yellow solid: yield 18.0 mg (52%); silica gel TLC Rf 0.2 (1:1 hexanes–
ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) 3.42 (d, 2H, J = 4.4 Hz), 3.74 (s, 3H),  3.76 
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(s, 3H), 3.92 (s, 3H), 4.52-4.73 (m, 3H), 5.44 (d, 1H, J = 16 Hz), 5.69 (d, 1H, J = 16 Hz), 
7.03 (s, 1H), 7.14-7.18 (m, 2H), 7.63 (dd, 1H, J =8.0 and 1.2 Hz), 7.69 (s, 1H) and 8.33 
(dd, 1H, J = 4.8 and 1.2 Hz); 
13
C NMR (CDCl3, 100 MHz) 27.9, 32.9, 48.4, 55.5, 56.3, 
56.5, 63.6, 108.1, 109.1, 109.2, 114.4, 116.9, 117.3, 129.5, 130.5, 132.0, 139.2, 142.2, 
145.3, 147.8, 153.9, 156.4 and 170.3; mass spectrum (APCI), m/z 498.1635 (M+H)
+
 
(C23H24N5O8 requires m/z 498.1625). 
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(S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-methyl-1H-
pyrrolo[3,2-b]pyridin-3-yl)-pdCpA (2.3). To a solution containing 5.20 mg (4.0 μmol) 
of pdCpA tetrabutylammonium salt in 100 L of 9:1 anhydrous DMF–triethylamine was 
added 10.4 mg (21 μmol) of cyanomethyl (S)-2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonylamino)-3-(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)propionate 
(2.33). The reaction mixture was sonicated for 6 h. The reaction mixture was purified by 
HPLC on a reversed phase column (C18, 10 × 250 mm) using a linear gradient of 99:1 → 
1:99 50 mM aq ammonium acetate (pH 4.5)–acetonitrile. The retention time of the 
desired product was 23.7 min. The fractions containing the product were lyophilized to 
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afford 2.3 as a colorless solid: yield 1.60 mg (39%); mass spectrum (ESI), 1075.2357 (M-
H)
- 
(C40H45N12O20P2 requires m/z 1075.2348). 
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3-(((2S, 5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1H-
pyrrolo[2,3-b]pyridine (2.34). To a stirred solution containing 303 mg (0.65 mmol) of  
3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-
pyrrolo[2,3-b]pyridine (2.24) in 5 mL of  2:1 THF–methanol was added 685 mg (1.94 
mmol) of Cs2CO3. The reaction mixture was stirred at room temperature for 12 h under 
argon, then diluted with 20 mL of brine and extracted with two 50-mL portions of 
EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with ethyl acetate gave 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-
dihydropyrazin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridine (2.34) as a yellow oil: yield 77.0 
mg (39%); silica gel TLC Rf 0.3 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) 
 0.60 (d, 3H, J = 6.8 Hz), 0.91 (d, 3H, J = 6.8 Hz), 2.10-2.13 (m, 1H), 3.26-3.29 (m, 
2H), 3.36-3.38 (m, 1H), 3.65 (s, 3H), 3.68 (s, 3H), 4.34-4.35 (m, 1H), 7.02 (dd, 1H, J = 
4.4 and 4.4 Hz), 7.08 (s, 1H), 7.95 (d, 1H, J = 6.8 Hz), 8.26 (d, 1H, J = 4.8 Hz) and 11.52 
(s, 1H); 
13
C NMR (CDCl3, 100 MHz) 16 .5, 19.0, 29.7, 31.4, 52.3, 52.4, 56.7, 60.5, 
 78 
 
109.8, 114.5, 121.3 123.9, 127.8, 142.0, 148.8, 162.8 and 163.9; mass spectrum (APCI), 
m/z 315.1829 (M+H)
+
 (C17H23N4O2 requires m/z 315.1821). 
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3-(((2S, 5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-methyl-
1H-pyrrolo[2,3-b]pyridine (2.35). To a stirred solution containing 76.0 mg (0.24 mmol) 
of 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1H-
pyrrolo[2,3-b]pyridine (2.34) in 3 mL of  anhydrous DMF at 0 °C was added 11.5 mg 
(0.48 mmol) of NaH followed by 0.03 mL (69.0 mg, 0.48 mmol) of MeI. The reaction 
mixture was stirred at 0 °C under argon for 30 min, then diluted with 100 mL of satd aq 
NaHCO3 and extracted with two 50-mL portions of EtOAc. The combined organic phase 
was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with ethyl acetate 
gave 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-methyl-
1H-pyrrolo[2,3-b]pyridine (2.35) as a yellow oil: yield 68.0 mg (83%); silica gel TLC Rf 
0.4 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz)  0.59 (d, 3H, J = 6.8 Hz), 
0.91 (d, 3H, J = 7.2 Hz), 2.09-2.13 (m, 1H), 3.22 (d, 2H, J = 4.4 Hz), 3.40-3.41 (m, 1H), 
3.62 (s, 3H), 3.66 (s, 3H), 3.79 (s, 3H), 4.28-4.29 (m, 1H), 6.86 (s, 1H), 6.95-6.98 (m, 
1H), 7.87 (dd, 1H, J = 8.0 and 1.6 Hz) and 8.25 (dd, 1H, J = 8.4 and 1.6 Hz); 
13
C NMR 
(CDCl3, 100 MHz)  16.6, 19.1, 29.6, 31.1, 31.5, 52.2, 52.3, 56.7, 60.6, 108.9, 114.8, 
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121.3, 127.6, 127.7, 142.6, 147.7, 162.8 and 163.9; mass spectrum (APCI), m/z 329.1977 
(M+H)
+
 (C18H25N4O2 requires m/z 329.1977). 
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-methyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)propionate (2.37). To a stirred solution containing 67.0 mg 
(0.21 mmol) of 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-
1-methyl-1H-pyrrolo[2,3-b]pyridine (2.35) in 4 mL of THF at 0 °C was added 4 mL of 2 
N aq HCl. The reaction mixture was stirred at room temperature for 2 h. The reaction 
mixture was then poured slowly into 30 mL of satd aq NaHCO3 and then extracted with 
two 30-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. Methyl (S)-2-amino-3-(1-methyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)propionate was obtained as a yellow oil and was used directly 
in the next step without further purification. To a stirred solution containing 36.0 mg 
(0.15 mmol) of methyl (S)-2-amino-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-
yl)propionate (2.36) in 2 mL of 1:1 dioxane–water was added 75.0 mg (0.54 mmol) of 
K2CO3 followed by 52.0 mg (0.24 mmol) of NVOC-Cl. The reaction mixture was stirred 
at room temperature for 14 h under argon, then diluted with 50 mL of brine and extracted 
with two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 1:3 hexanes–ethyl acetate gave methyl (S)-
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2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-methyl-1H-pyrrolo[2,3-
b]pyridin-3-yl)propionate (2.37) as a yellow oil: yield 58.0 mg (62% for two steps); silica 
gel TLC Rf 0.3 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz)  3.24-3.26 (m, 
2H), 3.66 (s, 3H), 3.78 (s, 3H), 3.83 (s, 3H), 3.88 (s, 3H), 4.65-4.67 (m, 1H), 5.46 (d, 1H, 
J = 8 Hz), 5.57 (d, 1H, J = 8.4 Hz), 6.88 (s, 1H), 6.96-6.99 (m, 2H), 7.63 (s, 1H), 7.76 (d, 
1H, J = 7.2 Hz), 8.27 (dd, 1H, J = 4.8 and 1.2 Hz) and 8.60 (d, 1H, J = 7.2 Hz); 
13
C NMR 
(CDCl3, 100 MHz)  27.9, 31.1, 52.5, 54.5, 56.4, 56.4, 63.9, 106.8, 108.1, 110.0, 115.3, 
120.3, 126.8, 127.7, 127.8, 139.6, 143.1, 147.8, 148.0, 153.6, 155.3 and 172.2; mass 
spectrum (APCI), m/z 473.1673 (M+H)
+
 (C22H25N4O8 requires m/z 473.1672). 
                                  
N N
HN
O
O
O
O
NO2
O
ONC
 
Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-methyl-
1H-pyrrolo[2,3-b]pyridin-3-yl)propionate (2.38). To a stirred solution containing 31.0 
mg (0.07 mmol) of methyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-
methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propionate (2.37) in 1 mL of 1:3:1 water–THF–
methanol was added 214 µL (5.03 mg, 0.21 mmol) of 1 N LiOH. The reaction mixture 
was stirred at room temperature for 3 h, and then concentrated under diminished pressure.  
The residue was dissolved in 1 mL of anhydrous DMF and 30.0 µL (22.0 mg, 0.21  
mmol) of Et3N was added followed by 13.0 µL (16.0 mg, 0.21 mmol) of 
chloroacetonitrile. The reaction mixture was stirred at 23 °C for 16 h, then diluted with 
20 mL of satd aq NaHCO3 and extracted with two 50-mL portions of EtOAc. The 
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combined organic phase was dried (MgSO4) and concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution 
with ethyl acetate gave cyanomethyl (S)-2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonylamino)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propionate 
(2.38) as a light yellow solid: yield 22.1 mg (71%); silica gel TLC Rf 0.4 (1:1 hexanes–
ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) 3.32 (d, 2H, J = 5.6 Hz), 3.84 (s, 3H), 3.89 
(s, 3H), 3.93 (s, 3H), 4.62-4.81 (m, 3H), 5.43-5.55 (m, 2H), 6.90 (s, 1H), 7.04-7.07 (m, 
2H), 7.69 (s, 1H), 7.83 (d, 1H, J = 7.6 Hz) and 8.33 (dd, 1H, J = 4.8 and 1.6 Hz); 
13
C 
NMR (CDCl3, 100 MHz)   27.9, 31.3, 49.1, 54.6, 56.5, 56.6, 64.3, 105.9, 108.3, 110.3, 
113.9, 115.7, 120.2, 126.8, 127.5, 128.1, 139.9, 143.5, 147.9, 148.4, 153.7, 155.4 and 
170.7; mass spectrum (APCI), m/z 498.1638 (M+H)
+
 (C23H24N5O8 requires m/z 
498.1625). 
                                            
N
NN
N
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(S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-methyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)pdCpA (3.4). To a solution containing 5.20 mg (4.00 μmol) 
of pdCpA tetrabutylammonium salt in 100 µL of 9:1 anhydrous DMF–triethylamine was 
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added 10.4 mg (21.0 μmol) of cyanomethyl (S)-2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonylamino)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propionate 
(2.38). The reaction mixture was sonicated for 2 h. The reaction mixture was purified by 
HPLC on a C18 reversed phase column (250 × 10 mm) using a linear gradient of 99:1 → 
1:99 50 mM aq ammonium acetate (pH 4.5) – acetonitrile. The retention time of the 
desired product was 23.4 min. The fractions containing the product were lyophilized to 
afford 2.4 as a colorless solid: yield 1.30 mg (31%); mass spectrum (ESI), 1075.2356 (M-
H)
- 
(C40H45N12O20P2 requires m/z 1075.2348). 
N
NH2
 
4-Aminoisoquinoline (2.39). To a stirred suspension containing 2.50 g (12.0 mmol) of 4-
bromoisoquinoline in 20 mL of conc NH4OH were added 38.0 mg (0.60 mmol) of Cu 
followed by 59.0 mg (0.60 mmol) of CuCl. The reaction mixture was heated at 100 °C in 
a high pressure tube for overnight. The cooled reaction mixture was diluted with 20 mL 
of water and extracted with three 40-mL portions of ethyl acetate. The combined organic 
solution was dried (MgSO4) and concentrated under diminished pressure. The residue 
was purified by chromatography on a silica gel column (10 × 5 cm). Elution with 10:1 
ethyl acetate–methanol gave the desired product 2.39 as a brown solid: yield 1.30 g 
(74%); mp 107-108 °C; silica gel TLC Rf 0.3 (10:1 ethyl acetate–methanol); 
1
H 
NMR(CD3OD, 500 MHz)  5.31 (br s, 2H), 7.26-7.29 (m, 1H), 7.37-7.40 (m, 1H), 7.58 
(d, 1H, J = 8.0 Hz), 7.85-7.90 (m, 2H) and 8.36 (s, 1H); 
13
C NMR( CD3OD, 125 MHz) 
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121.7, 126.9, 127.0, 128.2, 128.4, 129.88, 129.91, 140.6 and 141.5; mass spectrum 
(APCI), m/z 145.0769 (M+H)
+
 (C9H9N2 requires m/z 145.0766). 
N
NH2
I
 
4-Amino-3-iodoisoquinoline (2.40). To a stirred solution containing 1.76 g (6.94 mmol) 
of iodine in 60 mL of ethanol was added 2.60 g (8.33 mmol) of silver (I) sulfate. The 
reaction mixture was stirred at 23 °C for 5 min and then 1.00 g (6.94 mmol) of 4-
aminoisoquinoline (2.39) was added. The reaction mixture was stirred in the dark at 23 
°C for 16 h, then filtered and the filtrate was concentrated under diminished pressure. The 
residue was dissolved into 100 mL of ethyl acetate and washed with a satd aq solution of 
sodium thiosulfate. The organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 5 cm). Elution with 1:1 hexanes–ethyl acetate gave the desired product as a brown 
solid: yield 1.32 g (71%); mp 167-168 °C; silica gel TLC Rf 0.7 (1:1 hexanes–ethyl 
acetate); 
1
H NMR(CDCl3, 400 MHz)  4.59 (br s, 2H), 7.59-7.69 (m, 2H), 7.76 (d, 1H, J 
= 8.8 Hz), 7.88 (d, 1H, J = 8.0 Hz) and 8.49 (s, 1H); 
13
C NMR(CDCl3, 100 MHz) 99.8, 
120.6, 125.0, 127.8, 127.9, 128.5, 129.9, 138.6 and 142.9; mass spectrum (APCI), m/z 
270.9734 (M+H)
+
 (C9H8N2I requires m/z 270.9733).   
N
NH2 Si
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4-Amino-3-acetylenetrimethylsililisoquinoline (2.41). To a stirred solution containing 
742 mg (2.75 mmol) of 4-amino-3-iodoisoquinoline (2.40) in 20 mL of degassed THF 
were added 27.0 mg (0.14 mmol) of CuI followed by 98.0 mg (0.14 mmol) of 
Pd2Cl2(PPh3)2, 1.52 mL (11.0 mmol) of triethylamine and 0.78 mL (5.50 mmol) of 
trimethylsilylacetylene (TMSA). The reaction mixture was stirred at 23 °C for 16 h, then 
filtered and the filtrate was concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 4 cm). Elution with 4:1 
hexanes–ethyl acetate gave the desired product as a brown solid: yield 602 mg (91%); 
silica gel TLC Rf 0.2 (4:1 hexanes–ethyl acetate); 
1
H NMR(CDCl3, 500 MHz) 0.22 (s, 
9H), 4.98 (br s, 2H), 7.44-7.49 (m, 2H), 7.72-7.76 (m, 2H) and 8.53 (s, 1H); 
13
C 
NMR(CDCl3, 125 MHz)  -0.02, 100.6, 101.7, 118.5, 120.5, 124.7, 127.7, 127.8, 128.2, 
129.3, 140.6 and 142.2; mass spectrum (APCI), m/z 241.1160 (M+H)
+
 (C14H17N2Si 
requires m/z 241.1161).   
N
N
H
 
1H-Pyrrolo[3,2-c]isoquinoline (2.42). To a stirred solution containing 650 mg (2.70 
mmol) of 2.41 in 25 mL of anhydrous DMF was added 316 mg (8.10 mmol) of sodium 
amide and the reaction mixture was heated at 100 °C for 16 h. The cooled reaction 
mixture was then poured into 50 mL of water and extracted with three 30-mL portions of 
of ethyl acetate. The combined organic solution was dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 4 cm). Elution with ethyl acetate gave the expected product as a yellow 
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solid: yield 355 mg (78%); silica gel TLC Rf 0.4 (10:1 ethyl acetate–methanol); 
1
H 
NMR(CD3OD, 400 MHz)  6.65 (d, 1H, J = 3.2 Hz), 7.28-7.31 (m, 1H), 7.32 (d, 1H, J = 
3.2 Hz), 7.53-7.57 (m, 1H), 7.85 (d, 1H, J = 8.4 Hz), 8.05 (d, 1H, J = 8.4 Hz) and 8.70 (s, 
1H); 
13
C NMR( CD3OD, 100 MHz) 120.7, 124.2, 125.6, 125.8, 126.1, 129.8, 
130.0, 131.4, 140.2 and 146.6; mass spectrum (APCI), m/z 169.0763 (M+H)
+
 (C11H9N2 
requires m/z 169.0766).   
N
N
O
S
O
O
 
1-Tosyl-1H-pyrrolo[3,2-c]isoquinoline-3-carbaldehyde (2.44). To a stirred solution 
containing 719 mg (4.27 mmol) of 1H-pyrrolo[3,2-c]isoquinoline (2.42) in 7 mL of 1:1 
AcOH–H2O was added 900 mg (6.42 mmol) of hexamethylenetetramine (HMTA). The 
reaction mixture was heated at reflux under argon overnight. The cooled reaction mixture 
was diluted with 40 mL of water. The pH was adjusted to >12 and the reaction mixture 
was extracted with three 50-mL portions of EtOAc. The organic phase was dried 
(MgSO4) and concentrated under diminished pressure. 1H-Pyrrolo[3,2-c]isoquinoline-3-
carbaldehyde (2.43) was obtained as a light brown solid and was used directly in the next 
step without further purification. To a stirred solution containing 545 mg (2.78 mmol) of 
1H-pyrrolo[3,2-c]isoquinoline-3-carbaldehyde (2.43) in 20 mL of anhydrous DMF at 0 
°C was added 133 mg (5.56 mmol) of NaH. The reaction mixture was stirred at 0 °C for 
10 min under argon and then 1.06 g (5.56 mmol) of p-TsCl was added. The reaction 
mixture was stirred at 0 °C under argon for 3 h, diluted with 100 mL of satd aq NaHCO3 
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and extracted with two 50-mL portions of EtOAc. The combined organic phase was dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 4 cm). Elution with ethyl acetate gave 1-
tosyl-1H-pyrrolo[3,2-c]isoquinoline-3-carbaldehyde (2.44) as a yellow solid: yield 691 
mg (46% for two steps); silica gel TLC Rf 0.65 (1:2 hexanes–ethyl acetate); 
1
H 
NMR(CDCl3, 400 MHz)  2.25 (s, 3H), 7.16 (d, 2H, J = 8.4 Hz), 7.56 (t, 1H, J = 7.6 
Hz), 7.64 (d, 2H, J = 8.4 Hz), 7.72-7.76 (m, 1H), 8.00 (d, 1H, J = 8.0 Hz), 8.62 (s, 1H), 
8.95 (d, 1H, J = 8.8 Hz), 9.13 (s, 1H) and 10.50 (s, 1H); 
13
C NMR(CDCl3, 100 MHz)   
21.7, 121.3, 122.6, 123.5, 124.9, 126.5, 127.1, 127.2, 129.3, 130.4, 131.5, 134.1, 134.8, 
140.7, 146.5, 152.5 and 185.6; mass spectrum (APCI), m/z 351.0811 (M+H)
+
 
(C19H15N2O3S requires m/z 351.0803). 
N
N
HO
S
O
O
 
1-Tosyl-1H-pyrrolo[3,2-c]isoquinolin-3-yl)methanol (2.45). To a suspension of 690 mg 
 (1.97 mmol) of 1-tosyl-1H-pyrrolo[3,2-c]isoquinoline-3-carbaldehyde (2.44) in 10 mL of 
EtOH was added 149 mg (3.94 mmol) of NaBH4. The reaction mixture was stirred at 
room temperature for 2 h, diluted with 100 mL of satd aq NaHCO3 and extracted with 
two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 4 cm). Elution with ethyl acetate gave 1-tosyl-1H-pyrrolo[3,2-
c]isoquinolin-3-yl)methanol (2.45) as an off-white solid: yield 779 mg (96%); silica gel 
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TLC Rf 0.1 (1:1 hexanes–ethyl acetate); 
1
H NMR(CDCl3, 400 MHz) 2.25 (s, 3H), 5.06 
(s, 2H), 7.11 (d, 2H, J = 8.0 Hz), 7.53-7.56 (m, 1H), 7.59 (d, 2H, J = 8.4 Hz), 7.73-7.77 
(m, 1H), 7.98 (s, 1H), 8.00 (s, 1H), 9.00 (s, 1H) and 9.05 (d, 1H, J = 8.8 Hz); 
13
C 
NMR(CDCl3, 100 MHz) 122.9, 123.5, 125.7, 126.0, 126.8, 126.9, 128.6, 
129.3, 130.1, 131.2, 132.1, 135.1, 143.1, 145.5 and 150.7; mass spectrum (APCI), m/z 
353.0979 (M+H)
+
 (C19H17N2O3S requires m/z 353.0960). 
N
N
Cl
S
O
O
 
3-(Chloromethyl)-1-tosyl-1H-pyrrolo[3,2-c]isoquinoline (2.46). To a cooled (0 °C) 
solution containing 0.35 g (0.99 mmol) of 1-tosyl-1H-pyrrolo[3,2-c]isoquinolin-3-
yl)methanol (2.45) in 10 mL of anhydrous CH2Cl2  and 0.25 mL (0.18 g, 1.79 mmol) of 
Et3N was added dropwise 0.29 mL (177 mg, 1.5 mmol) of SOCl2. The reaction was left 
to warm slowly to room temperature and stirred for 2 h, then diluted with 50 mL of brine 
and extracted with two 50-mL portions of EtOAc. The combined organic phase was dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 4:1 hexanes–ethyl 
acetate gave 3-(chloromethyl)-1-tosyl-1H-pyrrolo[3,2-c]isoquinoline (2.46) as a yellow 
oil: yield 283 mg (77%); silica gel TLC Rf 0.7 (1:1 hexanes–ethyl acetate); 
1
H NMR 
(CDCl3, 400 MHz)  2.21 (s, 3H), 4.95 (s, 2H), 7.10 (d, 2H, J = 8.4 Hz), 7.52 (t, 1H, J = 
7.6 Hz), 7.58 (d, 2H, J = 8.4 Hz), 7.71-7.75 (m, 1H), 7.97 (d, 1H, J = 8.4 Hz), 8.10 (s, 
1H), 9.02 (d, 1H, J = 8.8 Hz) and 9.06 (s, 1H); 
13
C NMR(CDCl3, 100 MHz) 
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120.3, 122.7, 123.3, 125.4, 126.0, 126.81, 126.84, 128.7, 129.2, 130.1, 131.1, 134.8, 
141.9, 145.6 and 151.2; mass spectrum (APCI), m/z 371.0621 (M+H)
+
 (C19H16N2O2ClS 
requires m/z 371.0621). 
N
N
S
O
N
N
O
O
O
 
3-(((2S,5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-
pyrrolo[3,2-c]isoquinoline (2.47). To a stirred solution containing 0.15 mL (164 mg, 
0.89 mmol) of Schöllkopf’s reagent in 5 mL of anhydrous THF at _78 °C was added 0.11 
mL (78.0 mg, 1.22 mmol) of 2.5 M BuLi. The reaction mixture was stirred at 
_
78 °C for 
30 min under argon and then a solution containing 301 mg (0.81 mmol) of  3-
(chloromethyl)-1-tosyl-1H-pyrrolo[3,2-c]isoquinoline (2.46) in 5 mL of  anhydrous THF 
was added. The reaction mixture was left to warm slowly to room temperature and stirred 
for 30 min under argon, then diluted with 50 mL of satd aq NH4Cl and extracted with two 
50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 3:1 hexanes–ethyl acetate gave 3-(((2S,5R)-
5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-pyrrolo[3,2-
c]isoquinoline (2.47) as a yellow oil: yield 251 mg (60%); silica gel TLC Rf 0.65 (1:1 
hexanes–ethyl acetate); 1H NMR(CDCl3, 400 MHz) 0.64 (d, 3H, J = 6.8 Hz), 0.93 (d, 
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3H, J = 6.8 Hz), 2.12-2.16 (m, 1H), 2.18 (s, 3H), 3.24-3.29 (m, 1H), 3.50-3.58 (m, 2H), 
3.62 (s, 3H), 3.66 (s, 3H), 4.41-4.42 (m, 1H), 7.04 (d, 2H, J = 8.4 Hz), 7.44-7.54 (m, 3H), 
7.66-7.70 (m, 1H), 7.82 (s, 1H), 7.93 (d, 1H, J = 8.0 Hz), 9.01 (s, 1H) and 9.04 (t, 1H, J = 
8.8 Hz); 
13
C NMR(CDCl3, 100 MHz)   
 122.8, 125.5, 125.6, 126.6, 126.7, 128.4, 129.0, 129.9, 130.8, 135.3, 
144.4, 145.0, 150.6, 163.0 and 163.8; mass spectrum (APCI), m/z 519.2067 (M+H)
+
 
(C28H31N4O4S requires m/z 519.2066). 
N
N
NH2
O
O
S
O O
 
Methyl (S)-2-Amino-3-(1-tosyl-1H-pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.48). 
To a stirred  solution containing 251 mg (0.48 mmol) of 3-(((2S,5R)-5-isopropyl-3,6-
dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-pyrrolo[3,2-c]isoquinoline (2.47) 
in 10 mL of  THF at 0 °C was added 7 mL of 2 N aq HCl. The reaction mixture was 
stirred at room temperature for 2 h. The reaction mixture was then slowly poured into 50 
mL of satd aq NaHCO3 and then extracted with two 50-mL portions of EtOAc. The 
combined organic phase was dried (MgSO4) and concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution 
with 5:1 ethyl acetate–methanol gave methyl (S)-2-amino-3-(1-tosyl-1H-pyrrolo[3,2-
c]isoquinolin-3-yl)propionate (2.48) as a yellow oil: yield 150 mg (73%); silica gel TLC 
Rf 0.45 (1:1 ethyl acetate–methanol); 
1
H NMR(CD3OD, 400 MHz)  2.24 (s, 3H), 3.24-
3.29 (m, 1H), 3.33-3.38 (m, 1H), 3.68 (s, 3H), 4.04 (t, 1H, J = 6.4 Hz), 7.19 (d, 2H, J = 
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8.4 Hz), 7.56-7.60 (m, 3H), 7.76-7.80 (m, 1H), 7.98 (s, 1H), 8.09 (d, 1H, J = 8.0 Hz) and 
9.04-9.07 (m, 2H); 
13
C NMR(CD3OD, 100 MHz)  21.5, 30.0, 52.7, 55.2, 120.2, 123.9, 
124.6, 126.8, 127.3, 128.0, 128.1, 130.1, 130.5, 131.2, 132.4, 136.2, 144.5, 147.2, 151.9 
and 175.8; mass spectrum (APCI), m/z 424.1327 (M+H)
+
 (C22H22N3O4S requires m/z 
424.1331). 
N
N
HN
O
O
S
O O
O
O
NO2
O
O
 
Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-tosyl-1H- 
pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.49). To a stirred  solution containing 88.0 
mg (0.21 mmol) of methyl (S)-2-amino-3-(1-tosyl-1H-pyrrolo[3,2-c]isoquinolin-3-
yl)propionate (2.48) in 1 mL of  1:1 dioxane–water was added 101 mg (0.73 mmol) of 
K2CO3 followed by 59.0 mg (0.28 mmol) of NVOCCl. The reaction mixture was stirred 
at room temperature for 12 h under argon, then diluted with 50 mL of brine and extracted 
with two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)-
2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-tosyl-1H-pyrrolo[3,2-
c]isoquinolin-3-yl)propionate (2.49) as a yellow oil: yield 123 mg (90%); silica gel TLC 
Rf 0.45 (1:1 hexanes–ethyl acetate); 
1
H NMR(CDCl3, 400 MHz) 2.23 (s, 3H), 3.42-
3.43 (m, 2H), 3.59 (s, 3H), 3.68 (s, 3H), 3.87 (s, 3H), 4.68-4.70 (m, 1H), 5.49 (ABq, 2H, 
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J = 16 Hz), 6.90 (s, 1H), 7.11 (d, 2H, J = 8.4 Hz), 7.51-7.55 (m, 3H), 7.63 (s, 1H), 7.73-
7.74 (m, 2H), 7.87 (s, 1H), 7.97 (d, 1H, J = 8.0 Hz) and 9.01-9.04 (m, 2H); 
13
C 
NMR(CDCl3, 100 MHz)  21.5, 26.8, 52.3, 55.0, 56.1. 56.3, 63.5, 108.0, 109.2, 118.4, 
122.8, 123.4, 125.5, 126.1, 126.7, 128.5, 129.0, 129.15, 129.24, 130.1, 131.4, 134.9, 
139.2, 143.0, 145.6, 147.7, 150.5, 153,7, 155.9 and 171.7; mass spectrum (APCI), m/z 
663.1765 (M+H)
+
 (C32H31N4O10S requires m/z 663.1760). 
N
H
N
HN
O
O
O
O
NO2
O
O
 
Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[3,2-
c]isoquinolin-3-yl)propionate (2.50). To a stirred  solution containing 123 mg (0.19 
mmol) of methyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-tosyl-1H-
pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.49) in 3 mL of  2:1 THF–methanol was 
added 197 mg (0.56 mmol) of Cs2CO3. The reaction mixture was stirred at room 
temperature for 2 h under argon, then diluted with 50 mL of brine and extracted with two 
50-mL portions of EtOAc. The organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)-2-((4,5-dimethoxy-
2-nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.50) 
as a yellow solid: yield 69.1 mg (73%); silica gel TLC Rf 0.40 (1:1 hexanes–ethyl 
acetate); 
1
H NMR(DMSO-d6, 500 MHz) 3.19-3.23 (m, 1H), 3.38-3.41 (m, 1H), 3.61 (s, 
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3H), 3.74 (s, 3H), 3.85 (s, 3H), 4.53-4.57 (m, 1H), 5.34 (ABq, 2H, J = 15.0 Hz), 7.09 (s, 
1H), 7.43 (br s, 1H), 7.54 (t, 1H, J = 7.5 Hz), 7.68 (s, 1H), 7.79 (t, 1H, J = 7.5 Hz), 8.14 
(d, 1H, J = 8.0 Hz), 8.31 (d, 1H, J = 8.5 Hz), 8.39 (d, 1H, J = 7.5 Hz) and 8.97 (s, 1H); 
13
C NMR (DMSO-d6, 125 MHz) 
123.5, 124.1, 124.4, 124.5, 127.9, 128.5, 129.9, 138.2, 138.9, 
145.1, 147.5, 153.3, 155.4 and 172.3; mass spectrum (APCI), m/z 509.1682 (M+H)
+
 
(C25H25N4O8 requires m/z 509.1672). 
N
H
N
HN
O
O
O
O
NO2
O
ONC
 
Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-
pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.51). To a stirred  solution containing 26.0 
mg (0.05 mmol) of methyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-
(1H-pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.50) in 1 mL of 1:3:1 water–THF–
methanol was added 150 µL (0.15 mmol) of 1 N LiOH. The reaction mixture was stirred 
at room temperature for 2 h, then concentrated under diminished pressure. The residue 
was redissolved in 1 mL of anhydrous DMF under argon. To the stirred solution was 
added 20 µL (15.0 mg, 0.15 mmol) of Et3N followed by 10.0 µL (11.0 mg, 0.15 mmol) of 
chloroacetonitrile. The reaction mixture was stirred at 23 °C for 16 h and then diluted 
with 20 mL of satd aq NaHCO3 and extracted with two 50-mL portions of EtOAc. The 
combined organic phase was dried (MgSO4) and concentrated under diminished pressure. 
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The residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution 
with ethyl acetate gave cyanomethyl (S)-2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.51) 
as a light yellow solid: yield 14.0 mg (54%); silica gel TLC Rf 0.4 (1:1 hexanes–ethyl 
acetate); 
1
H NMR(DMSO-d6, 400 MHz) 3.24-3.30 (m, 1H), 3.38-3.43 (m, 1H), 3.75 (s, 
3H), 3.85 (s, 3H), 4.64-4.69 (m, 1H), 4.99 (s, 2H), 5.36 (ABq, 2H, J = 15.2 Hz), 7.10 (s, 
1H), 7.43-7.44 (m, 1H), 7.55 (t, 1H, J = 7.6 Hz), 7.69 (s, 1H), 7.78-7.82 (m, 1H), 8.14-
8.16 (m, 1H), 8.32 (d, 1H, J = 8.4 Hz), 8.53 (d, 1H, J = 7.6 Hz) and 8.98 (s, 1H); 
13
C 
NMR( DMSO-d6, 100 MHz) 
124.1, 124.5, 127.7, 128.5, 129.9, 138.1, 139.0, 
145.2, 147.6, 153.3, 155.4 and 171.0; mass spectrum (APCI), m/z 534.1634 (M+H)
+
 
(C26H24N5O8 requires m/z 534.1625).
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(S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[3,2-
c]isoquinolin-3-yl)-pdCpA (2.5). To a solution containing 5.20 mg (4.0 μmol) of pdCpA 
tetrabutylammonium salt in 100 µL of 9:1 anhydrous DMF–triethylamine was added 11.0 
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mg (21 μmol) of cyanomethyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-
3-(1H-pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.51). The reaction mixture was 
sonicated for 6 h. The reaction mixture was purified by HPLC on a reversed phase 
column (C18, 10 × 250 mm) using a linear gradient of 99:1 → 1:99 50 mM aq ammonium 
acetate (pH 4.5)–acetonitrile. The retention time of the desired product was 27.2 min. The 
fractions containing the product were lyophilized to afford 2.5 as a colorless solid: yield 
2.21 mg (55%); mass spectrum (ESI), m/z 1111.2344 (M-H)
- 
(C43H45N12O20P2 requires 
m/z 1111.2348). 
N
O
S
O
O
N
 
1-Tosyl-1H-pyrrolo[2,3-f]quinoline-3-carbaldehyde (2.53). To a stirred  solution 
containing 600 mg (3.59 mmol) of 1H-pyrrolo[2,3-f]quinoline in 7 mL of 1:1 AcOH–
H2O was added 754 mg (5.34 mmol) of HMTA. The reaction mixture was heated at 
reflux under argon overnight. The cooled reaction mixture was diluted with 40 mL of 
water. The pH was adjusted to >12 and the reaction mixture was extracted with three 50-
mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. 1H-pyrrolo[2,3-f]quinoline-3-carbaldehyde 
(2.52) was obtained as a light brown solid and was used directly in the next step without 
further purification. To a stirred  solution containing 545 mg (2.78 mmol) of 1H-
pyrrolo[2,3-f]quinoline-3-carbaldehyde (2.52) in 20 mL of anhydrous DMF at 0 °C was 
added 133 mg (5.56 mmol) of NaH. The reaction mixture was stirred at 0 °C for 10 min 
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under argon and then 1.06 g (5.56 mmol) of p-TsCl was added. The reaction mixture was 
stirred at 0 °C under argon for 3 h, diluted with 100 mL of satd aq NaHCO3 and extracted 
with two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with ethyl acetate gave 1-tosyl-1H-pyrrolo[2,3-
f]quinoline-3-carbaldehyde (2.53) as a colorless solid: yield 691 mg (55% for two steps); 
silica gel TLC Rf 0.6 (1:2 hexanes–ethyl acetate); 
1
H NMR(CDCl3, 400 MHz)  2.20 (s, 
3H), 7.11 (d, 2H, J = 8.4 Hz), 7.37 (dd, 1H, J = 8.8 and 4.4 Hz), 7.56 (d, 2H, J = 8.4 Hz), 
7.93 (d, 1H, J = 8.8 Hz), 8.49 (d, 1H, J = 8.8 Hz), 8.57 (s, 1H), 8.78 (dd, 1H, J = 4.4 and 
1.6 Hz), 9.28 (d, 1H, J = 8.8 Hz) and 10.11 (s, 1H); 
13
C NMR(CDCl3, 100 MHz) 
 121.0, 121.5, 123.3, 125.4, 127.0, 128.6, 130.0, 130.4, 131.6, 133.8, 139.3, 
146.4, 147.5, 149.0 and 185.6; mass spectrum (APCI), m/z 351.0812 (M+H)
+
 
(C19H15N2O3S requires m/z 351.0803). 
N
HO
S
O
O
N
 
 1-Tosyl-1H-pyrrolo[2,3-f]quinolin-3-yl)methanol (2.54). To a suspension of 690 mg 
(1.97 mmol) of 1-tosyl-1H-pyrrolo[2,3-f]quinoline-3-carbaldehyde (2.53) in 10 mL of 
EtOH was added 149 mg (3.94 mmol) of NaBH4. The reaction mixture was stirred at 
room temperature for 2 h, diluted with 100 mL of satd aq NaHCO3 and extracted with 
two 50-mL portions of EtOAc. The organic phase was dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a silica gel 
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column (10 × 4 cm). Elution with ethyl acetate gave 1-tosyl-1H-pyrrolo[2,3-f]quinolin-3-
yl)methanol (2.54) as an off-white solid: yield 569 mg (82%); silica gel TLC Rf 0.25 (1:2 
hexanes–ethyl acetate); 1H NMR(CDCl3, 400 MHz)  2.22 (s, 3H), 4.83 (s, 2H), 7.14 (d, 
2H, J = 8.0 Hz), 7.49-7.53 (m, 3H), 7.84 (d, 1H, J = 8.8 Hz), 7.95-7.97 (m, 2H), 8.72 (d, 
1H, J = 4.4 Hz) and 9.52 (d, 1H, J = 8.4 Hz); 
13
C NMR(5:1 CD3OD-CDCl3, 100 
MHz) 
and 148.9; mass spectrum (APCI), m/z 353.0965 
(M+H)
+
 (C19H17N2O3S requires m/z 353.0960).
N
Cl
S
O
O
N
 
3-(Chloromethyl)-1-tosyl-1H-pyrrolo[2,3-f]quinoline (2.55). To a cooled (0 °C) 
solution containing 0.35 g (0.99 mmol) of 1-tosyl-1H-pyrrolo[2,3-f] quinolin-3-
yl)methanol (2.54) in 10 mL of anhydrous CH2Cl2  and 0.25 mL (0.18 g, 1.79 mmol) of 
Et3N was added dropwise 0.29 mL (177 mg, 1.5 mmol) of SOCl2. The reaction mixture 
was allowed to warm slowly to room temperature and stirred for 2 h. The reaction 
mixture was then diluted with 50 mL of brine and extracted with two 50-mL portions of 
EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with 4:1 hexanes–ethyl acetate gave 3-(chloromethyl)-1-tosyl-1H-
pyrrolo[2,3-f] quinoline (2.55) as a yellow oil: yield 226 mg (62%); silica gel TLC Rf 
0.55 (1:2 hexanes–ethyl acetate); 1H NMR(CDCl3, 400 MHz)  2.01 (s, 3H), 4.72 (s, 
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2H), 6.92 (d, 2H, J = 8.4 Hz), 7.32 (dd, 1H, J = 8.8 and 4.4 Hz), 7.42 (d, 2H, J = 8.4 Hz), 
7.77 (d, 1H, J = 9.2 Hz), 7.86 (d, 1H, J = 9.2 Hz), 7.92 (s, 1H), 8.72 (d, 1H, J = 4.4 Hz) 
and 9.32 (d, 1H, J = 8.8 Hz); 
13
C NMR (CDCl3, 100 MHz) 21.2, 36.8, 118.9, 120.7, 
121.1, 126.5, 127.1, 127.7, 128.8, 129.7, 129.8, 131.6, 134.3, 145.3, 147.0 and 148.4; 
mass spectrum (APCI), m/z 371.0621 (M+H)
+
 (C19H16N2O2ClS requires m/z 371.0621). 
N
S
O
N
N
O
O
O
N
 
3-(((2S,5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-
pyrrolo[2,3-f]quinoline (2.56). To a stirred solution containing 0.15 mL (164 mg, 0.89 
mmol) of Schöllkopf’s reagent in 5 mL of anhydrous THF at _78 °C was added 0.11 mL 
(78.0 mg, 1.22 mmol) of 2.5 M BuLi. The reaction mixture was stirred at 
_
78 °C for 30 
min under argon and then a solution containing 300 mg (0.81 mmol) of  3-
(chloromethyl)-1-tosyl-1H-pyrrolo[2,3-f]quinoline (2.55) in 5 mL of anhydrous THF was 
added. The reaction mixture was allowed to warm slowly to room temperature and stirred 
under argon for 30 min. The reaction mixture was then diluted with 50 mL of satd aq 
NH4Cl and extracted with two 50-mL portions of EtOAc. The combined organic phase 
was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with 3:1 
hexanes–ethyl acetate gave 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-
yl)methyl)-1-tosyl-1H-pyrrolo[2,3-f]quinoline (2.56) as a yellow oil: yield 312 mg 
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(66%); silica gel TLC Rf 0.5 (1:2 hexanes–ethyl acetate); 
1
H NMR(CDCl3, 400 MHz) 
0.62 (d, 3H, J = 6.8 Hz), 0.91 (d, 3H, J = 6.8 Hz), 2.10-2.14 (m, 1H), 2.21 (s, 3H), 3.29-
3.31 (m, 2H), 3.39-3.41 (m, 1H), 3.65 (s, 3H), 3.69 (s, 3H), 4.36-4.39 (m, 1H), 7.04 (d, 
2H, J = 8.0 Hz), 7.36-7.42 (m, 3H), 7.68 (s, 1H), 7.87 (s, 2H), 8.78 (d, 1H, J = 4.4 Hz) 
and 9.46 (d, 1H, J = 8.8 Hz); 
13
C NMR(CDCl3, 100 MHz) 
118.9, 120.7, 122.5, 126.4, 126.6, 129.0, 129.3, 129.9, 
130.6, 132.0, 135.0, 145.1, 147.2, 148.2, 162.3 and 164.1; mass spectrum (APCI), m/z 
519.2059 (M+H)
+
 (C28H31N4O4S requires m/z 519.2066).
N
NH2
O
O
S
O O
N
 
Methyl (S)-2-Amino-3-(1-tosyl-1H-pyrrolo[2,3-f]quinolin-3-yl)propionate (2.57). To 
a stirred  solution containing 249 mg (0.47 mmol) of 3-(((2S,5R)-5-isopropyl-3,6-
dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-pyrrolo[2,3-f]quinoline (2.56) in 
10 mL of THF at 0 °C was added 7 mL of 2 N aq HCl. The reaction mixture was stirred 
at room temperature for 2 h, slowly poured into 50 mL of satd aq NaHCO3 and extracted 
with two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 5:1 ethyl acetate–methanol gave methyl (S)-
2-amino-3-(1-tosyl-1H-pyrrolo[2,3-f]quinolin-3-yl)propionate (2.57) as a yellow oil: 
yield 174 mg (84%); silica gel TLC Rf 0.35 (1:1 ethyl acetate–methanol); 
1
H NMR
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(CD3OD, 500 MHz) 2.26 (s, 3H), 3.17-3.27 (m, 2H), 3.64 (s, 3H), 3.89 (t, 1H, J = 6.5 
Hz), 7.19 (d, 2H, J = 8.5 Hz), 7.53 (d, 2H, J = 8.5 Hz), 7.55-7.56 (m, 1H), 7.87-7.94 (m, 
3H), 8.75 (dd, 1H, J = 4.5 Hz, J = 1.5 Hz) and 9.54 (d, 1H, J = 9.0 Hz); 
13
C 
NMR(CD3OD, 125 MHz) 
126.9, 128.0, 130.6, 131.2, 131.4, 134.2, 135.9, 147.3, 147.8, 149.3 and 175.8; 
mass spectrum (APCI), m/z 424.1337 (M+H)
+
 (C22H22N3O4S requires m/z 424.1331).
N
HN
O
O
S
O O
O
O
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-tosyl-1H-
pyrrolo[2,3-f]quinolin-3-yl)propionate (2.58). To a stirred solution containing 88.0 mg 
(0.21 mmol) of methyl (S)-2-amino-3-(1-tosyl-1H-pyrrolo[2,3-f]quinolin-3-yl)propionate 
(2.57) in 1 mL of  dioxane–water was added 101 mg (0.73 mmol) of K2CO3 followed by 
59.0 mg (0.28 mmol) of NVOCCl. The reaction mixture was stirred at room temperature 
for 12 h under argon, then diluted with 50 mL of brine and extracted with two 50-mL 
portions of EtOAc. The combined organic phase was dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 2 cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)-2-((4,5-
dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-tosyl-1H-pyrrolo[2,3-f]quinolin-3-
yl)propionate (2.58) as a yellow oil: yield 126 mg (92%); silica gel TLC Rf 0.4 (1:1 
hexanes–ethyl acetate); 1H NMR(CDCl3, 400 MHz) 2.16 (s, 3H), 3.24-3.30 (m, 1H), 
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3.33-3.38 (m, 1H), 3.68 (s, 3H), 3.72 (s, 3H), 3.85 (s, 3H), 4.75-4.77 (m, 1H), 5.47 (ABq, 
2H, J = 15.2 Hz), 6.12 (d, 1H, J = 8.0 Hz), 6.89 (s, 1H), 7.02 (d, 2H, J = 8.4 Hz), 7.33-
7.40 (m, 3H), 7.60 (s, 1H), 7.68 (d, 1H, J = 9.2 Hz), 7.74 (s, 1H), 7.82 (d, 1H, J = 8.8 
Hz), 8.71-8.72 (m, 1H) and 9.33 (d, 1H, J = 8.4 Hz); 
13
C NMR(CDCl3, 100 MHz) 

121.0, 126.6, 127.1, 127.8, 128.6, 129.5, 129.9, 131.9, 134.5, 139.4, 145.4, 147.0, 
148.0, 148.3, 153.6, 155.5 and 171.8; mass spectrum (APCI), m/z 663.1770 (M+H)
+
 
(C32H31N4O10S requires m/z 663.1760).
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Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-
pyrrolo[2,3-f]quinolin-3-yl)propionate (2.60). To a stirred  solution containing 120 mg 
(0.18 mmol) of methyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-
tosyl-1H-pyrrolo[2,3-f]quinolin-3-yl)propionate (2.58) in 3 mL of 2:1 THF–methanol 
was added 197 mg (0.56 mmol) of Cs2CO3. The reaction mixture was stirred at room 
temperature for 3 h under argon, then diluted with 50 mL of brine and extracted with two 
50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. Methyl (S)-2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[2,3-f]quinolin-3-yl)propionate (2.59) was 
obtained as a yellow solid and was used directly in the next step without further 
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purification. Mass spectrum (APCI), m/z 509.1665(M+H)
+
 (C25H25N4O8 requires m/z 
509.1672). To a stirred  solution containing 25.1 mg (50.0 μmol) of methyl (S)-2-((4,5-
dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[2,3-f]quinolin-3-
yl)propionate (2.59) in 1 mL of 1:3:1 water–THF–methanol was added 150 µL (0.15 
mmol) of 1 N LiOH. The reaction mixture was stirred at room temperature for 2 h, then 
concentrated under diminished pressure. The residue was dissolved in 1 mL of anhydrous 
DMF under argon. To the stirred solution was added 21.0 µL (15.0 mg, 0.15 mmol) of 
Et3N followed by 10.0 µL (11.0 mg, 0.15 mmol) of chloroacetonitrile. The reaction 
mixture was stirred at 23 °C for 16 h and then diluted with 20 mL of satd aq NaHCO3 and 
extracted with two 50-mL portions of EtOAc. The organic layer was washed with brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 1 cm). Elution with ethyl acetate gave 
cyanomethyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-
pyrrolo[2,3-f]quinolin-3-yl)propionate (2.60) as a light yellow solid: yield 14.0 mg (40%, 
for two steps); silica gel TLC Rf 0.35 (1:1 hexanes–ethyl acetate); 
1
H NMR( CDCl3, 400 
MHz) 3.41-3.46 (m, 1H), 3.69 (s, 2H), 3.83 (s, 3H), 3.92 (s, 3H), 4.61-4.67 (m, 1H), 
4.74-4.88 (m, 1H), 5.45-5.57 (m, 2H), 6.89 (s, 1H), 7.19-7.21 (m, 1H), 7.41-7.44 (m, 
1H), 7.66 (s, 1H), 7.78-7.86 (m, 2H), 8.33 (d, 1H, J = 8.0 Hz), 8.85 (d, 1H, J = 4.4 Hz) 
and 9.37 (s, 1H); 
13
C NMR(CDCl3, 100 MHz) 
121.8,122.0, 122.7, 127.6, 128.3, 130.1, 
139.7, 146.2, 147.8, 148.3, 153.7, 155.7 and 170.9; mass spectrum (APCI), m/z 534.1630 
(M+H)
+
 (C26H24N5O8 requires m/z 534.1625). 
 102 
 
                                           
N
NN
N
NH2
O
OH
O
O
N
N
NH2
O
OP
OH
O
OP
O
OH
HO
HN
HN
O
O
O
O
MeO
NO2
OMe
N
 
(S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1H-pyrrolo[2,3-
f]quinolin-3-yl)-pdCpA (2.6). To a solution containing 5.20 mg (4.0 μmol) of pdCpA 
tetrabutylammonium salt in 100 L of 9:1 anhydrous DMF–triethylamine was added 11.1 
mg (21.0 μmol) of cyanomethyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-
(1H-pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.60). The reaction mixture was sonicated 
for 2 h. The reaction mixture was purified by HPLC on a C18 reversed phase column (10 
× 250 mm) using a linear gradient of 99:1 → 1:99 50 mM aq ammonium acetate (pH 
4.5)–acetonitrile. The retention time of the desired product was 23.9 min. The fractions 
containing the product were lyophilized to afford 2.6 as a colorless solid: yield 2.10 mg 
(54%); mass spectrum (ESI), m/z 1111.2344 (M-H)
- 
(C43H45N12O20P2 requires m/z 
1111.2348). 
                                           
N
O
S
O
O
NC
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3-Formyl-1-tosyl-1H-indole-6-carbonitrile (2.62). Oxalyl chloride (0.60 mL, 0.89 g, 
7.00 mmol) was added in a dropwise manner to 3 mL of cooled (ice bath) DMF with 
stirring. The reaction mixture was then stirred at 0 
o
C for 1 h. A solution of 1.00 g (7.03 
mmol) of 6-cyanoindole in 3 mL of DMF was then added to the reaction mixture in a 
dropwise manner. The resulting reaction mixture was stirred at room temperature for 
overnight and 2 mL of 2 N NaOH was then added. The reaction mixture was heated at 
100 
o
C for 30 min. The cooled reaction mixture was diluted with 50 mL of brine and then 
extracted with two 50-mL portions of EtOAc. The organic phase was dried (MgSO4) and 
concentrated under diminished pressure to give 3-formyl-1H-indole-6-carbonitrile (2.61) 
as a yellow solid which was used directly in the next step without further purification. To 
a stirred solution containing 956 mg (5.62 mmol) of 2.61 in 20 mL of anhydrous DMF at 
0 °C was added 450 mg (11.2 mmol) of NaH (60% suspension in mineral oil). The 
reaction mixture was stirred at 0 °C for 10 min under argon and then 1.50 g (7.86 mmol) 
of pTsCl was added. The reaction mixture was stirred at 0 °C under argon for 3 h, diluted 
with 150 mL of brine and extracted with two 50-mL portions of EtOAc. The organic 
phase was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 4 cm). Elution with 4:1 
hexanes–ethyl acetate gave the desired product 2.62 as a yellow solid: yield 1.55 g (68% 
for two steps); silica gel TLC Rf 0.82 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 
MHz) 2.37 (s, 3H), 7.33 (d, 2H, J = 8.4 Hz), 7.56 (d, 1H, J = 8.4 Hz), 7.86 (d, 2H, J = 
8.4 Hz), 8.26 (s, 1H), 8.31 (d, 1H, J = 8.4 Hz), 8.42 (s, 1H) and 10.10 (s, 1H); 
13
C NMR 
(CDCl3, 100 MHz) 21.7, 109.4, 117.6, 118.9, 121.6, 123.6, 127.3, 128.0, 129.5, 130.7, 
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133.7, 134.1, 138.5, 147.0 and 184.9; mass spectrum (APCI), m/z 325.0650 (M+H)
+
 
(C17H13N2SO3 requires m/z 325.0647). 
                                          
N
HO
SO
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3-(Hydroxymethyl)-1-tosyl-1H-indole-6-carbonitrile (2.63). To a suspension of 1.29 g 
(4.46 mmol) of 3-formyl-1-tosyl-1H-indole-6-carbonitrile (2.62) in 15 mL of EtOH was 
added 339 mg (8.92 mmol) of NaBH4 and the reaction mixture was stirred at room 
temperature for 2 h. The reaction mixture was diluted with 100 mL of satd aq NaHCO3
 
and the formed precipitate was filtered and dried under vacuum. 3-(Hydroxymethyl)-1-
tosyl-1H-indole-6-carbonitrile (2.63) was obtained as an off-white solid: yield 1.11 g 
(80%); silica gel TLC Rf 0.41 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz)  
2.27 (s, 3H), 4.68 (s, 2H), 7.18 (d, 2H, J = 8.0 Hz), 7.62 (dd, 1H, J = 8.0 and 1.6 Hz), 
7.62 (d, 1H, J = 8.4 Hz), 7.64 (s, 1H), 7.69 (d, 2H, J = 8.8 Hz) and 8.20 (s, 1H); 
13
C 
NMR (CDCl3, 100 MHz) 21.4, 55.8, 107.4, 117.8, 119.4, 121.1, 122.7, 126.2, 126.8, 
126.9, 130.2, 132.9, 134.2, 134.5 and 145.8; mass spectrum (GCMS), m/z 326.0711 (M)
+
 
(C17H14N2SO3 requires m/z 326.0725). 
                                    
N
SO
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O
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3-(Chloromethyl)-1-tosyl-1H-indole-6-carbonitrile (2.64). To a cooled (_10 °C) 
solution containing 1.11 g (3.40 mmol) of 2.63 in 20 mL of anhydrous CH2Cl2  and 2.18 
mL (1.58 g, 15.6 mmol) of Et3N was added dropwise 0.58 mL (947 mg, 7.93 mmol) of 
SOCl2. The reaction mixture was allowed to warm slowly to room temperature and was 
then stirred for 6 h, diluted with 50 mL of brine and extracted with two 50-mL portions of 
EtOAc. The organic phase was dried (MgSO4) and concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (10 × 2 
cm). Elution with 3:1 hexanes–ethyl acetate gave the expected product 2.64 as a 
yellowish solid: yield 832 mg (71%); silica gel TLC Rf 0.91 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) 2.33 (s, 3H), 4.71 (s, 2H), 7.25 (d, 2H, J = 8.0 Hz), 7.48 
(dd, 1H, J = 8.4 and 1.2 Hz), 7.69 (d, 1H, J = 8.4 Hz), 7.75 (s, 1H), 7.77 (s, 2H) and 8.26 
(s, 1H); 
13
C NMR (CDCl3, 100 MHz) 21.6, 36.6, 108.3, 118.0, 118.8, 119.3, 120.9, 
126.4, 127.0, 128.2, 130.4, 132.2, 134.2, 134.4 and 146.1; mass spectrum (APCI), m/z 
345.0463 (M+H)
+
 (C17H14N2O2SCl requires m/z 345.0465). 
                                     
N
S
O
N
N
O
O
O
NC
 
3-(((2S, 5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-
indole-6-carbonitrile (2.65). To a stirred solution containing 0.62 mL (650 mg, 3.53 
mmol) of Schöllkopf’s reagent in 5 mL of anhydrous THF at _78 °C was added 0.45 mL 
(308 mg, 4.82 mmol) of 2.5 M BuLi. The reaction mixture was stirred at 
_
78 °C for 30 
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min under argon and then a solution containing 1.10 g (3.21 mmol) of 2.64 in 5 mL of 
anhydrous THF was added. The reaction mixture was stirred at 
_
78 °C for 30 min under 
argon, then diluted with 50 mL of satd aq NH4Cl and extracted with two 50-mL portions 
of EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with 3:1 hexanes–ethyl acetate gave the expected product 2.65 as a 
yellow oil: yield 1.01 g (65%); silica gel TLC Rf 0.89 (1:1 hexanes–ethyl acetate); 
1
H 
NMR (CDCl3, 400 MHz) 0.57 (d, 3H, J = 6.8 Hz), 0.85 (d, 3H, J = 7.2 Hz), 2.03–2.09 
(m, 1H), 2.34 (s, 3H), 3.12–3.19 (m, 3H), 3.61 (s, 3H), 3.63 (s, 3H), 4.27–4.30 (m, 1H), 
7.23(d, 2H, J = 8.4 Hz), 7.41 (d, 1H, J = 8.0 Hz), 7.44 (s, 1H), 7.60 (d, 1H, J = 8.4 Hz), 
7.67 (d, 2H, J = 8.0 Hz) and 8.23 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) 16.6, 19.0, 
21.7, 28.9, 31.6, 52.4, 52.5, 55.5, 60.6, 107.4, 117.9, 118.5, 119.7, 121.1, 125.9, 126.8, 
128.1, 130.3, 133.8, 134.8, 134.9, 145.6, 161.9 and 164.3; mass spectrum (APCI), m/z 
493.1910 (M+H)
+
 (C26H29N4SO4 requires m/z 493.1909). 
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(6-cyano-1-tosyl-
1H-indol-3-yl)propionate (2.67). To a stirred solution containing 468 mg (0.95 mmol) 
of 2.65 in 10 mL of THF at 0 °C was added 8 mL of 2 N aq HCl. The reaction mixture 
was stirred at room temperature for 2 h. The reaction mixture was then poured slowly 
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into 30 mL of satd aq NaHCO3 and then extracted with two 30-mL portions of EtOAc. 
The combined organic phase was dried (MgSO4) and concentrated under diminished 
pressure. Methyl (S)-2-amino-3-(6-cyano-1-tosyl-1H-indol-3-yl)propionate (2.66) was 
obtained as a yellow solid and was used directly in the next step without further 
purification. To a stirred solution containing 180 mg (0.45 mmol) of 2.66 in 2 mL of 1:1 
dioxane–water was added 150 mg (1.08 mmol) of K2CO3 followed by 104 mg (0.48 
mmol) of NVOC-Cl. The reaction mixture was stirred at room temperature for 14 h under 
argon, then diluted with 50 mL of brine and extracted with two 50-mL portions of 
EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with 1:1 hexanes–ethyl acetate gave the expected product 2.67 as a 
yellow oil: yield 256 mg (79% for two steps); silica gel TLC Rf 0.38 (1:1 hexanes–ethyl 
acetate); 
1
H NMR (CDCl3, 400 MHz)  2.35 (s, 3H), 3.17–3.31 (m, 2H), 3.66 (s, 3H),  
3.93 (s, 3H), 3.94 (s, 3H), 4.66–4.71 (m, 1H), 5.47–5.57 (m, 3H), 6.95 (s, 1H), 7.26 (d, 
2H, J = 8.4 Hz), 7.44 (d, 1H, J = 8.0 Hz), 7.54 (s, 1H), 7.57 (s, 1H), 7.69–7.73 (m, 3H) 
and 8.24 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) 21.7, 27.7, 52.8, 54.0, 56.5, 56.6, 64.2, 
108.0, 108.3, 110.4, 116.9,118.1, 119.4, 120.4, 126.4, 126.89, 126.93, 127.4, 127.9, 
130.3, 133.9, 134.0, 134.6, 146.0, 148.4, 153.7, 155.3 and 171.5; mass spectrum (APCI), 
m/z 637.1590 (M+H)
+
 (C30H29N4O10S requires m/z 637.1604). 
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Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(6-cyano-1-
tosyl-1H-indol-3-yl)propionate (2.69). To a stirred solution containing 55.0 mg (0.08 
mmol) 2.67 of in 1.5 mL of anhydrous 2:1 THF–methanol was added 56.5 mg (0.16 
mmol) of Cs2CO3. The reaction mixture was stirred at room temperature for 3 h under 
argon, then diluted with 20 mL of brine and extracted with two 50-mL portions of 
EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with ethyl acetate gave 2.68 as a yellow oil: yield 27.0 mg (64%); 
silica gel TLC Rf 0.3 (1:1 hexanes–ethyl acetate). To a stirred solution containing 27.0 
mg (0.05 mmol) of 2.68 in 1 mL of 1:3:1 water–THF–methanol was added 150 µL (3.59 
mg, 0.15 mmol) of 1 N LiOH. The reaction mixture was stirred at room temperature for 2 
h, and then concentrated under diminished pressure. The residue was redissolved into 1 
mL of anhydrous DMF and 24.7 µL (18.1 mg, 0.15 mmol) of Et3N was added followed 
by 10.0 L (11.3 mg, 0.15 mmol) of chloroacetonitrile. The reaction mixture was stirred 
at 23 °C for 16 h and then diluted with 20 mL of satd aq NaHCO3 and extracted with two 
50-mL portions of EtOAc. The organic layer was washed with brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 1:2 hexanes–ethyl acetate gave the desired 
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product 2.69 as a light yellow solid: yield 19.2 mg (44% for three steps); silica gel TLC 
Rf 0.25 (1:1 hexanes–ethyl acetate); 
1
H NMR (DMSO-d6, 400 MHz)  3.12–3.27 (m, 
2H), 3.84 (s, 3H), 3.87 (s, 3H), 4.43–4.48 (m, 1H), 5.00 (s, 2H), 5.33 (ABq, 2H, J = 14.8 
Hz), 7.10 (s, 1H), 7.31 (d, 1H, J = 8.4 Hz), 7.52 (s, 1H), 7.69-7.73 (m, 2H), 7.85 (s, 1H), 
8.22 (d, 1H, J = 7.6 Hz) and 11.50 (br s, 1H); 
13
C NMR (DMSO-d6, 400 MHz) 26.1, 
49.4, 54.5, 55.98, 56.03, 62.6, 102.3, 108.0, 110.2, 110.3, 115.5, 116.3, 119.2, 120.6, 
121.1, 127.5, 128.6, 130.0, 134.8, 139.0, 147.6, 153.3, 155.5 and 170.9; mass spectrum 
(APCI), m/z 508.1488 (M+H)
+
 (C24H22N5O8 requires m/z 508.1468).  
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(S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(6-cyano-1-tosyl-1H-
indol-3-yl)propionic Acid pdCpA Ester (2.7). To a solution containing 5.20 mg (4.00 
μmol) of pdCpA tetrabutylammonium salt in 100 µL of 9:1 anhydrous DMF–
triethylamine was added 10.7 mg (21.0 μmol) of cyanomethyl (S)-2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonyl)-3-(6-cyano-1-tosyl-1H-indol-3-yl)propionate (2.69). The 
reaction mixture was sonicated for 5 h. The reaction mixture was purified by HPLC on a 
C18 reversed phase column (250 × 10 mm) using a linear gradient of 99:1 → 1:99 50 mM 
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aq ammonium acetate, pH 4.5–acetonitrile. The retention time of the desired product was 
24.2 min. The fractions containing the product were lyophilized to afford 2.7 as a 
colorless solid: yield 2.90 mg (71%); mass spectrum (ESI), m/z 1085.2208 (M-H)
-
 
(C41H43N12O20P2 requires m/z 1085.2192). 
N
O
S
O
O
CN
 
3-Formyl-1-tosyl-1H-indole-7-carbonitrile (2.71). Oxalyl chloride (0.6 mL, 0.89 g, 7.0 
mmol) was added dropwise to 3 mL of cooled (ice-bath) DMF with stirring. The reaction 
mixture was then stirred at 0 °C for 1 h. A solution of 1.0 g (7.0 mmol) of 7-cyanoindole 
in DMF (3 mL) was then added to the reaction mixture in a dropwise manner. The 
resulting mixture was stirred at room temperature for overnight and 2 mL of 2 N NaOH 
was then added. The reaction mixture was heated at 100 
o
C for 30 min. The cooled 
reaction mixture was diluted with 50 mL of brine and then extracted with two 50-mL 
portions of EtOAc. The organic phase was dried (MgSO4) and concentrated under 
diminished pressure to give 3-formyl-1H-indole-7-carbonitrile (2.70) as a yellow solid, 
which was used directly in the next step without further purification. To a stirred solution 
containing 954 mg (5.61 mmol) of 2.70 in 20 mL of anhydrous DMF at 0 °C was added 
448 mg (11.2 mmol) of NaH (60% in mineral oil). The reaction mixture was stirred at 0 
°C for 10 min under argon and then 1.49 g (7.85 mmol) of pTsCl was added. The 
reaction mixture was stirred at 0 °C under argon for 3 h. The reaction mixture was diluted 
with 150 mL of brine and extracted with two 50-mL portions of EtOAc. The organic 
 111 
 
phase was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 4 cm). Elution with 4:1 
hexanes–ethyl acetate gave the desired product 2.71 as a yellow solid: yield 1.50 g (66% 
for two steps); silica gel TLC Rf 0.78 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 
MHz)  2.36 (s, 3H), 7.31-7.39 (m, 3H), 7.67 (d, 1H, J = 7.6 Hz), 7.97 (d, 2H, J = 8.8 
Hz), 8.53 (d, 1H, J = 8.4 Hz), 8.57 (s, 1H) and 10.13 (s, 1H); 
13
C NMR (CDCl3, 100 
MHz) 21.6, 98.0. 116.7, 120.7, 124.9, 127.8, 128.3, 128.5, 130.3, 132.0, 133.69, 
133.72, 139.2, 146.6 and 185.0; mass spectrum (APCI), m/z 325.0642 (M+H)
+
 
(C17H13N2SO3 requires m/z 325.0647). 
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3-(Hydroxymethyl)-1-tosyl-1H-indole-7-carbonitrile (2.72). To a suspension of 880 
mg (2.70 mmol) of 3-formyl-1-tosyl-1H-indole-7-carbonitrile (2.71) in 15 mL of EtOH 
was added 206 mg (5.42 mmol) of NaBH4 and the reaction mixture was stirred at room 
temperature for 2 h. The reaction mixture was diluted with 100 mL of satd aq NaHCO3
 
and the formed precipitate was filtered and dried under vacuum. 3-(Hydroxymethyl)-1-
tosyl-1H-indole-7-carbonitrile (2.72) was obtained as an off-white solid: yield 682 mg 
(77%); silica gel TLC Rf 0.40 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) 
2.29 (s, 3H), 4.81 (s, 2H), 7.18-7.22 (m, 3H), 7.52 (d, 1H, J = 7.6 Hz), 7.78 (s, 1H) and 
7.82-7.84 (m, 3H); 
13
C NMR (CDCl3, 100 MHz)  21.6, 56.4, 97.8, 117.4, 121.4, 123.1, 
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125.6, 126.9, 127.8, 130.1, 131.7, 132.0, 132.5, 134.8 and 145.7; mass spectrum 
(GCMS), m/z 326.0711 (M)
+
 (C17H14N2SO3 requires m/z 326.0725). 
N
Cl
S
O O
CN
 
3-(Chloromethyl)-1-tosyl-1H-indole-7-carbonitrile (2.73). To a cooled (
_
10 °C) 
solution containing 831 mg (2.55 mmol) of 3-(hydroxymethyl)-1-tosyl-1H-indole-7-
carbonitrile (2.72) in 15 mL of anhydrous CH2Cl2  and 1.42 mL (1.03 g, 10.2 mmol) of 
Et3N was added dropwise 0.37 mL (606 mg, 5.09 mmol) of SOCl2. The reaction mixture 
was allowed to warm slowly to room temperature and was then stirred for 6 h, diluted 
with 50 mL of brine and extracted with two 50-mL portions of EtOAc. The combined 
organic phase was dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution with 
4:1 hexanes–ethyl acetate gave 3-(chloromethyl)-1-tosyl-1H-indole-7-carbonitrile (2.73) 
as a yellow oil: yield 650 mg (74%); silica gel TLC Rf 0.88 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) 2.27 (s, 3H), 4.81 (s, 2H), 7.24 (d, 2H, J = 8.5 Hz), 7.29 
(d, 1H, J = 5.0 Hz), 7.57 (d, 1H, J = 7.5 Hz), 7.69 (d, 1H, J = 8.0 Hz) and 7.92-7.95 (m, 
3H); 
13
C NMR (CDCl3, 125 MHz) 21.3, 36.5, 97.8, 116.9, 117.7, 123.0, 125.0, 127.6, 
128.0, 129.9, 130.8, 131.6, 132.5, 134.3 and 145.6; mass spectrum (APCI), m/z 345.0466 
(M+H)
+
 (C17H14N2O2SCl requires m/z 345.0465). 
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3-(((2S, 5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-
indole-7-carbonitrile (2.74). To a stirred solution containing 0.35 mL (365 mg, 1.98 
mmol) of Schöllkopf’s reagent in 5 mL of anhydrous THF at _78 °C was added 0.25 mL 
(172 mg, 2.68 mmol) of 2.5 M BuLi. The reaction mixture was stirred at 
_
78 °C for 30 
min under argon, and then a solution containing 618 mg (1.79 mmol) of 3-
(chloromethyl)-1-tosyl-1H-indole-7-carbonitrile (2.73) in 5 mL of  anhydrous THF was 
added. The reaction mixture was stirred at 
_
78 °C for 30 min under argon, then diluted 
with 50 mL of satd aq NH4Cl and extracted with two 50-mL portions of EtOAc. The 
combined organic phase was dried (MgSO4) and concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution 
with 3:1 hexanes–ethyl acetate gave 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-
dihydropyrazin-2-yl)methyl)-1-tosyl-1H-indole-7-carbonitrile (2.74) as a yellow oil: 
yield 547 mg (62%); silica gel TLC Rf 0.85 (1:1 hexanes–ethyl acetate); 
1
H NMR 
(CDCl3, 400 MHz)  0.58 (d, 3H, J = 6.8 Hz), 0.88 (d, 3H, J = 6.8 Hz), 2.07-2.12 (m, 
1H), 2.32 (s, 3H), 3.19-3.32 (m, 3H), 3.63 (s, 6H), 4.30-4.31 (m, 1H), 7.18-7.24 (m, 3H), 
7.53 (d, 1H, J = 7.6 Hz), 7.55 (s, 1H) and 7.79-7.81 (m, 3H); 
13
C NMR (CDCl3, 100 
MHz)  16.5, 19.0, 21.6, 28.7, 31.6, 52.3, 52.4, 55.6, 60.6, 97.9, 117.1, 117.4, 122.5, 
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125.4, 127.7, 127.8, 130.0, 131.4, 132.2, 133.7, 135.2, 145.3, 162.0 and 164.1; mass 
spectrum (APCI), m/z 493.1909 (M+H)
+
 (C26H29N4SO4 requires m/z 493.1909). 
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(7-cyano-1-tosyl-
1H-indol-3-yl)propionate (2.76). To a stirred  solution containing 466 mg (0.94 mmol) 
of 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-
indole-7-carbonitrile (2.74) in 16 mL of THF at 0 °C was added 14 mL of 2 N aq HCl. 
The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was 
then slowly poured into 50 mL of satd aq NaHCO3 and then extracted with two 50-mL 
portions of EtOAc. The combined organic phase was dried (MgSO4) and concentrated 
under diminished pressure. Methyl (S)-2-amino-3-(7-cyano-1-tosyl-1H-indol-3-
yl)propionate (2.75) was obtained as a yellow oil and was used directly in the next step 
without further purification. To a stirred solution containing 179 mg (0.44 mmol) of 2.75 
in 2 mL of 1:1 dioxane–water was added 149 mg (1.07 mmol) of K2CO3 followed by 104 
mg (0.48 mmol) of NVOC-Cl. The reaction mixture was stirred at room temperature for 
12 h under argon, then diluted with 50 mL of brine and extracted with two 50-mL 
portions of EtOAc. The combined organic phase was dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 2 cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)-2-((4,5-
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dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(7-cyano-1-tosyl-1H-indol-3-
yl)propionate (2.76) as a yellow oil: yield 237 mg (73% for two steps); silica gel TLC Rf  
0.35 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz)  2.30 (s, 3H), 3.16-3.32 
(m, 2H), 3.66 (s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 4.66-4.68 (m, 1H),  5.42 (ABq, 2H, J = 
15.2 Hz), 5.78 (d, 1H, J = 7.6 Hz), 6.92 (s, 1H), 7.21-7.24 (m, 3H), 7.54 (d, 1H, J = 7.6 
Hz), 7.61 (s, 1H), 7.67 (s, 1H), 7.73 (d, 1H, J = 7.6 Hz) and 7.80 (d, 2H, J = 7.2 Hz); 
13
C 
NMR (CDCl3, 100 MHz) 21.6, 27.4, 52.7, 54.0, 56.3, 56.4, 63.9, 98.2, 108.1, 110.0, 
115.9, 117.1, 123.1, 124.6, 127.6, 127.7, 130.0, 130.1, 131.7, 132.5, 132.8, 134.8, 139.5, 
145.6, 148.1, 153.7, 155.3 and 171.6; mass spectrum (APCI), m/z 637.1578 (M+H)
+
 
(C30H29N4O10S requires m/z 637.1604). 
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Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(7-cyano-1-
tosyl-1H-indol-3-yl)propionate (2.78). To a stirred solution containing 160 mg (0.25 
mmol) of methyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(7-cyano-1-
tosyl-1H-indol-3-yl)propionate (2.76) in 3 mL of 2:1 anhydrous THF–methanol was 
added 261 mg (0.74 mmol) of Cs2CO3. The reaction mixture was stirred at room 
temperature for 3 h under argon, then diluted with 50 mL of brine and extracted with two 
50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
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a silica gel column (10 × 2 cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)-
2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(7-cyano-1-tosyl-1H-indol-3-
yl)propionate (2.77) as a yellow oil. To a stirred solution containing 43.0 mg (0.09 mmol) 
of 2.77 in 1 mL of 1:3:1 water–THF–methanol was added 275 µL (6.59 mg, 0.27 mmol) 
of 1 N LiOH. The reaction mixture was stirred at room temperature for 2 h, and then 
concentrated under diminished pressure. The residue was dissolved in 1 mL of anhydrous 
DMF under argon. To the stirred solution was added 38.0 µL (28.0 mg, 0.27 mmol) of 
Et3N followed by 17.0 L (20.0 mg, 0.27 mmol) of chloroacetonitrile. The reaction 
mixture was stirred at 23 °C for 16 h and then diluted with 20 mL of satd aq NaHCO3 and 
extracted with two 50-mL portions of EtOAc. The organic layer was washed with brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 1 cm). Elution with 1:2 hexanes–ethyl 
acetate gave cyanomethyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(7-
cyano-1-tosyl-1H-indol-3-yl)propionate (2.78) as a light yellow solid: yield 23.0 mg 
(55% for three steps); silica gel TLC Rf 0.21 (1:1 hexanes–ethyl acetate); 
1
H NMR 
(CDCl3, 400 MHz)  3.34-3.37 (m, 2H), 3.92 (s, 3H), 3.93 (s, 3H), 4.62-4.68 (m, 1H), 
4.80 (d, 2H, J = 15.2 Hz), 5.45-5.51 (m, 2H), 6.92 (s, 1H), 7.17-7.21 (m, 2H), 7.51 (d, 
1H, J = 7.6 Hz), 7.67 (s, 1H), 7.80 (d, 1H, J = 8.0 Hz) and 9.08 (br s, 1H); mass spectrum 
(APCI), m/z 508.1470 (M+H)
+
 (C24H22N5O8 requires m/z 508.1468). 
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 (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(7-cyano-1-tosyl-1H-
indol-3-yl)propionic Acid pdCpA Ester (2.8). To a solution containing 5.24 mg (3.85 
μmol) of pdCpA tetrabutylammonium salt in 100 L of 9:1 anhydrous DMF–
triethylamine was added 10.7 mg (21.1 μmol) of cyanomethyl (S)-2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonylamino)-3-(7-cyano-1-tosyl-1H-indol-3-yl)propionate (2.78). The 
reaction mixture was sonicated for 6 h. The reaction mixture was purified by HPLC on a 
C18 reversed phase column (250 × 10 mm) using a linear gradient of 99:1 → 1:99 50 mM 
aq ammonium acetate, pH 4.5–acetonitrile. The retention time of the desired product was 
21.6 min. The fractions containing the product were lyophilized to afford 2.8 as a 
colorless solid: yield 2.70 mg (65%); mass spectrum (ESI), m/z 1085.2209 (M-H)
-
 
(C41H43N12O20P2 requires m/z 1085.2192). 
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3-(((2S, 5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1H-indole-
7-carbonitrile (2.79). To a stirred  solution containing 326 mg (0.67 mmol) of 3-
(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-tosyl-1H-
indole-7-carbonitrile (2.74) in 5 mL of  2:1 anhydrous THF–methanol was added 699 mg 
(1.98 mmol) of Cs2CO3. The reaction mixture was stirred at room temperature for 
overnight under argon. The reaction mixture was poured into 20 mL of brine, and then 
extracted with two 20-mL portions of EtOAc. The organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 1:1 hexanes–ethyl acetate gave 3-(((2S,5R)-
5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1H-indole-7-carbonitrile 
(2.79) as a yellow oil: yield 152 mg (68%); silica gel TLC Rf 0.75 (1:1 hexanes–ethyl 
acetate); 
1
H NMR (CDCl3, 400 MHz) 0.62 (d, 3H, J = 6.8 Hz), 0.93 (d, 3H, J = 7.2 Hz), 
2.13-2.15 (m, 1H), 3.29 (d, 2H, J = 8.8 Hz), 3.41 (d, 1H, J = 3.6 Hz), 3.64 (s, 3H), 3.67 
(s, 3H), 4.33-4.36 (m, 1H), 7.05-7.12 (m, 2H), 7.46 (d, 1H, J = 7.6 Hz), 7.88 (d, 1H, J = 
8.0 Hz) and 9.00 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) 16.6, 19.1, 29.4, 31.6, 52.3, 
56.5, 60.6, 94.2, 113.0, 117.7, 118.9, 124.6, 125.0, 126.4, 128.2, 129.2, 136.3, 162.7 and 
164.1; mass spectrum (APCI), m/z 339.1817 (M+H)
+
 (C19H23N4O2 requires 
m/z 339.1821). 
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3-(((2S, 5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-methyl-
1H-indole-7-carbonitrile (2.80). To a stirred solution containing 156 mg (0.46 mmol) of 
3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1H-indole-7-
carbonitrile (2.79) in 3 mL of  anhydrous DMF at 0 °C was added 21.4 mg (0.89 mmol) 
of NaH followed by 0.06 mL (127 mg, 0.89 mmol) of MeI. The reaction mixture was 
stirred at 0 °C for 1 h under argon. The reaction mixture was diluted with 100 mL of satd 
aq NaHCO3 and was extracted with two 20-mL portions of EtOAc and then dried under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with 1:1 hexanes–ethyl acetate gave 3-(((2S,5R)-5-isopropyl-3,6-
dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-methyl-1H-indole-7-carbonitrile (2.80) as 
a yellow oil: yield 120 mg (74%); silica gel TLC Rf 0.78 (1:1 hexanes–ethyl acetate); 
1
H 
NMR (CDCl3, 400 MHz) 0.61 (d, 3H, J = 6.8 Hz), 0.93 (d, 3H, J = 6.8 Hz), 2.10-2.15 
(m, 1H), 3.14-3.20 (m, 1H), 3.50-3.55 (m, 1H), 3.59-3.60 (m, 1H), 3.61 (s, 3H), 3.66 (s, 
3H), 3.68 (s, 3H), 4.31-4.33 (m, 1H), 6.79 (s, 1H), 7.01-7.06 (m, 1H), 7.44 (d, 1H, J = 7.6 
Hz) and 7.83 (d, 1H, J = 8.0 Hz); 
13
C NMR (CDCl3, 100 MHz) 16.6, 19.1, 29.1, 31.7, 
34.6, 52.3, 52.4, 56.6, 60.7, 93.4, 111.5, 118.3, 119.0, 125.1, 128.2, 130.3, 130.6, 134.8, 
162.8 and 164.0; mass spectrum (APCI), m/z 353.1971 (M+H)
+
 (C20H25N4O2 requires m/z 
353.1977).  
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(7-cyano-1-
methyl-1H-indol-3-yl)propionate (2.82). To a stirred solution containing 117 mg (0.33 
mmol) of 3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1-
methyl-1H-indole-7-carbonitrile (2.80) in 4 mL of THF at 0 °C was added 4 mL of 2 N 
aq HCl. The reaction mixture was stirred at room temperature for 2 h. The reaction 
mixture was then poured slowly into 50 mL of satd aq NaHCO3 and extracted with two 
50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. Methyl (S)-2-amino-3-(7-cyano-1-methyl-1H-
indol-3-yl)propionate (2.81) was obtained as a yellow oil and was used directly in the 
next step without further purification. To a stirred solution containing 31.0 mg (0.12 
mmol) of 2.81 in 2 mL of 1:1 dioxane–water was added 56.0 mg (0.41 mmol) of K2CO3 
followed by 39.0 mg (0.18 mmol) of NVOC-Cl. The reaction mixture was stirred at room 
temperature for 12 h under argon, then diluted with 50 mL of brine and extracted with 
two 50-mL portions of EtOAc. The organic phase was dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 1 cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)-2-((4,5-
dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(7-cyano-1-methyl-1H-indol-3-
yl)propionate (2.82) as a yellow oil: yield 33.1 mg (65% for two steps); silica gel TLC Rf  
0.25 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) 3.27-3.31 (m, 2H), 3.69 
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(s, 3H), 3.90 (s, 3H), 3.93 (s, 3H), 4.07 (s, 3H), 4.66-4.71 (m, 1H), 5.47-5.49 (m, 2H), 
6.92 (s, 2H), 7.07-7.10 (m, 1H), 7.50 (d, 1H, J = 7.6 Hz), 7.68 (s, 1H) and 7.71 (d, 1H, J 
= 8.0 Hz); 
13
C NMR (CDCl3, 100 MHz)27.4, 34.7, 52.6, 54.5, 56.46, 56.50, 64.0,  
94.0, 108.2, 109.5, 110.3, 118.6, 119.0,  124.1, 127.7, 128.7, 129.7, 130.3, 135.0, 139.8, 
148.2, 153.6, 155.3 and 172.1; mass spectrum (APCI), m/z 497.1677 (M+H)
+
 
(C24H25N4O8 requires m/z 497.1672).  
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Cyanomethyl (S)- 2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(7-cyano-
1-methyl-1H-indol-3-yl)propionate (2.83). To a stirred solution containing 35.0 mg 
(0.07 mmol) of methyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(7-
cyano-1-methyl-1H-indol-3-yl)propionate (2.82) in 1 mL of 1:3:1 water–THF–methanol 
was added 214 L (5.13 mg, 0.21 mmol) of 1 N aq LiOH. The reaction mixture was 
stirred at room temperature for 3 h, then concentrated under diminished pressure. The 
residue was dissolved in 1 mL of anhydrous DMF and 30.0 L (22.0 mg, 0.21 mmol) of 
Et3N was added followed by 13.0 L (16.0 mg, 0.21 mmol) of chloroacetonitrile. The 
reaction mixture was stirred at 23 °C for 16 h and then diluted with 20 mL of satd aq 
NaHCO3 and extracted with two 50-mL portions of EtOAc. The organic layer was 
washed with brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (10 × 1 cm). Elution with 
1:1 hexanes–ethyl acetate gave cyanomethyl (S)-2-((4,5-dimethoxy-2-
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nitrobenzyloxy)carbonylamino)-3-(7-cyano-1-methyl-1H-indol-3-yl)propionate (2.83) as 
a light yellow solid: yield 20.0 mg (52%); silica gel TLC Rf 0.42 (1:1 hexanes–ethyl 
acetate); 
1
H NMR (CDCl3, 400 MHz)  2.87-2.89 (m, 1H), 3.34-3.35 (m, 1H), 3.93 (s, 
3H), 3.96 (s, 3H), 4.10 (s, 3H), 4.62-4.69 (m, 1H), 4.75-4.85 (m, 2H), 5.37 (d, 1H, J = 8.0 
Hz), 5.51 (ABq, 2H, J = 14.0 Hz), 6.92 (s, 1H), 7.00 (s, 1H), 7.13-7.16 (m, 1H), 7.56 (d, 
1H, J = 7.5 Hz), 7.70 (s, 1H) and 7.75 (d, 1H, J = 8.0 Hz); mass spectrum (APCI), m/z 
522.1623 (M+H)
+
 (C25H24N5O8 requires m/z 522.1625).  
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(S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1-methyl-1H- 
pyrrolo[3,2-b]pyridin-3-yl)propionic Acid pdCpA Ester (2.9). To a solution 
containing 5.24 mg (3.85 μmol) of pdCpA tetrabutylammonium salt in 100 L of 9:1 
anhydrous DMF–triethylamine was added 11.0 mg (21.1 μmol) of cyanomethyl (S)-2-
((4,5-dimethoxy-2-nitrobenzyloxy) carbonylamino)-3-(7-cyano-1-methyl-1H-indol-3-
yl)propionate (2.83). The reaction mixture was sonicated for 6 h. The reaction mixture 
was purified by HPLC on a C18 reversed phase column (250 × 10 mm) using a linear 
gradient of 99:1 → 1:99 50 mM aq ammonium acetate, pH 4.5–acetonitrile. The retention 
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time of the desired product was 22.0 min. The fractions containing the product were 
lyophilized to afford 2.9 as a colorless solid: yield 2.90 mg (69%); mass spectrum (ESI), 
m/z 1099.2358 (M-H)
-
 (C42H45N12O20P2 requires m/z 1099.2348). 
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Methyl (S)-2-Acetamido-3-(1-tosyl-1H-pyrrolo[3,2-b]pyridin-3-yl)propionate (2.84). 
To a stirred solution containing 16.0 mg (0.04 mmol) of methyl (S)-2-amino-3-(1-tosyl-
1H-pyrrolo[3,2-b]pyridin-3-yl)propionate (2.16) in 3 mL dry CH2Cl2 under a N2 
atmosphere was added 13.0 μL (10.3 mg, 0.08 mmol) of DIPEA followed by 4.0 μL 
(4.10 mg, 0.04 mmol) of acetic anhydride. The reaction mixture was stirred at room 
temperature for 2 h. The reaction mixture was then diluted with 20 mL of satd aq 
NaHCO3 and extracted with two 50-mL portions of EtOAc. The combined organic phase 
was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with ethyl acetate 
gave methyl (S)-2-acetamido-3-(1-tosyl-1H-pyrrolo[3,2-b]pyridin-3-yl)propionate (2.84) 
as a yellow oil: yield 15.1 mg (79%); silica gel TLC Rf 0.25 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) 1.95 (s, 3H), 2.32 (s, 3H), 3.17-3.30 (m, 2H), 3.56 (s, 3H), 
4.73-4.76 (m, 1H), 7.21-7.25 (m, 2H), 7.58 (s, 1H), 7.69 (d, 2H, J = 8.4 Hz), 8.23 (dd, 
1H, J = 8.4 and 1.6 Hz), 8.31 (d, 1H, J = 6.8 Hz) and 8.48 (dd, 1H, J = 4.8 and 1.6 Hz); 
13
C NMR (CDCl3, 100 MHz)  21.7, 23.2, 27.0, 52.2, 52.4, 118.8, 119.7, 121.5, 126.8, 
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128.1, 129.1, 130.3, 134.9, 145.6, 145.8, 147.9, 170.3 and 171.6; mass spectrum (APCI), 
m/z 416.1265 (M+H)
+
 (C20H22N3O5S requires m/z 416.1280). 
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Methyl (S)-2-Acetamido-3-(1H-pyrrolo[3,2-b]pyridin-3-yl)propionate (2.85). To a 
stirred solution containing 12.0 mg (29 μmol) of methyl (S)-2-amino-3-(1-tosyl-1H-
pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.84) in 1 mL of 2:1 THF–methanol was 
added 31.1 mg (87 μmol) of Cs2CO3. The reaction mixture was stirred at room 
temperature for 1 h under argon, then diluted with 50 mL of brine and extracted with two 
50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 1 cm). Elution with ethyl acetate gave the expected product 
methyl (S)-2-acetamido-3-(1H-pyrrolo[3,2-b]pyridin-3-yl)propionate (2.85) as a yellow 
solid: yield 4.10 mg (58%); silica gel TLC Rf 0.45 (10:1 ethyl acetate–methanol); 
1
H 
NMR (CDCl3, 400 MHz) 2.03 (s, 3H), 3.27-3.40 (m, 2H), 3.62 (s, 3H), 4.71-4.76 (m, 
1H), 7.12-7.15 (m, 1H), 7.23-7.24 (m, 1H), 7.66 (d, 1H, J = 8.0 Hz), 8.43 (d, 1H, J = 4.8 
Hz), 8.65 (s, 1H) and 9.13-9.14 (m, 1H); mass spectrum (APCI), m/z 262.1187 (M+H)
+
 
(C13H16N3O3 requires m/z 262.1192). 
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Methyl (S)-2-Acetamido-3-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propionate (2.86). 
To a stirred solution containing 32.0 mg (0.08 mmol) of methyl (S)-2-amino-3-(1-tosyl-
1H-pyrrolo [2,3-b]pyridin-3-yl)propionate (2.25) in 3 mL dry CH2Cl2 under a N2 
atmosphere was added 26 μL (20.7 mg, 0.16 mmol) of DIPEA followed by 8.0 μL (8.16 
mg, 0.08 mmol) of acetic anhydride. The reaction mixture was stirred at room 
temperature for 2 h. The reaction mixture was then diluted with 50 mL of satd aq 
NaHCO3 and extracted with two 50-mL portions of EtOAc. The combined organic phase 
was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with ethyl acetate 
gave methyl (S)-2-acetamido-3-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propionate (2.86) 
as a yellow oil: yield 31.0 mg (79%); silica gel TLC Rf 0.25 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) 1.93 (s, 3H), 2.32 (s, 3H), 3.11-3.25 (m, 1H), 3.65 (s, 3H), 
4.83-4.88 (m, 1H), 6.35 (d, 1H, J = 7.6 Hz), 7.12-7.15 (m, 1H), 7.22 (d, 2H, J = 8.4 Hz), 
7.48 (s, 1H), 7.78 (d, 1H, J = 7.6 Hz), 7.98 (d, 1H, J = 8.0 Hz) and 8.37 (dd, 1H, J = 4.8 
and 1.2 Hz); 
13
C NMR (CDCl3, 100 MHz)  21.6, 23.1, 27.7, 52.5, 52.6, 113.8, 118.8, 
123.1, 124.4, 127.88, 127.94, 129.7, 135.3, 145.2, 145.3, 147.3, 170.0 and 171.9; mass 
spectrum (APCI), m/z 416.1293 (M+H)
+
 (C20H22N3O5S requires m/z 416.1280). 
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Methyl (S)-2-Acetamido-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propionate (2.87). To a 
stirred solution containing 25.0 mg (60 μmol) of methyl (S)-2-acetamido-3-(1-tosyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)propionate (2.86) in 1 mL of 2:1 anhydrous THF–methanol 
was added 43.1 mg (120 μmol) of Cs2CO3. The reaction mixture was stirred at room 
temperature for 1 h under argon, then diluted with 50 mL of brine and extracted with two 
50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 1 cm). Elution with ethyl acetate gave the expected product 
methyl (S)-2-acetamido-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propionate (2.87) as a yellow 
solid: yield 11.1 mg (69 %); silica gel TLC Rf 0.45 (10:1 ethyl acetate-methanol); 
1
H 
NMR (CDCl3, 400 MHz)2.01 (s, 3H), 3.25-3.38 (m, 2H), 3.60 (s, 3H), 4.69-4.74 (m, 
1H), 7.10-7.13 (m, 1H), 7.22-7.23 (m, 1H), 7.65 (d, 1H, J = 8.0 Hz), 8.42 (d, 1H, J = 4.8 
Hz), 8.64 (s, 1H) and 9.12-9.13 (m, 1H); mass spectrum (APCI), m/z 262.1192 (M+H)
+
 
(C13H16N3O3 requires m/z 262.1192). 
                                                       
N
N
HN
O
O
O
                                        
 127 
 
Methyl (S)-2-Acetamido-3-(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)propionate 
(2.88). To a stirred solution containing 9.10 mg (0.04 mmol) of methyl (S)-2-amino-3-(1-
methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)propionate (2.31) in 3 mL dry CH2Cl2 under a N2 
atmosphere was added 13.0 μL (10.3 mg, 0.08 mmol) of DIPEA followed by 4.0 μL 
(4.10 mg, 0.04 mmol) of acetic anhydride. The reaction mixture was stirred at room 
temperature for 2 h, then diluted with 20 mL of satd aq NaHCO3 and extracted with two 
20-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 1 cm). Elution with ethyl acetate gave methyl (S)-2-acetamido-
3-(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)propionate (2.88) as a yellow oil: yield 8.10 
mg (81%); silica gel TLC Rf 0.25 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 
MHz) 2.01 (s, 3H), 3.23-3.37 (m, 2H), 3.64 (s, 3H), 3.75 (s, 3H), 4.69-4.73 (m, 1H), 
7.10 (s, 1H), 7.13-7.16 (m, 1H), 7.60 (dd, 1H, J = 8.0 and 1.2 Hz), 8.41 (d, 1H, J = 4.4 
Hz) and 9.03-9.05 (m, 1H); 
13
C NMR (CDCl3, 100 MHz) 23.2, 27.2, 33.0, 52.1, 54.6, 
110.7, 116.9, 117.1, 130.4, 131.3, 142.3, 145.6, 170.7 and 172.2; mass spectrum (APCI), 
m/z 276.1341 (M+H)
+
 (C14H18N3O3 requires m/z 276.1348). 
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Methyl (S)-2-Acetamido-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propionate 
(2.89). To a stirred solution containing 80.0 mg (0.15 mmol) of methyl (S)-2-amino-3-(1-
methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propionate (2.36) in 3 mL dry CH2Cl2 under a N2 
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atmosphere was added 50.0 μL (38.8 mg, 0.30 mmol) of DIPEA followed by 15.0 μL 
(15.2 mg, 0.15 mmol) of acetic anhydride. The reaction mixture was stirred at room 
temperature for 2 h. The reaction mixture was then diluted with 50 mL of satd aq 
NaHCO3 and extracted with two 50-mL portions of EtOAc. The combined organic phase 
was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with ethyl acetate 
gave methyl (S)-2-acetamido-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propionate 
(2.89) as a yellow oil: yield 29.1 mg (67 %); silica gel TLC Rf 0.1 (1:2 hexanes-ethyl 
acetate); 
1
H NMR (CDCl3, 400 MHz) 1.93 (s, 3H), 3.19-3.25 (m, 2H), 3.64 (s, 3H), 
3.79 (s, 3H), 4.84-4.88 (m, 1H), 6.92 (s, 1H), 6.98-7.01 (m, 1H), 7.77 (d, 1H, J = 7.6 Hz) 
and 8.26 (d, 1H, J = 4.8 Hz); 
13
C NMR (CDCl3, 100 MHz) 23.2, 27.7, 31.0, 52.4, 57.2, 
107.2, 115.3, 120.5, 126.9, 127.5, 143.1, 147.8, 169.9 and 172.4; mass spectrum (APCI), 
m/z 276.1349 (M+H)
+
 (C14H18N3O3 requires m/z 276.1348). 
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Methyl (S)-2-Acetamido-3-(1-tosyl-1H-pyrrolo[3,2-c]isoquinolin-3-yl)propionate 
(2.90). To a stirred solution containing 16.0 mg (0.04 mmol) of methyl (S)-2-amino-3-(1-
tosyl-1H-pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.48) in 3 mL of dry DCM under N2 
atmosphere was added 0.02 mL (10.3 mg, 0.08 mmol) of DIPEA followed by 4.0 µL (4.1 
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mg, 0.04 mmol) of acetic anhydride. The reaction mixture was stirred at room 
temperature for 1 h, diluted with 30 mL of satd aq NaHCO3 and extracted with two 50-
mL portions of EtOAc. The organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 1 cm). Elution with hexanes–ethyl acetate 1:1 gave the expected product methyl 
(S)-2-amino-3-(1-tosyl-1H-pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.90) as a yellow 
oil: yield 14.0 mg (79%); silica gel TLC Rf 0.45 (1:1 hexanes–ethyl acetate); 
1
HNMR(CDCl3, 400 MHz) 1.99 (s, 3H), 2.27 (s, 3H), 3.39-3.40 (m, 2H), 3.69 (s, 3H), 
4.82-4.84 (m, 1H), 7.15 (d, 2H, J = 8.0 Hz), 7.52-7.59 (m, 3H), 7.75-7.79 (m, 1H), 7.86 
(s, 1H), 8.03 (d, 1H, J = 8.0 Hz), 8.31-8.33 (m, 1H) and 9.05-9.07 (m, 2H), 
13
CNMR(CDCl3, 100 MHz)
and 
171.8; mass spectrum (APCI) m/z 466.1439 (M+H)
+
 (C24H24N3O5S requires m/z 
466.1437).
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N
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Methyl (S)-2-Acetamido-3-(1H-pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.91). 
To a stirred solution containing 14.0 mg (0.03 mmol) of methyl (S)-2-amino-3-(1-tosyl-
1H-pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.90) in 1 mL of  2:1 anhydrous THF–
methanol was added 32.1 mg (0.09 mmol) of Cs2CO3. The reaction mixture was stirred at 
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room temperature for 3 h under argon, diluted with 50 mL of brine and extracted with 
two 50-mL portions of EtOAc. The organic phase was dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 1 cm). Elution ethyl acetate gave the expected product methyl (S)-2-
acetamido-3-(1H-pyrrolo[3,2-c]isoquinolin-3-yl)propionate (2.91) as a yellow solid: yield 
5.10 mg (57%); silica gel TLC Rf 0.45 (10:1 ethyl acetate–methanol); 
1
H NMR(CDCl3, 
500 MHz) 2.10 (s, 3H), 3.40-3.42 (m, 2H), 3.66 (s, 3H), 4.78-4.80 (m, 1H), 7.10-7.11 
(m, 1H), 7.47-7.50 (m, 1H), 7.66-7.67 (m, 1H), 7.94-7.97 (m, 2H), 8.91 (d, 1H, J = 7.5 
Hz), 9.16-9.20 (m, 1H) and 9.45 (s, 1H); 
13
C NMR(CDCl3, 125 MHz)

and 172.6; mass spectrum (APCI) m/z 312.1354 (M+H)+ (C17H18N3O3 
requires m/z 312.1348).
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Methyl (S)-2-Acetamido-3-(1-tosyl-1H-pyrrolo[2,3-f]quinolin-3-yl)propionate (2.92). 
To a stirred solution containing 80.0 mg (0.15 mmol) of methyl (S)-2-amino-3-(1-tosyl-
1H-pyrrolo[2,3-f]quinolin-3-yl)propionate (2.57) in 3 mL of dry DCM under N2 
atmosphere was added 0.05 mL (38.8 mg, 0.30 mmol) of DIPEA followed by 15.0 µL 
(15.2 mg, 0.15 mmol) of acetic anhydride. The reaction mixture was stirred at room 
temperature for 1 h. The reaction mixture was then diluted with 50 mL of satd aq 
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NaHCO3 and extracted with two 50-mL portions of EtOAc. The organic phase was dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with ethyl acetate gave the 
expected product methyl (S)-2-acetamido-3-(1-tosyl-1H-pyrrolo[2,3-f]quinolin-3-
yl)propionate (2.92) as a yellow oil: yield 75.1 mg (85%); silica gel TLC Rf 0.25 (1:1 
hexanes–ethyl acetate); 1H NMR(CDCl3, 500 MHz) 1.98 (s, 3H), 2.27 (s, 3H), 3.28-
3.32 (m, 1H), 3.40-3.44 (m, 1H), 3.72 (s, 3H), 4.96-4.99 (m, 1H), 6.13 (d, 1H, J = 7.5 
Hz), 7.11 (d, 2H, J = 8.0 Hz), 7.41-7.43 (m, 1H), 7.45 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H), 
7.76 (d, 1H, J = 9.0 Hz), 7.93 (d, 1H, J = 8.5 Hz), 8.81-8.83 (m, 1H) and 9.44 (d, 1H, J = 
8.5 Hz); 
13
C NMR(CDCl3, 125 MHz) 
a
nd 171.9; mass spectrum (APCI) m/z 466.1447 (M+H)
+
 (C24H24N3O5S requires m/z 
466.1437).
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Methyl (S)-2-Acetamido-3-(1H-pyrrolo[2,3-f]quinolin-3-yl)propionate (2.93). To a 
stirred solution containing 42.0 mg (0.09 mmol) of methyl (S)-2-amino-3-(1-tosyl-1H-
pyrrolo[2,3-f]quinolin-3-yl)propionate (2.92) in 2 mL of  2:1 anhydrous THF–methanol 
was added  96.0 mg (0.27 mmol) of Cs2CO3. The reaction mixture was stirred at room 
temperature for 2 h under argon, diluted with 50 mL of brine and extracted with two 50-
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mL portions of EtOAc. The organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with hexanes–ethyl acetate 1:1 gave the expected product methyl 
(S)-2-acetamido-3-(1H-pyrrolo[2,3-f]quinolin-3-yl)propionate (2.93) as a yellow oil: 
yield 17.1 mg (59%); silica gel TLC Rf 0.2 (10:1 ethyl acetate–methanol); 
1
H NMR( 
CD3OD, 500 MHz) 1.93 (s, 3H), 3.24-3.29 (m, 1H), 3.36-3.41 (m, 1H), 3.68 (s, 3H), 
4.77-4.80 (m, 1H), 7.28 (s, 1H), 7.53-7.56 (m, 1H), 7.65 (d, 1H, J = 8.5 Hz), 7.95 (d, 1H, 
J = 9.0 Hz) and 8.71 (d, 2H, J = 8.0 Hz); 
13
C NMR( CD3OD, 125 MHz) 

and 173.9; mass spectrum (APCI) m/z 312.1339 (M+H)+ (C17H18N3O3 requires m/z 
312.1348).
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Methyl (S)-2-Acetamido-3-(6-cyano-1-tosyl-1H-indol-3-yl)propionate (2.94). To a 
stirred solution containing 20.0 mg (0.05 mmol) of methyl (S)-2-amino-3-(6-cyano-1-
tosyl-1H-indol-3-yl)propionate (2.66) in 3 mL of dry CH2Cl2 under a N2 atmosphere was 
added 17.4 μL (12.9 mg, 0.10 mmol) of DIPEA followed by 5.0 μL (5.1 mg, 50 µmol) of 
acetic anhydride. The reaction mixture was stirred at room temperature for 2 h, then 
diluted with 20 mL of satd aq NaHCO3 and extracted with two 50-mL portions of EtOAc. 
The combined organic phase was dried (MgSO4) and concentrated under diminished 
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pressure. The residue was purified by chromatography on a silica gel column (10 × 1 
cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)-2-acetamido-3-(6-cyano-1-
tosyl-1H-indol-3-yl)propionate (2.94) as a yellow oil:  yield 17.2 mg (78%); silica gel 
TLC Rf 0.45 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) 1.95 (s, 3H), 
2.35 (s, 3H), 3.15-3.29 (m, 2H), 3.66 (s, 3H), 4.86-4.88 (m, 1H), 6.27 (br s, 3H), 7.46-
7.57 (m, 3H), 7.71-7.73 (m, 2H) and 8.23 (s, 1H); 
13
C NMR (CDCl3, 100 MHz)  21.7, 
23.2, 27.5, 52.4, 52.7, 107.9, 117.2, 118.0, 119.4, 120.5, 126.3, 126.9, 127.8, 130.3, 
133.9, 134.0, 134.6, 145.9, 169.9 and 171.7; mass spectrum (APCI), m/z 440.1272 
(M+H)
+
 (C22H22N3O5S requires m/z 440.1280). 
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Methyl (S)-2-Acetamido-3-(6-cyano-1H-indol-3-yl)propionate (2.95). To a stirred 
solution containing 13.0 mg (29.0 μmol) of methyl (S)-2-acetamido-3-(6-cyano-1-tosyl-
1H-indol-3-yl)propionate (2.94) in 1 mL of 2:1 anhydrous THF–methanol was added 
31.2 mg (87.1 μmol) of Cs2CO3. The reaction mixture was stirred at room temperature for 
1 h under argon, then diluted with 50 mL of brine and extracted with two 50-mL portions 
of EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 1 cm). Elution with ethyl acetate gave methyl (S)-2-acetamido-3-(6-cyano-1H-
indol-3-yl)propionate (2.95) as a yellow solid: yield 5.10 mg (57%); silica gel TLC Rf 
0.50 (ethyl acetate); 
1
H NMR (CD3OD, 400 MHz) 1.91 (s, 3H), 3.15-3.20 (m, 2H), 3.66 
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(s, 3H), 4.71-4.74 (m, 1H), 7.30 (d, 1H, J = 8.4 Hz), 7.37 (s, 1H), 7.67 (d, 1H, J = 8.4 Hz) 
and 7.75 (s, 1H);
 13
C NMR (CD3OD, 100 MHz)  22.4, 28.2, 52.8, 54.9, 104.5, 112.2, 
117.4, 120.4, 121.7, 122.6, 129.1, 132.1, 136.8, 173.2 and 173.7;  mass spectrum (APCI), 
m/z 286.1199 (M+H)
+
 (C15H16N3O3 requires m/z 286.1192). 
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Methyl (S)-2-Acetamido-3-(7-cyano-1-tosyl-1H-indol-3-yl)propionate (2.96). To a 
stirred solution containing 32.0 mg (0.08 mmol) of methyl (S)-2-amino-3-(7-cyano-1-
tosyl-1H-indol-3-yl)propionate (2.75) in 3 mL of dry CH2Cl2 under a N2 atmosphere was 
added 26.8 μL (20.7 mg, 0.16 mmol) of DIPEA followed by 7.56 μL (8.16 mg, 0.08 
mmol) of acetic anhydride. The reaction mixture was stirred at room temperature for 2 h. 
The reaction mixture was then diluted with 50 mL of satd aq NaHCO3 and extracted with 
two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 1 cm). Elution with 1:1 hexanes–ethyl acetate gave methyl (S)- 
2-acetamido-3-(7-cyano-1-tosyl-1H-indol-3-yl)propionate (2.96) as a yellow oil: yield 
28.1 mg (80%); silica gel TLC Rf 0.41 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 
MHz) 1.93 (s, 3H), 2.32 (s, 3H), 3.11-3.25 (m, 2H), 3.65 (s, 3H), 4.83-4.88 (m, 1H), 
6.35 (d, 1H, J = 7.6 Hz), 7.12-7.15 (m, 1H), 7.22 (d, 2H, J = 8.4 Hz), 7.48 (s, 1H), 7.78 
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(d, 1H, J = 7.6 Hz), 7.98 (d, 1H, J = 8.0 Hz) and 8.37 (dd, 1H, J = 4.8 and 1.2 Hz); mass 
spectrum (APCI), m/z 440.1278 (M+H)
+
 (C22H22N3O5S requires m/z 440.1280). 
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Methyl (S)-2-Acetamido-3-(7-cyano-1H-indol-3-yl)propionate (2.97). To a stirred 
solution containing 26.2 mg (0.06 mmol) of methyl (S)-2-acetamido-3-(7-cyano-1-tosyl-
1H-indol-3-yl)propionate (2.96) in 1 mL of 2:1 anhydrous THF–methanol was added 
43.1 mg (120 μmol) of Cs2CO3. The reaction mixture was stirred at room temperature for 
1 h under argon, then diluted with 50 mL of brine and extracted with two 50-mL portions 
of EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 1 cm). Elution with ethyl acetate gave methyl (S)-2-acetamido-3-(7-cyano-1H-
indol-3-yl)propionate (2.97) as a yellow solid: yield 12.0 mg (68%); silica gel TLC Rf 
0.18 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz)2.01 (s, 3H), 3.25-3.38 
(m, 2H), 3.60 (s, 3H), 4.69-4.74 (m, 1H), 7.10-7.13 (m, 1H), 7.22-7.23 (m, 1H), 7.65 (d, 
1H, J = 8.0 Hz), 8.42 (d, 1H, J = 4.8 Hz), 8.64 (s, 1H) and 9.12-9.13 (m, 1H); mass 
spectrum (APCI), m/z 286.1192 (M+H)
+
 (C15H16N3O3 requires m/z 286.1192). 
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Methyl (S)-2-Acetamido-3-(7-cyano-1-methyl-1H-indol-3-yl)propionate (2.98). To a 
stirred solution containing 38.6 mg (0.15 mmol) of methyl (S)-2-amino-3-(7-cyano-1-
methyl-1H-indol-3-yl)propionate (2.81) in 3 mL dry CH2Cl2 under a N2 atmosphere was 
added 50.8 μL (38.8 mg, 0.30 mmol) of DIPEA followed by 15.0 μL (15.2 mg, 0.15 
mmol) of acetic anhydride. The reaction mixture was stirred at room temperature for 2 h, 
diluted with 50 mL of satd aq NaHCO3 and extracted with two 50-mL portions of EtOAc. 
The combined organic phase was dried (MgSO4) and concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (10 × 1 
cm). Elution with ethyl acetate gave methyl (S)-2-acetamido-3-(7-cyano-1-methyl-1H-
indol-3-yl)propionate (2.98) as a yellow oil: yield 30.0 mg (69%); silica gel TLC Rf 0.21 
(1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) 1.93 (s, 3H), 3.20-3.26 (m, 
2H), 3.65 (s, 3H), 4.02 (s, 3H), 4.84-4.88 (m, 1H), 6.17 (s, 1H), 6.84 (s, 1H), 7.07 (t, 1H, 
J = 8.0 Hz), 7.46 (d, 1H, J = 7.2 Hz) and 7.69 (d, 1H, J = 8.0 Hz); 
13
C NMR (CDCl3, 100 
MHz) 23.2, 27.2, 34.6, 52.5, 53.0, 93.9, 109.8, 118.6, 119.0, 124.2, 128.6, 129.9, 130.1, 
134.9, 169.8 and 172.4; mass spectrum (APCI), m/z 300.1344 (M+H)
+
 (C16H18N3O3 
requires m/z 300.1348). 
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Methyl (S)-3-(4-Aminophenyl)-2-(tert-butoxycarbonylamino)propionate (2.99). 
To a cooled (
_
10 °C) solution containing 1.00 g (3.50 mmol) of (S)-3-(4-aminophenyl)-2-
(tert-butoxycarbonylamino)propionic acid in 10 mL of anhydrous MeOH  was added 
dropwise 0.25 mL (416 mg, 3.50 mmol) of SOCl2. The reaction mixture was left to warm 
slowly to room temperature and stirred for 3 h, then diluted with 50 mL of brine and 
extracted with two 50-mL portions of EtOAc. The combined organic phase was dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 4:1 hexanes–ethyl 
acetate gave 2.99 as a yellow oil: yield 594 mg (55%); silica gel TLC Rf 0.7 (1:1 
hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz)  1.34 (s, 9H), 2.87 (t, 2H, J = 6.4 
Hz ), 3.59 (s, 3H), 3.68 (s, 2H), 4.40-4.42 (m, 1H), 5.14 (d, 1H, J = 8.0 Hz), 6.49 (d, 2H, 
J = 8.4 Hz) and 6.80 (d, 2H, J = 8.4 Hz); 
13
C NMR (CDCl3, 100 MHz)28.4, 37.1, 51.8, 
54.5, 79.4, 114.9, 125.0, 129.8, 145.5, 155.0 and 172.4; mass spectrum (APCI), m/z 
295.1652 (M+H)
+
 (C15H23N2O4 requires m/z 295.1658).  
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(S)-2-(4-(2-(tert-Butoxycarbonylamino)-3-methoxy-3-oxopropyl)phenylamino) 
benzoic acid (2.100). A mixture containing 3.32 g (11.3 mmol) of 2.99, 0.88 g (5.65 
mmol) of 2-chlorobenzoic acid, 0.39 g (2.8 mmol) of K2CO3, 0.23 g of Cu powder in 4 
mL DMF was heated at reflux for 2 h. After cooling to room temperature, the reaction 
mixture was filtered, the filtrate slowly added to 30 mL of H2O, and extracted with two 
50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 4 cm). Elution with 4:1 hexanes–ethyl acetate gave 2.100 as a 
yellow oil: yield 1.10 g (47%); silica gel TLC Rf 0.7 (1:1 hexanes–ethyl acetate); 
1
H 
NMR (CDCl3, 400 MHz) 1.44 (s, 9H), 3.01-3.15 (m, 2H), 3.74 (s, 3H), 4.61-4.63 (m, 
1H),  5.12-5.14 (m, 1H), 6.73-6.76 (m, 1H), 7.11-7.20 (m, 4H), 7.31-7.35 (m, 1H), 8.04 
(d, 1H, J = 8.0 Hz) and 9.34 (s, 1H); 
13
C NMR (CDCl3, 100 MHz)28.4, 38.0, 52.4, 
54.6, 80.2, 110.9, 114.1, 117.3, 123.1, 130.4, 131.6, 132.7, 135.1, 139.5, 148.8, 155.3, 
172.6 and 173.3; mass spectrum (APCI), m/z 415.1871 (M+H)
+
 (C22H27N2O6 requires m/z 
415.1869).          
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(9-oxo-9,10-
dihydroacridin-2-yl)propionate (2.102). Polyphosphoric acid (13.0 mL) was preheated 
to 80 °C and added to 413 mg (1.35 mmol) of 2.101. The reaction mixture was stirred 
mechanically at 100 °C for 1 h, cooled to 50 °C, and poured into 50 mL of ice-water and 
and extracted with two 50-mL portions of EtOAc. The combined organic phase was dried 
(MgSO4) and concentrated under diminished pressure. The residue was redissolved 4 mL 
of dioxane-water (1:1) and 83.1 mg (4.22 mmol) of K2CO3 was added to the reaction 
mixture followed by 336 mg (1.56 mmol) of NVOC-Cl. The reaction mixture was stirred 
at room temperature for 14 h under argon. The reaction mixture was then diluted with 50 
mL of brine and extracted with two 50-mL portions of EtOAc. The organic phase was 
dried (MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 1:1 hexanes–ethyl 
acetate gave the expected product 2.102 as a yellow oil: yield 51.0 mg (10% for two 
steps); silica gel TLC Rf 0.55 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz)  
3.16-3.35 (m, 2H), 3.79 (s, 3H), 3.89 (s, 3H), 3.92 (s, 3H), 4.71-4.72 (m, 1H), 5.47-5.52 
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(m, 2H), 6.94 (s, 1H), 7.27-7.31 (m, 3H), 7.64-7.67 (m, 2H), 8.24 (s, 1H), 8.29 (br s, 1H) 
and 8.44 (d, 1H, J = 8.0 Hz); 
13
C NMR (CDCl3, 100 MHz) 36.0, 51.9, 55.5, 56.0, 62.4, 
108.0, 109.9, 117.2, 117.3, 120.2, 120.3, 120.8, 125.9, 126.0, 127.8, 129.9, 133.3, 134.4, 
138.9, 139.6, 140.7, 147.5, 153.3, 155.5, 172.1 and 176.5; mass spectrum (APCI), m/z 
536.1671 (M+H)
+
 (C27H26N3O9 requires m/z 536.1669). 
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Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(9-oxo-
9,10-dihydroacridin-2-yl)propionate (2.103). To a stirred solution containing 46.0 mg 
(0.09 mmol) of methyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(9-
oxo-9,10-dihydroacridin-2-yl)propionate (2.102) in 1 mL of 1:3:1 water–THF–methanol 
was added 275 µL (6.46 mg, 0.27 mmol) of 1N LiOH. The reaction mixture was stirred 
at room temperature for 2 h, and then concentrated under diminished pressure. The 
residue was redissolved in 1 mL of anhydrous DMF under argon. To the stirred solution 
was added 38.0 µL (28.0 mg, 0.27 mmol) of Et3N followed by 17.0 µL (20.0 mg, 0.27 
mmol) of chloroacetonitrile. The reaction mixture was stirred at 23 °C for 16 h and then 
diluted with 20 mL of EtOAc. The organic layer was washed with brine, dried (MgSO4) 
and concentrated under diminished pressure. The residue was purified by 
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chromatography on a silica gel column (10 × 2 cm). Elution with ethyl acetate gave the 
expected product cyanomethyl (S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-
3-(9-oxo-9,10-dihydroacridin-2-yl)propionate (2.103) as a light yellow solid: yield 20.0 
mg (40%); silica gel TLC Rf 0.5 ethyl acetate; 
1
H NMR (CDCl3, 400 MHz)  3.00-3.22 
(m, 2H), 3.77 (s, 3H), 3.81(s, 3H), 4.41-4.47 (m, 3H), 5.69 (ABq, 2H, J = 14.8 Hz), 7.04 
(s, 1H), 7.19-7.23 (m, 1H), 7.43 (d, 1H, J = 8.4 Hz), 7.49 (d, 1H, J = 8.4 Hz), 7.62-7.71 
(m, 3H), 8.11 (s, 2H), 8.18 (d, 1H, J = 8.0 Hz) and 8.25 (d, 1H, J = 8.0 Hz); 
13
C NMR 
(CDCl3, 100 MHz) 35.6, 49.5, 55.2, 56.0, 62.5, 108.0, 110.0, 115.5, 117.2, 117.4, 
120.2, 120.4, 120.8, 125.9, 126.2, 127.5, 129.5, 133.3, 134.4, 139.0, 139.7, 140.7, 147.6, 
153.3, 155.5, 170.8 and 176.5; mass spectrum (APCI), m/z 561.1613 (M+H)
+
 
(C28H25N4O9 requires m/z 561.1621). 
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(S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(9-oxo-9,10-
dihydroacridin-2-yl)-pdCpA (2.10). To a solution containing 5.20 mg (4.0 μmol) of 
pdCpA tetrabutylammonium salt in 100 L of 9:1 anhydrous DMF–triethylamine was 
added 12.1 mg (21.0 μmol) of cyanomethyl (S)-2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonylamino)-3-(9-oxo-9,10-dihydroacridin-2-yl)propionate (2.103). 
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The reaction mixture was sonicated for 6 h. The reaction mixture was purified by HPLC 
on a reversed phase column (C18, 10 × 250 mm) using a linear gradient of 99:1 → 1:99 
50 mM aq ammonium acetate (pH 4.5)–acetonitrile. The retention time of the desired 
product was 23.4 min. The fractions containing the product were lyophilized to afford 
2.103 as a colorless solid: yield 1.51 mg (34%); mass spectrum (ESI), m/z 1138.2372 (M-
H)
- 
(C45H46N11O21P2 requires m/z 1138.2345. 
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CHAPTER 3 
SYNTHESIS OF ALANYL NUCLEOBASE AMINO ACIDS FOR INCORPORATION 
INTO DNA-BINDING PROTEINS 
3.1. Introduction            
            Molecules which can bind with high sequence specificity to a chosen target in a 
gene sequence are of interest for the development of gene therapeutic agents, diagnostic 
devices for genetic analysis, and as molecular tools for nucleic acid manipulations.
149
 
Since interactions between nucleobases are important for controlling nucleic acid 
structures and gene expression, and base-base recognition can be highly selective, 
polypeptides containing nucleobases at defined positions could potentially be used to 
bind to DNA and RNA specifically.
150,151
  
            Peptide nucleic acid (PNA), first described by Nielsen’s group in 1991, is a DNA 
analogue in which the entire negatively charged sugar-phosphate backbone has been 
replaced with a neutral, peptide-like backbone usually formed from N-2-
aminoethylglycine units (Figure 3.1).
152
 PNA is achiral and uncharged. It is chemically 
stable and not prone to degradation by nucleases or proteases, and thus not expected to be 
degraded inside a living cell.
149
 Owing to its neutral backbone and proper interbase 
spacing, a PNA molecule binds to its complementary nucleic acid sequence (both single-
stranded DNA and RNA as well as double-stranded DNA) with higher affinity compared 
to natural DNA and RNA.
149,152
 The neutral backbone also predicts a lack of electrostatic 
repulsion between the PNA and DNA strands (compared to that existing between two 
negatively-charged DNA oligomers), and hence a higher thermal stability of PNA–DNA 
duplexes.
152
 Although the poor cellular uptake of free PNA is still considered a major 
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obstacle for the application of PNA for gene targeting, PNA has attracted major attention 
due to its potential for diagnostic
153,154
 as well as biotechnological
155,156
 and 
pharmaceutical
157,158
 applications.                                           
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Figure 3.1. Schematic chemical model of PNA and DNA, showing their different 
backbone linkages. 
 
 
            Although PNA contains an amide bond in its backbone, it has never been 
observed to form protein-like tertiary structures. Therefore, a simple PNA molecule may 
not discriminate highly structured nucleic acids in the same fashion as nucleic acid 
binding proteins. To obtain molecules capable of recognizing nucleobases in nucleic 
acids, but also capable of forming protein-like structues, a series of peptides 
containing L-α-amino acids with a nucleobase side chain (nucleobase amino acid (NBA)) 
was designed by Mihara’s group.159-161 They reported the use of L-amino-γ-nucleobase-
butyric acids (nucleobase amino acids or NBAs) (Figure 3.2) for the construction of 
different RNA binding peptides. In order to realize selective binding within more 
complex protein–DNA structures, our laboratory has employed the same strategy 
involving nucleobase interaction for DNA–protein interaction, anticipating that the 
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nucleobase moieties in the proteins could specifically recognize base sequence in nucleic 
acids through H-bonding and base stacking interactions.  
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Figure 3.2. Chemical structures of the cytosine (CNBA), thymine (TNBA), adenine (ANBA), 
and guanine (GNBA) residues within the RNA binding peptide chain. 
 
            Recently, Diederichsen’s group presented an enantioselective preparation of 
alanyl nucleobase amino acids with MMT-protected α-amino groups and acyl-protected 
exocyclic amino functions of the nucleobases for the solid phase synthesis of alanyl-
PNA/DNA chimeras as a tool for very sensitive DNA detection (Figure 3.3).
162 
In this 
thesis, a series of alanyl nucleobase amino acids (ANA-1 – ANA-8) (Figure 3.4) have 
been prepared. A site-specific mutagenesis technique, which permits the insertion of 
unnatural amino acids into any predetermined position of a protein by the suppression of 
TAG or four base codons with misacylated-tRNAs, has not been used before for 
incorporation of amino acids having nucleobase side chains. Therefore, this strategy was 
attempted for the incorporation of ANAs into the DNA-binding protein RRM1. In order 
to synthesize the requisite aminoacylated tRNAs for protein synthesis, the pdCpA 
derivatives (3.1-3.8) of alanyl nucleobase amino acids were prepared (Figure 3.5). 
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Figure 3.3. Chemical structures of the MMT/acyl-protected nucleobase amino acids for 
the solid phase synthesis of DNA/alanyl-PNA chimeras.
162
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Figure 3.4. Series of alanyl nucleobase amino acids synthesized for site-directed 
incorporation at position 24 of RRM1. 
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Figure 3.5. Series of aminoacylated pdCpA derivatives synthesized for site-directed 
incorporation at position 24 of RRM1. 
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            As discussed Chapter 1, ribosomes having modifications in their 23S rRNA 
enabled the incorporation of the dipeptides and dipeptidomimetics into DHFR have been 
realized. The selection of ribosomes having modifications in specific regions of the 23S 
rRNA was done using puromycin derivatives. Using the same strategy, a 
dipeptidylpuromycin 3.9 (Figure 3.6) was synthesized to enable the selection of 
ribosomes that could accept the dipeptide ANA-8 during protein synthesis.      
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Figure 3.6. Structure of puromycin derivative 3.9. 
 
 
            The protein RRM1 (14 kD) is a DNA binding domain of human transcription 
factor hnRNP LL.
163
 The transcription factor hnRNP LL (heterogeneous nuclear 
ribonucleoprotein) has been shown to bind to the i-motif in the BCL2 promoter region, 
and to unfold the i-motif to initiate transcription. hnRNP LL has four RNA recognition 
motif (RRM) domains, each potentially capable of binding to the i-motif.  
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Figure 3.7. (a) Structure of i-motif DNA.
163
 The cytidine rich i-motif stem is shown in 
yellow with two of the lateral loops and the central loop: blue–T; red –G ; green –A. (b) 
Structure of RRM1 of human hnRNP LL, including His24 generated by I-Tasser software 
using the structure of Mus musculus RRM domain of BAB28521 protein (pdb 1WEX) as 
a template.
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3.2. Results 
Synthesis of pdCpAs Esters 
            In this study, proteins have been synthesized with different ANA units as 
constituents to enable a study of the ability of the protein nucleobase moiety to enforce 
the selectivity of nucleic acid interaction. In order to synthesize the requisite 
aminoacylated tRNAs for protein synthesis, the pdCpA derivatives were prepared from 
their respective amino acids. The asymmetric syntheses of alanyl nucleobase amino 
amino acids were acheived either by nucleophilic ring opening of N-Boc-L-serine β-
lactone, or by using the Schöllkopf chiral auxiliary. 
            The synthesis of the aminoacylated pdCpA derivative of alanyl nucleobase amino 
acid ANA-1 was accomplished starting from commercially available cytosine (Scheme 
3.1). CBz protection of cytosine afforded compound 3.10 in 74% yield.
165
 Compound 
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3.10 underwent coupling with N-Boc-L-serine β-lactone to afford compound 3.11 in 56% 
yield,
162
 the latter of which reacted with SOCl2 in methanol to form methyl ester 3.12. 
The CBz protecting group was removed by hydrogenolysis over Pd/C to afford 3.13. Boc 
deprotection and subsequent NVOC protection of compound 3.13 afforded compound 
3.14 in 35% overall yield. N-protected methyl ester 3.14 was subsequently hydrolyzed to 
afford the free acid, the latter of which was treated with chloroacetonitrile to afford the  
desired cyanomethyl ester
 
3.15 in 34% yield over two steps. The key intermediate 
cyanomethyl ester of the N-protected amino acid (3.15) was coupled with 
tris(tetrabutylammonium) salt of pdCpA to give a pdCpA ester 3.1 in 25% yield. 
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Scheme 3.1. Synthesis of ANA-1 and its Aminoacyl-pdCpA. 
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            The synthesis of the aminoacylated pdCpA derivative of alanyl nucleobase amino 
acid ANA-2 was accomplished starting from commercially available uracil (Scheme 3.2)  
which underwent coupling with N-Boc-L-serine β-lactone to afford compound 3.16 in 
41% yield. Free acid 3.16 reacted with SOCl2 in methanol to form the methyl ester 3.17 
in 75% yield. Boc deprotection and subsequent NVOC protection of methyl ester 3.17 
afforded NVOC-carbamate 3.18 in 54% yield. Methyl ester 3.18 was subjected to 
saponification in the presence of aqueous LiOH to produce the free acid, which was 
activated as cyanomethyl ester 3.19 in 30% overall yield. Treatment of cyanomethyl ester 
3.19 with the tris(tetrabutylammonium) salt of pdCpA in anhydrous DMF afforded 
pdCpA ester 3.2 in 46% yield.   
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Scheme 3.2. Synthesis of ANA-2 and its Aminoacyl-pdCpA. 
 
The synthesis of the aminoacylated pdCpA derivative of amino acid ANA-3 was 
accomplished starting from commercially available thymine (Scheme 3.3) which          
underwent coupling with N-Boc-L-serine β-lactone to afford compound 3.20 in 33% 
yield. Compound 3.20 was treated with SOCl2 in methanol to afford the methyl ester 3.21 
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in 65% yield. Boc deprotection and subsequent NVOC protection of methyl ester 3.21 
afforded NVOC-carbamate 3.22 in 47% overall yield. NVOC methyl ester 3.22 was 
hydrolyzed to afford the free acid, the latter of which was treated with chloroacetonitrile 
to afford the desired cyanomethyl ester 3.23 in 35% yield over two steps. Cyanomethyl 
ester 3.23 was used to ligate the dinucleotide pdCpA to afford the pdCpA ester 3.3 in 
45% yield. 
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Scheme 3.3. Synthesis of ANA-3 and its Aminoacyl-pdCpA. 
 
 
            The synthesis of the aminoacylated pdCpA derivative of amino acid ANA-4 was 
accomplished starting from 1,3-diaza-2-oxophenothiazine
166,167
 which was synthesized 
from commercially available 5-bromouracil and 2-aminothiophenol following a literature 
procedure
167
 (Scheme 3.4). Compound 3.24 underwent coupling with N-Boc-L-serine β- 
lactone to afford compound 3.25 in 59% yield. Free acid 3.25 was treated with SOCl2 
in methanol to form the methyl ester 3.26 in 70% yield. Boc deprotection and subsequent 
NVOC protection of methyl ester 3.26 afforded NVOC-protected methyl ester 3.27 in 
40% yield over two steps. Hydrolysis of NVOC methyl ester 3.27 afforded the free acid, 
 153 
 
which was activated as cyanomethyl ester 3.28 in 31% overall yield. Treatment of 
cyanomethyl ester 3.28 with the tris(tetrabutylammonium) salt of pdCpA in anhydrous 
DMF afforded pdCpA ester 3.4 in 46% yield.                 
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Scheme 3.4. Synthesis of ANA-4 and its Aminoacyl-pdCpA. 
 
 
The synthesis of the aminoacylated pdCpA derivative of ANA-5 was 
accomplished starting from commercially available thiocytosine (Scheme 3.5). Pentenoyl 
protection of thiocytosine afforded compound 3.29, the latter of which underwent 
coupling with N-Boc-L-serine β-lactone to afford compound 3.30 in 63% yield. Boc 
deprotection and subsequent protection using 4-pentenoic acid succinimide ester in the 
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presence of K2CO3 afforded dipentenoyl amide 3.31 in 41% yield over two steps. Free 
acid 3.31 was activated as the cyanomethyl ester 3.32 in 53% yield. The pdCpA 
derivative of ANA-5 was prepared from cyanomethyl ester 3.32 in 65% yield.     
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Scheme 3.5. Synthesis of ANA-5 and its Aminoacyl-pdCpA.          
 
The synthesis of the aminoacylated pdCpA derivative of amino acid ANA-6 
(Scheme 3.6) was accomplished starting from commercially available 5-methyl-2-  
nitropyridine which underwent bromination with NBS to afford 3.33.
 
Regioselective 
lithiation of the Schöllkopf chiral auxiliary with n-BuLi, followed by treatment with 
bromide 3.33 at 
_
78 °C afforded adduct 3.34 as a single diastereomer in 22% yield. Mild 
hydrolysis with 2 N HCl
 
afforded the α-substituted amino acid methyl ester 3.35 in 84% 
yield. NVOC protection of free amine 3.35 afforded NVOC-carbamate 3.36 in 54% yield. 
Methyl ester 3.36 was hydrolyzed to afford the free acid, the latter of which was treated 
with chloroacetonitrile to afford the desired cyanomethyl ester 3.37 in 34% overall yield. 
 155 
 
Treatment of the cyanomethyl ester 3.37 with a solution of the tris(tetrabutylammonium) 
salt of pdCpA
 
in anhydrous DMF gave the aminoacylated pdCpA 3.6 in 60% yield. 
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Scheme 3.6. Synthesis of ANA-6 and its Aminoacyl-pdCpA. 
 
            The synthesis of the aminoacylated pdCpA derivative of amino acid ANA-7 was 
accomplished starting from the intermediate 3.35 (Scheme 3.7). Nitro group reduction 
and subsequent NVOC protection afforded NVOC-carbamate 3.38 in 23% yield over two 
steps. NVOC methyl ester 3.38 was hydrolyzed to afford the free acid which was treated 
with chloroacetonitrile to afford the cyanomethyl ester 3.39 in 32% overall yield. 
Treatment of cyanomethyl ester 3.39 with the tris(tetrabutylammonium) salt of pdCpA in 
anhydrous DMF afforded pdCpA ester 3.7 in 54% yield. 
            The synthesis of the pdCpA derivative of amino acid ANA-8 commenced with 
CBz protection of the intermediate 3.35 (Scheme 3.8). Methyl ester 3.40 was subjected to 
saponification in the presence of aqueous LiOH to produce 3.41. This CBz protected acid 
was subsequently condensed with 3.35 in the presence of HBTU and Et3N to afford the  
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Scheme 3.7. Synthesis of ANA-7 and its Aminoacyl-pdCpA. 
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Scheme 3.8. Synthesis of ANA-8 and its Aminoacyl-pdCpA. 
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N-protected dipeptide methyl ester 3.42 in 53% overall yield.
168
 CBz deprotection and 
subsequent NVOC protection afforded NVOC-carbamate 3.43 in 21% yield over two 
steps. N-NVOC dipeptide methyl ester 3.43 was hydrolyzed to afford the free acid which 
was converted to the corresponding cyanomethyl ester 3.44 in 49% overall yield. 
Treatment of cyanomethyl ester 3.44 with the tris(tetrabutylammonium) salt of pdCpA in 
anhydrous DMF afforded dipeptidyl-pdCpA ester 3.8 in 55% yield. 
 
Synthesis of Dipeptidylpuromycin 3.9 
            The synthesis of the dipeptidylpuromycin 3.9 commenced with the CBz 
protection of phenylalanine (Scheme 3.9). CBz-protected phenylalanine (3.45) was 
subsequently condensed with phenylalanine methyl ester in the presence of HBTU and 
DIPEA to afford the N-protected dipeptide methyl ester 3.46 in 62% yield (Scheme 3.9). 
The methyl ester was saponified in the presence of aqueous LiOH to produce 3.47 in 85% 
yield. Dipeptide acid 3.47 was treated with NHS in the presence of DCC to form N-
hydroxysuccinimide ester, which was condensed with puromycin aminonucleoside to 
afford CBz-protected dipeptidylpuromycin 3.48 (Scheme 3.9).
168
 Dipeptidylpuromycin 
3.9 was then prepared in 47% yield from 3.48 by hydrogenolysis over Pd/C. 
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Scheme 3.9. Synthesis of Dipeptidylpuromycin 3.9. 
 
Activation of Suppressor tRNACUA and Synthesis of Modified RRM1s 
            The individual N-protected aminoacylated pdCpA derivatives were ligated to a 
suppressor tRNACUA lacking its 3′-terminal cytidine and adenosine residues (tRNACUA-
COH) via the agency of T4 RNA ligase. The N-NVOC and N-pentenoyl protected 
misacylated tRNAs were deprotected by exposure to high intensity UV light at 4 
o
C and 
by treatment with aqueous iodine, respectively, to afford the activated tRNAs having 
ANAs with free α-amines. The aminoacyl-tRNAs so obtained were employed in an in 
vitro cell free transcription-translation system, which was programmed with pETRRM1-
24 plasmid containing a TAG codon at the position corresponding to residue His24 of 
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RRM1. The incorporation of all the alanyl nucleobase amino acids into position 24 was 
evaluated via denaturing PAGE analysis and the incorporation yields were 5% to 71% as 
compared to the wild-type RRM1 (Table 3.1). It was found that four of the alanyl 
nucleobase amino acids (ANA-1, ANA-2, ANA-6  and ANA-7) can suppress TAG codon 
for full size RRM1 synthesis with good suppression yields ranging from 23% to 71% 
(Table 3.1 and Figure 3.8) compared to wild-type RRM1. To incorporate dipeptide ANA-
8, S30 010328R4, having modified ribosomes, selected against Phe-Gly-puromycin
168
 
was used and the incorporation yield was 5% to as compared to wild type. 
 
Table 3.1. Expression Yields of RRM1s Modified at Position 24. The experiment was 
performed by Dr. Larisa Dedkova. 
 
 
                                                                            position 24 (His)                                                   
 RRM1                                                                     yield (%)   
     
 wild-type                                                                             100                                                                
 
  ANA-1                                                                         23  
        
  ANA-2                                                                         24 
          
  ANA-3                                                                         6   
   
  ANA-4                                                                         6 
    
  ANA-5                                                                         6  
   
  ANA-6                                                                         35  
   
  ANA-7                                                                         71 
   
  ANA-8
a
                                                                        5          
     
   
a 
S30 010328R4, having modified ribosome was used 
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            Since, ANA-7 was best among the series of alanyl nucleobase amino acids for 
suppressing a TAG codon for full size RRM1 synthesis, its aminoacyl-tRNA (ANA7-  
tRNACUA) was employed in an in vitro cell free transcription-translation system, which 
was programmed with pETRRM1-26 plasmid (containing TAG codon at the position 
corresponding to residue Arg26 of RRM1) or pETRRM1-2426 plasmid in which CAC 
(His24) and CGT (Arg26) both these codons simultaneously were substituted by TAG 
codon during PCR mutagenesis. The suppression efficiencies, relative to RRM1 
 synthesized from the wild-type gene, were 54% and 6%, respectively (Figure 3.9). 
 
RRM1wt                    RRM1-24  
                no     ANA-7   ANA-1   ANA-2       
 
 
      100       2         71       23        24      % 
 
Figure 3.8. SDS-polyacrylamide gel analysis of translation of RRM1 from wild type 
(RRM1wt) and modified RRM1 mRNAs in the absence (no) and in the presence of 
tRNAs with ANA7, ANA1 and ANA2 respectively. 
 
 
wt              24TAG          26TAG         2426TAG 
                no     ANA7   no   ANA7     no    ANA7   
 
  100        1         55        1         54      0.3        6   
 
 
Figure 3.9.  SDS-polyacrylamide gel electrophoresis of samples, obtained during in vitro 
translation of RRM1 from wild type (wt) and mutant (TAG codon in positions 
corresponding to His24 (24TAG); Arg26 (26TAG) and both His24 and Arg26 
(2426TAG)) genes in the absence (no) and in the presence of ANA7-tRNACUA. The 
experiment was performed by Dr. Larisa Dedkova. 
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Electrophoretic mobility shift assay (EMSA) 
            The binding interaction between modified RRM1 and an i-motif DNA was 
studied and compared to wild-type RRM1 by employing a gel shift assay, EMSA.
169
 
RRM1 protein samples containing ANA-7 at position 24 or 26, or at both positions, were 
tested in this assay and their binding ability was compared (Figure 3.10). It was shown 
that substitution of His24 or Arg26 by ANA-7 has resulted in a 1.5-2 fold increased 
ability to form a complex with the 39 nt oligonucleotide 5’ 
CAGCCCCGCTCCCGCCCCCTTCCTCCCGCGCCCGCCCCT 3’, corresponding to  
 
       RRM1-24His26Arg(wt) 
      0    25   50   100  200 
 
     BC50=480±64 fmol 
          RRM1-24ANA7 
    0    25    50  100  200 
 
 BC50=266±58 fmol 
         RRM1-26ANA7 
   0      25   50   100  200  
 
   BC50=317±55 fmol 
     RRM1-24ANA7-26ANA7 
   0      25    50   100  200 
 
  BC50=630±140 fmol 
 
               
Figure 3.10. EMSA comparison of BCL2 i-motif DNA binding ability of different 
samples of RRM1 at varying concentration (wild-type RRM1: blue, RRM1-24-ANA-7: 
red, RRM1-26-ANA-7: green, RRM1-2426-ANA-7: purple). The experiment was 
performed by Dr. Larisa Dedkova. 
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BCL2 i-motif, whereas substitution of both the positions simultaneously has decreased 
the ability of RRM1 to bind to the i-motif DNA (Figure 3.10). Comparison of binding 
activity of control and analyzed samples was expressed in BC50 (concentration at which 
50% of the protein was complexed with the i-motif DNA). 
 
4.3. Discussion 
            As part of our ongoing efforts to develop molecules which can bind with high 
sequence specificity to a chosen target in a gene sequence, a series of alanyl nucleobase 
amino acids was synthesized. Their aminoacyl-tRNA derivatives were used for their 
incorporation into predetermined positions of RRM1 by suppression of nonsense codons. 
Boc-protected alanyl nucleobase amino acids were obtained by ring opening of N-Boc-L-
serine β-lactone with the DNA bases (Scheme 3.1 – Scheme 3.5). The yields are quite 
low due to their low solubility in DMSO, regioselectivity problems (SN2 vs. carbonyl 
attack on the serine lactone and N
7
 vs. N
9
 alkylation) and racemization.
162 
Uracil and 
thymine are the only nucleobases that did not require protection. The synthesis of the 
aminoacylated pdCpA derivative of cytosinylalanine (ANA-1) commenced with CBz 
protection of cytosine (Scheme 3.1). Similarly, for the synthesis of the aminoacylated 
pdCpA derivative of thiocytosinylalanine (ANA-5) the starting material, thiocytosine, 
was protected as its N-pentenoylamide (Scheme 3.5). The asymmetric syntheses of the 
ANA-6 – ANA-8 were challenging and started with the asymmetric synthesis using Ni 
chiral auxiliary.
47
 Several attempts were made to alkylate the Ni chiral auxiliary with 
bromide 3.33 but none of them resulted in successful asymmetric synthesis in reasonable 
yield. Finally, lithiation of the Schöllkopf chiral auxiliary with n-BuLi, followed by 
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treatment with bromide 3.33 at 
_
78 °C, afforded the adduct 3.34 as a single diastereomer 
in 22% yield (Scheme 3.6). Despite extensive efforts to improve the yield of the 
asymmetric synthesis, so far the route involving the Schöllkopf reagent has turned out to 
be the most efficient. Cyanomethyl esters of the N-protected amino acids were coupled 
with pdCpA TBA salt to give dinucleotide esters (3.1–3.8) which was obtained as 
colorless solids after reversed-phase HPLC purification. Misacylated tRNAs were 
produced by ligating abbreviated tRNA-COH, with pdCpA derivatives 3.1–3.8 using T4 
tRNA ligase. The activated tRNAs were deprotected by UV irradiation or iodine 
treatment to afford free aminoacyl-tRNAs. 
 
Based on calculations (done by Dr. Sashka Daskalova) using different computer 
programs, positions His24 and Arg26 of RRM1 which participate in binding of the 
protein RRM1 with the BCL2 i-motif were chosen for mutagenesis. Alanyl nucleobase 
amino acids (ANAs) were incorporated into position 24 of RRM1 and ANA-7, exhibiting 
the best suppression yield, was further used for incorporation into 26 position of RRM1. 
As shown in Figure 3.10, RRM1-24-ANA7 and RRM1-26-ANA7, both had stronger 
affinity (BC50= 266 ± 58 fmol and 317 ± 55 fmol, respectively) for the i-motif DNA 
compared to wild-type RRM1 (BC50= 480 ± 64 fmol). Arg26 probably plays a more 
important role (possibly through H-bonding and electrostatic interaction) in binding than 
His24. Therefore, RRM1-26-ANA7 has decreased binding ability compared to RRM1-
24-ANA7. Substitution of the two amino acids by ANA-7 decreased the binding affinity 
significantly (BC50= 630 ± 140 fmol), probably due to perturbation of the secondary 
structure used for DNA recognition. 
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            To incorporate ANA-8, S30 010328R4, having modified ribosomes, selected 
against Phe-Gly-puromycin
168
 was used for incorporation, but yield was only 5% as 
compared to the wild type. Therefore, to improve the incorporation yield, puromycin 3.9 
has been synthesized anticipating that it will enable the selection of ribosomes that will 
accept dipeptide ANA-8 more efficiently during protein synthesis.      
 
3.4. Experimental Procedures 
 
            The chemicals used were purchased from Aldrich Chemical Co., Sigma Chemical 
Co. or Combi-Blocks and were used without further purification. Anhydrous DMSO and 
DMF were used as purchased. Tetrahydrofuran and dichloromethane were distilled from 
sodium/benzophenone and calcium hydride, respectively. The tris-(tetrabutylammonium) 
salt of pdCpA was prepared by passing pdCpA through the activated TBA form of 
Dowex 50W×8 (200-400 mesh). All experiments requiring anhydrous conditions were 
conducted in flame-dried glassware fitted with rubber septa under a positive pressure of 
dry nitrogen, unless otherwise noted. Reactions were performed at room temperature 
unless indicated otherwise. Analytical thin-layer chromatography was performed using 
glass plates pre-coated with silica gel (0.25 mm, 60 Å pore size, 230-400 mesh, Silicycle) 
impregnated with a fluorescent indicator (254 nm). TLC plates were visualized by 
exposure to ultraviolet light (UV). Flash column chromatography was performed 
employing silica gel (60 Å pore size, 40-63 μm, standard grade, Silicycle). An acetone 
bath was cooled to the appropriate temperature by addition of small portions of dry ice. 
1
H NMR and 
13
C NMR spectra were recorded on Varian INOVA 400 (400 MHz) 
and Varian INOVA 500 (500 MHz) spectrometers at 25 °C. Proton chemical shifts are 
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expressed in parts per million (ppm, δ scale) and are referenced to residual protium in the 
NMR solvent (CDCl3 or DMSO-d6 or CD3OD).  Splitting patterns are designated as 
follows: s, singlet; br s, broad singlet; d, doublet; dd, doublet of doublets; t, triplet; q, 
quartet; m, multiplet. High resolution mass spectra were obtained at the Arizona State 
University CLAS High Resolution Mass Spectrometry Facility or the Michigan State 
University Mass Spectrometry Facility. HPLC purification was performed with a Waters 
600 pump coupled with a Varian ProStar 340 detector and a Grace Econosil C18 column 
(250 x 10 mm, 5 μm). The tetra-n-butylammonium (TBA) salt of pdCpA was prepared 
using Dowex 50WX8, 200–400 mesh activated in its TBA form. 
                                                  
                                              
N
N
NHCBz
O O
OMe
NHBoc
 
Methyl (S)-3-(4-(Benzyloxycarbonylamino)-2-oxopyrimidin-1(2H)-yl)-2-(tert 
butoxycarbonylamino)propionate (3.12). To a stirred suspension of 1.44 g (36.0 mmol) 
of NaH (60% in mineral oil) in 50 ml of DMF at 0 °C was added 1.00 g (9.01 mmol) of 
cytosine. The reaction mixture was stirred at 0 °C for 1 h, then 1.35 mL (9.50 mmol) of 
ClCOOBn was added. The reaction mixture was stirred at room temperature for 14 h, 
then diluted with 100 mL of H2O and ice. After neutralization with 5 N HCl, a colorless 
precipitate formed, and was filtered, washed with five 50-mL portions of H2O and dried 
to give 3.10 as a colorless powder: yield 1.71 g (74%); mass spectrum (APCI), m/z 
246.0890 (M+H)
+
 (C12H12N3O3 requires m/z 246.0879).  
 166 
 
To a stirred suspension containing 250 mg (1.02 mmol) of compound 3.10 in 5 mL of 
DMSO was added 0.18 mL (183 mg, 1.20 mmol) of DBU. Within 15 min, a solution 
containing 220 mg (1.20 mmol) of N-(tert-butoxycarbonyl)-L-serine β-lactone in 5 mL of 
DMSO was added. The reaction mixture was stirred at room temperature for 2 h under 
argon atmosphere, then diluted with 10 mL of 0.5 N HCl and extracted with two 20-mL 
portions of EtOAc. The combined organic phase was dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 2 cm). Elution with 5:1 ethyl acetate–methanol gave 3.11 as a colorless 
solid: yield 246 mg (56%); silica gel TLC Rf 0.31 (5:1 ethyl acetate–methanol). To a 
cooled (0 °C) solution containing 246 mg (0.60 mmol) of 3.11 in 5 mL of anhydrous 
MeOH was added dropwise 0.04 mL (67.7 mg, 0.60 mmol) of SOCl2. The reaction 
mixture was allowed to warm slowly to room temperature with stirring for 2 h, then 
diluted with 50 mL of brine and extracted with two 50-mL portions of EtOAc. The 
combined organic phase was dried (MgSO4) and concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution 
with 10:1 ethyl acetate–methanol gave 3.12 as a colorless solid: yield 165 mg (65%); 
silica gel TLC Rf 0.72 (5:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 500 MHz) δ 1.35 
(s, 9H), 3.64 (s, 3H), 4.01-4.60 (m, 3H), 5.19 (s, 2H), 5.86-5.96 (m, 4H), 6.29 (br s, 1H), 
7.17 (s, 1H), 7.55 (s, 1H), 7.75 (s, 1H) and 8.70 (br s, 1H); 
13
C NMR (CDCl3, 125 MHz) 
δ 28.2, 50.8, 52.1, 52.8, 67.9, 80.5, 94.8, 128.3, 128.58, 128.63, 135.09, 149.7, 150.5, 
152.5, 155.5, 162.9 and 170.4; mass spectrum (APCI), m/z 447.1890 (M+H)
+
 
(C21H27N4O7 requires m/z 447.1880). 
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Methyl (S)-3-(4-Amino-2-oxopyrimidin-1(2H)-yl)-2-(tert-
butoxycarbonylamino)propionate (3.13). To a solution containing 164 mg (0.36 mmol) 
of 3.12 in 5 mL of MeOH was added catalytic amount of 10% Pd/C and the reaction was 
placed under 1 atm of H2 (g) overnight. The catalyst was removed by filtration through a 
pad of Celite 545
®
 and the filtrate was concentrated under diminished pressure and 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with 3:1 ethyl 
acetate–methanol gave 3.13 as a colorless solid: yield 98.0 mg (85%); silica gel TLC Rf 
0.11 (5:1 ethyl acetate–methanol); 1H NMR (CD3OD, 400 MHz) δ 1.37 (s, 9H), 3.71-3.73 
(m, 4H), 4.34-4.59 (m, 2H), 5.83 (d, 1H, J = 7.2 Hz) and 7.44 (d, 1H, J = 7.2 Hz); 
13
C 
NMR (CD3OD, 100 MHz) δ 28.6, 53.0, 53.2, 53.5, 53.6, 80.9, 95.8, 147.9, 148.2, 157.6, 
158.7, 167.9 and 172.0; mass spectrum (APCI), m/z 313.1506 (M+H)
+
 (C13H21N4O5 
requires m/z 313.1512). 
                                             
N
N
NH2
O O
OMe
HN O
O NO2
O
O
 
Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(4-amino-2-
oxopyrimidin-1(2H)-yl)propionate (3.14). To a stirred solution containing 97.0 mg 
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(0.31 mmol) of 3.13 in 2 mL of anhydrous CH2Cl2 was added 0.24 mL (353 mg, 3.10 
mmol) of trifluoroacetic acid. The reaction mixture was stirred at room temperature for 2 
h and then concentrated under diminished pressure. To a stirred solution containing Boc-
deprotection product in 2 mL of 1:1 dioxane–water was added 129 mg (0.93 mmol) of 
K2CO3 followed by 85.5 mg (0.31 mmol) of NVOC-Cl. The reaction mixture was stirred 
at room temperature for 14 h under argon, then diluted with 50 mL of brine and extracted 
with two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 5:1 ethyl acetate–methanol gave 3.14 as a 
light yellow solid: yield 49.2 mg (35% for two steps); silica gel TLC Rf 0.25 (5:1 ethyl 
acetate–methanol); 1H NMR (CD3OD, 400 MHz) δ 3.71 (s, 3H), 3.84 (s, 3H), 3.90 (s, 
3H), 4.35-4.39 (m, 1H), 4.77-4.81 (m, 2H), 5.31 (ABq, 2H, J = 10.8 Hz), 5.83 (d, 1H, J = 
7.2 Hz), 7.04 (s, 1H), 7.48 (d, 2H, J = 7.2 Hz) and 7.58 (s, 1H); mass spectrum (APCI), 
m/z 452.1413 (M+H)
+
 (C18H22N5O9 requires m/z 452.1417). 
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Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(4-amino- 
2-oxopyrimidin-1(2H)-yl)propionate (3.15). To a stirred solution containing 14.0 mg 
(0.03 mmol) of 3.14 in 1 mL of 1:3:1 water–THF–methanol was added 90.0 µL (0.09 
mmol) of 1 N LiOH. The reaction mixture was stirred at room temperature for 2 h, and 
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then concentrated under diminished pressure. The residue was dissolved in 1 mL of 
anhydrous DMF under argon and 25.0 mg (0.30 mmol) of NaHCO3 was added followed 
by 4.0 µL (5.0 mg, 0.06 mmol) of chloroacetonitrile. The reaction mixture was stirred at 
23 °C for overnight, then diluted with 20 mL of brine and extracted with two 50-mL 
portions of EtOAc. The combined organic phase was dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 2 cm). Elution with 5:1 ethyl acetate–methanol gave 3.15 as a light yellow 
solid: yield 5.01 mg (34% for two steps); silica gel TLC Rf 0.26 (5:1 ethyl acetate–
methanol); 
1
H NMR (CD3OD, 400 MHz) δ 3.89 (s, 3H), 3.94-3.96 (m, 4H), 4.36-4.41 (m, 
1H), 4.71-4.75 (m, 1H), 4.92 (s, 2H), 5.38-5.48 (m, 2H), 5.84 (br s, 1H), 7.12 (s, 1H), 
7.48 (d, 2H, J = 7.6 Hz) and 7.71 (s, 1H); mass spectrum (APCI), m/z 477.1377 (M+H)
+
 
(C19H21N6O9 requires m/z 477.1370). 
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((S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(4-amino-2-
oxopyrimidin-1(2H)-yl)propionic Acid pdCpA Ester (3.1). To a solution containing 
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5.20 mg (4.00 μmol) of pdCpA tetrabutylammonium salt in 100 µL of 9:1 anhydrous 
DMF–triethylamine was added 10.0 mg (21.0 μmol) of 3.15. The reaction mixture was 
sonicated for 5 h. The reaction mixture was purified by HPLC on a C18 reversed phase 
column (250 × 10 mm) using a linear gradient of 99:1 → 1:99 50 mM aq ammonium 
acetate, pH 4.5–acetonitrile. The retention time of the desired product was 20.1 min. The 
fractions containing the product were lyophilized to afford 3.1 as a colorless solid: yield 
1.01 mg (25%); mass spectrum (ESI), m/z 1054.2106 (M-H)
-
 (C36H42N13O21P2 requires 
m/z 1054.2093).  
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Methyl (S)-2-(tert-Butoxycarbonyl)-3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)propionate (3.17). To a stirred suspension containing 250 mg (2.23 mmol) of 
nucleobase uracil in 5 mL of DMSO was added 0.40 mL (407 mg, 2.68 mmol) of DBU. 
Within 15 min, a solution containing 491 mg (2.68 mmol) of N-(tert-butoxycarbonyl)-L-
serine β-lactone in 5 mL of DMSO was added. The reaction mixture was stirred at room 
temperature for 2 h under argon, then diluted with 10 mL of 0.5 N HCl and extracted 
with two 20-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 5:1 ethyl acetate–methanol gave 3.16 as a 
colorless solid: yield 273 mg (41%); silica gel TLC Rf 0.25 (5:1 ethyl acetate–methanol). 
To a cooled (0 °C) solution containing 246 mg (0.91 mmol) of 3.16 in 5 mL of anhydrous 
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MeOH was added dropwise 0.07 mL (71.2 mg, 0.60 mmol) of SOCl2. The reaction 
mixture was allowed to warm slowly to room temperature with stirring for 2 h, then 
diluted with 50 mL of brine and extracted with two 50-mL portions of EtOAc. The 
combined organic phase was dried (MgSO4) and concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution 
with 10:1 ethyl acetate–methanol gave 3.17 as a colorless solid: yield 214 mg (75%); 
silica gel TLC Rf 0.81 (5:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 400 MHz) δ 1.36 
(s, 9H), 3.74 (s, 3H), 4.20-4.49 (m, 3H), 5.64 (s, 1H), 5.73 (s, 1H), 7.17 (s, 1H) and 10.10 
(s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 28.3, 49.7, 52.4, 53.1, 80.8, 102.2, 145.2, 151.4, 
155.4, 164.2 and 170.6; mass spectrum (APCI), m/z 314.1345 (M+H)
+
 (C13H20N3O6 
requires m/z 314.1352). 
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)propionate (3.18). To a stirred solution containing 94.0 mg 
(0.30 mmol) of 3.17 in 2 mL of anhydrous CH2Cl2 was added 0.23 mL (342 mg, 3.00 
mmol) of trifluoroacetic acid. The reaction mixture was stirred at room temperature for 2 
h and then concentrated under diminished pressure. To a stirred solution containing Boc-
deprotection product in 2 mL of 1:1 dioxane–water was added 124 mg (0.90 mmol) of 
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K2CO3 followed by 82.7 mg (0.30 mmol) of NVOC-Cl. The reaction mixture was stirred 
at room temperature for 14 h under argon, then diluted with 50 mL of brine and extracted 
with two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 10:1 ethyl acetate–methanol gave 3.18 as a 
light yellow solid: yield 73.3 mg (54% for two steps); silica gel TLC Rf 0.60 (10:1 ethyl 
acetate–methanol); 1H NMR (DMSO-d6, 500 MHz) δ 3.66 (s, 3H), 3.73-3.78 (m, 1H), 
3.87 (s, 3H), 3.91 (s, 3H), 4.19-4.23 (m, 1H), 4.43-4.45 (m, 1H), 5.34 (ABq, 2H, J = 14.5 
Hz), 5.46 (d, 1H, J = 7.5 Hz), 7.15 (s, 1H), 7.48 (d, 1H, J = 8.0 Hz), 7.70 (s, 1H) and 8.10 
(d, 1H, J = 8.5 Hz); 
13
C NMR (DMSO-d6, 125 MHz) δ 48.0, 52.1, 52.3, 56.0, 56.1, 62.8, 
100.7, 108.1, 110.5, 127.3, 139.2, 145.8, 147.7, 150.9, 153.3, 155.5, 163.5 and 170.0; 
mass spectrum (APCI), m/z 453.1259 (M+H)
+
 (C18H21N4O10 requires m/z 453.1257). 
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Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(2,4-dioxo-
3,4-dihydropyrimidin-1(2H)-yl)propionate (3.19). To a stirred solution containing 22.7 
mg (0.05 mmol) of 3.18 in 1 mL of 1:3:1 water–THF–methanol was added 150 µL (0.15 
mmol) of 1 N LiOH. The reaction mixture was stirred at room temperature for 2 h, and 
then concentrated under diminished pressure. The residue was redissolved into 1 mL of 
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anhydrous DMF and 25.0 mg (0.30 mmol) of NaHCO3 was added followed by 10.0 L 
(11.3 mg, 0.15 mmol) of chloroacetonitrile. The reaction mixture was stirred at 23 °C for 
overnight, then diluted with 20 mL of brine and extracted with two 50-mL portions of 
EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with 10:1 ethyl acetate–methanol gave the desired product 3.19 as a 
yellow solid: yield 7.17 mg (30% for two steps); silica gel TLC Rf 0.75 (5:1 ethyl 
acetate–methanol); 1H NMR (CD3OD, 400 MHz) δ 3.91 (s, 3H), 3.99 (s, 3H), 4.33-4.36 
(m, 2H), 4.67-4.71 (m, 2H), 4.87-4.93 (m, 2H), 5.41-5.51 (m, 2H), 5.67 (d, 1H, J = 7.6 
Hz), 7.13-7.15 (m, 1H), 7.33-7.43 (m, 1H), 7.73 (s, 1H) and 7.97 (s, 1H); mass spectrum 
(APCI), m/z 478.1213 (M+H)
+
 (C19H20N5O10 requires m/z 478.1210). 
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((S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)propionic Acid pdCpA Ester (3.2). To a solution 
containing 5.20 mg (4.00 μmol) of pdCpA tetrabutylammonium salt in 100 µL of 9:1 
anhydrous DMF–triethylamine was added 10.0 mg (21.0 μmol) of 3.19. The reaction 
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mixture was sonicated for 5 h. The reaction mixture was purified by HPLC on a C18 
reversed phase column (250 × 10 mm) using a linear gradient of 99:1 → 1:99 50 mM aq 
ammonium acetate, pH 4.5–acetonitrile. The retention time of the desired product was 
18.6 min. The fractions containing the product were lyophilized to afford 3.2 as a 
colorless solid: yield 2.02 mg (46%); mass spectrum (ESI), m/z 1055.1943 (M-H)
-
 
(C36H41N12O22P2 requires m/z 1055.1934). 
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Methyl (S)-2-(tert-Butoxycarbonylamino)-3-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)propionate (3.21). To a stirred suspension containing 280 
mg (2.23 mmol) of thymine in 5 mL of DMSO was added 0.40 mL (407 mg, 2.68 mmol) 
of DBU. Within 15 min, a solution containing 491 mg (2.68 mmol) of N-(tert-
butoxycarbonyl)-L-serine β-lactone in 5 mL of DMSO was added. The reaction mixture 
was stirred at room temperature for 2 h under argon, then diluted with 10 mL of 0.5 N 
HCl and extracted with two 20-mL portions of EtOAc. The combined organic phase was 
dried (MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 10:1 ethyl acetate–
methanol gave 3.20 as a colorless solid: yield 230 mg (33%); silica gel TLC Rf 0.30 (5:1 
ethyl acetate–methanol). To a cooled (0 °C) solution containing 230 mg (0.73 mmol) of 
3.20 in 5 mL of anhydrous MeOH was added dropwise 0.05 mL (87.4 mg, 0.73 mmol) of 
SOCl2. The reaction mixture was allowed to warm slowly to room temperature with 
 175 
 
stirring for 2 h, then diluted with 50 mL of brine and extracted with two 50-mL portions 
of EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with 10:1 ethyl acetate–methanol gave 3.21 as a colorless solid: 
yield 156 mg (65%); silica gel TLC Rf 0.81 (5:1 ethyl acetate–methanol); 
1
H NMR 
(CDCl3, 400 MHz) δ 1.41 (s, 9H), 1.88 (s, 3H), 3.78 (s, 3H), 4.03-4.20 (m, 2H), 4.47-4.50 
(m, 1H), 5.55 (s, 1H), 6.98 (s, 1H) and 9.34 (br s, 1H); 
13
C NMR (CD3OD, 100 MHz) δ 
12.4, 28.6, 50.0, 50.3, 53.1, 80.9, 110.7, 143.0, 152.6, 157.2, 166.5 and 171.4; mass 
spectrum (APCI), m/z 328.1500 (M+H)
+
 (C14H22N3O6 requires m/z 328.1509). 
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(5-methyl-2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-yl)propionate (3.22). To a stirred solution 
containing 49.2 mg (0.15 mmol) of 3.21 in 1.5 mL of anhydrous CH2Cl2 was added 0.12 
mL (171 mg, 1.50 mmol) of trifluoroacetic acid. The reaction mixture was stirred at room 
temperature for 2 h and then concentrated under diminished pressure. To a stirred 
solution containing Boc-deprotection product in 2 mL of 1:1 dioxane–water was added 
124 mg (0.90 mmol) of K2CO3 followed by 41.4 mg (0.15 mmol) of NVOC-Cl. The 
reaction mixture was stirred at room temperature for 14 h under argon, then diluted with 
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50 mL of brine and extracted with two 50-mL portions of EtOAc. The combined organic 
phase was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with 10:1 ethyl 
acetate–methanol gave 3.22 as a light yellow solid: yield 32.7 mg (47% for two steps); 
silica gel TLC Rf 0.75 (5:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 400 MHz) δ 1.88 
(s, 3H), 3.78 (s, 3H), 3.95 (s, 3H), 3.99 (s, 3H), 4.13-4.15 (m, 1H), 4.34-4.37 (m, 1H), 
4.57-4.59 (m, 1H), 5.49 (s, 2H), 6.03 (br s, 1H), 6.99 (s, 2H), 7.69 (s, 1H) and 9.08 (br s, 
1H); 
13
C NMR (CDCl3, 125 MHz) δ 12.3, 49.2, 53.2, 53.4, 56.5, 56.6, 64.3, 108.3, 110.4, 
111.2, 127.5, 139.8, 140.9, 148.3, 151.7, 153.7, 155.7, 164.4 and 170.0;  mass spectrum 
(APCI), m/z 467.1411 (M+H)
+
 (C19H23N4O10 requires m/z 467.1414). 
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Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(5-methyl-
2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propionate (3.23). To a stirred solution 
containing 23.3 mg (0.05 mmol) of 3.22 in 1 mL of 1:3:1 water–THF–methanol was 
added 150 µL (0.15 mmol) of 1 N LiOH. The reaction mixture was stirred at room 
temperature for 2 h, and then concentrated under diminished pressure. The residue was 
redissolved into 1 mL of anhydrous DMF and 25.0 mg (0.30 mmol) of NaHCO3 was 
added followed by 10.0 L (11.3 mg, 0.15 mmol) of chloroacetonitrile. The reaction 
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mixture was stirred at 23 °C for overnight, then diluted with 20 mL of brine and extracted 
with two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 10:1 ethyl acetate–methanol gave the 
desired product 3.23 as a yellow solid: yield 8.59 mg (35% for two steps); silica gel TLC 
Rf 0.77 (5:1 ethyl acetate–methanol); 
1
H NMR (CD3OD, 400 MHz) δ 1.83 (s, 3H), 3.91 
(s, 3H), 3.96 (s, 3H), 4.28-4.34 (m, 2H), 4.70-4.73 (m, 1H), 4.92 (s, 3H), 5.44 (ABq, 2H, 
J = 14.8 Hz), 7.10 (s, 2H), 7.26 (s, 1H) and 7.70 (s, 1H); 
13
C NMR (DMSO-d6, 100 MHz) 
δ 11.8, 47.7, 49.8, 51.9, 56.0, 56.2, 62.9, 108.1, 108.4, 110.6, 115.5, 127.1, 139.2, 141.5, 
147.7, 150.9, 153.3, 155.5, 164.1 and 168.9; mass spectrum (APCI), m/z 492.1363 
(M+H)
+
 (C20H22N5O10 requires m/z 492.1366). 
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((S)-2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)propionic Acid pdCpA Ester (3.3). To a solution 
containing 5.20 mg (4.00 μmol) of pdCpA tetrabutylammonium salt in 100 µL of 9:1 
anhydrous DMF–triethylamine was added 10.3 mg (21.0 μmol) of 3.23. The reaction 
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mixture was sonicated for 5 h. The reaction mixture was purified by HPLC on a C18 
reversed phase column (250 × 10 mm) using a linear gradient of 99:1 → 1:99 50 mM aq 
ammonium acetate, pH 4.5–acetonitrile. The retention time of the desired product was 
20.3 min. The fractions containing the product were lyophilized to afford 3.3 as a 
colorless solid: yield 1.81 mg (45%); mass spectrum (ESI), m/z 1069.2089 (M-H)
-
 
(C37H43N12O22P2 requires m/z 1069.2090).
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Methyl (S)-2-(tert-Butoxycarbonylamino)-3-(1,3-diaza-2-oxophenothiazinyl) 
propionate (3.26). To a stirred suspension containing 220 mg (1.01 mmol) of compound 
3.24 in 5 mL of DMSO was added 0.18 mL (185 mg, 1.22 mmol) of DBU. Within 15 
min, a solution containing 220 mg (1.20 mmol) of N-(tert-butoxycarbonyl)-L-serine β-
lactone in 5 mL of DMSO was added. The reaction mixture was stirred at room 
temperature for 2 h under argon, then diluted with 10 mL of 0.5 N HCl and extracted 
with two 20-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 5:1 ethyl acetate–methanol gave 3.25 as a 
yellow solid: yield 294 mg (59%); silica gel TLC Rf 0.34 (5:1 ethyl acetate–methanol). 
To a cooled (0 °C) solution containing 294 mg (0.73 mmol) of 3.25 in 5 mL of anhydrous 
MeOH was added dropwise 0.05 mL (86.6 mg, 0.73 mmol) of SOCl2. The reaction 
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mixture was allowed to warm slowly to room temperature with stirring for 2 h, then 
diluted with 50 mL of brine and extracted with two 50-mL portions of EtOAc. The 
combined organic phase was dried (MgSO4) and concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution 
with 10:1 ethyl acetate–methanol gave 3.26 as a colorless solid: yield 183 mg (70%); 
silica gel TLC Rf 0.75 (5:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 400 MHz) δ 1.42 
(s, 9H), 3.75 (s, 3H), 4.14-4.18 (m, 2H), 4.50-4.51 (m, 1H), 5.92 (d, 1H, J = 6.4 Hz) and 
6.87-7.13 (m, 4H); 
13
C NMR (CDCl3, 100 MHz) δ 28.4, 50.5, 52.9, 53.0, 80.4, 97.0, 
116.1, 118.4, 124.5, 125.8, 127.6, 135.7, 138.9, 155.5, 155.8, 160.8 and 170.6; mass 
spectrum (APCI), m/z 419.1401 (M+H)
+
 (C19H23N4O5S requires m/z 419.1389). 
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1,3-diaza-2-
oxophenothiazinyl)propionate (3.27). To a stirred solution containing 100 mg (0.24 
mmol) of 3.26 in 2 mL of anhydrous CH2Cl2 was added 0.18 mL (272 mg, 2.40 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 2 h and 
then concentrated under diminished pressure. To a stirred solution containing Boc-
deprotection product in 2 mL of 1:1 dioxane–water was added 198 mg (1.44 mmol) of 
K2CO3 followed by 66.2 mg (0.24 mmol) of NVOC-Cl. The reaction mixture was stirred 
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at room temperature for 14 h under argon, then diluted with 50 mL of brine and extracted 
with two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 10:1 ethyl acetate–methanol gave 3.27 as a 
light yellow solid: yield 53.3 mg (40% for two steps); silica gel TLC Rf 0.70 (5:1 ethyl 
acetate–methanol); 1H NMR (CDCl3, 400 MHz) δ 3.66 (s, 3H), 3.70-3.75 (m, 1H), 3.85 
(s, 3H), 3.91 (s, 3H), 4.20-4.25 (m, 1H), 4.46-4.50 (m, 1H), 5.34 (ABq, 2H, J = 10.8 Hz), 
6.90-6.92 (m, 2H), 6.98-7.08 (m, 2H), 7.16 (s, 1H), 7.52 (br s, 1H), 7.67 (s, 1H) and 8.09 
(d, 1H, J = 8.4 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 49.4, 52.2, 52.3, 56.0, 56.1, 62.7, 
93.4, 108.0, 110.2, 115.6, 123.8, 125.8, 127.3, 127.5, 136.17, 136.21, 139.0, 147.6, 153.3, 
154.4, 155.5 and 170.2; mass spectrum (APCI), m/z 558.1303 (M+H)
+
 (C24H24N5O9S 
requires m/z 558.1294). 
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Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1,3-diaza-
2-oxophenothiazinyl)propionate (3.28). To a stirred solution containing 28.0 mg (0.05 
mmol) of 3.27 in 1 mL of 1:3:1 water–THF–methanol was added 150 µL (0.15 mmol) of 
1 N LiOH. The reaction mixture was stirred at room temperature for 2 h, and then 
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concentrated under diminished pressure. The residue was redissolved into 1 mL of 
anhydrous DMF and 25.0 mg (0.30 mmol) of NaHCO3 was added followed by 4.0 µL 
(5.0 mg, 0.06 mmol) of chloroacetonitrile. The reaction mixture was stirred at 23 °C for 
overnight, then diluted with 20 mL of brine and extracted with two 50-mL portions of 
EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with 10:1 ethyl acetate–methanol gave 3.28 as a light yellow solid: 
yield 9.06 mg (31% for two steps); silica gel TLC Rf 0.71 (5:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 400 MHz) δ 3.59-3.61 (m, 2H), 3.87 (s, 3H), 3.96 (s, 3H), 4.32-4.36 
(m, 1H), 4.92 (s, 2H), 5.43-5.49 (m, 2H), 6.81 (d, 2H, J = 6.4 Hz), 6.91 (br s, 1H), 7.02-
7.05 (m, 1H), 7.13 (s, 1H), 7.22 (s, 1H), 7.69 (s, 1H) and 7.72 (s, 1H); mass spectrum 
(APCI), m/z 583.1232 (M+H)
+
 (C25H23N6O9S requires m/z 583.1247). 
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((S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(1,3-diaza-2-
oxophenothiazinyl)propionic Acid pdCpA Ester (3.4). To a solution containing 5.20 
mg (4.00 μmol) of pdCpA tetrabutylammonium salt in 100 µL of 9:1 anhydrous DMF–
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triethylamine was added 12.2 mg (21.0 μmol) of 3.28. The reaction mixture was 
sonicated for 5 h. The reaction mixture was purified by HPLC on a C18 reversed phase 
column (250 × 10 mm) using a linear gradient of 99:1 → 1:99 50 mM aq ammonium 
acetate, pH 4.5–acetonitrile. The retention time of the desired product was 24.9 min. The 
fractions containing the product were lyophilized to afford 3.4 as a colorless solid: yield 
2.10 mg (46%); mass spectrum (ESI), m/z 1160.1956 (M-H)
-
 (C42H44N13O21SP2 requires 
m/z 1160.1971).                                              
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N
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S O
OH
NHBoc
O
 
 (S)-2-(tert-butoxycarbonylamino)-3-(4-pent-4-enamido-2-thioxopyrimidin-1(2H)-
yl)propionic acid (3.30). To a stirred solution containing 1.44 g (36.0 mmol) of NaH 
(60% in mineral oil) in 30 mL of anhydrous DMF at 0 °C was added 1.14 g (9.00 mmol) 
of thiocytosine. The reaction mixture was stirred at 0 °C for 1 h under argon and then 
1.87 g (9.50 mmol) of pentenoyl-NHS ester was added. The reaction mixture was stirred 
at 0 °C under argon for 3 h, diluted with 150 mL of brine and extracted with two 50-mL 
portions of EtOAc. The organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 4 cm). Elution with 10:1 ethyl acetate–methanol gave the desired product 3.29 as a 
yellow solid: yield 844 mg (65%); silica gel TLC Rf 0.42 (10:1 ethyl acetate–methanol); 
1
H NMR (DMSO-d6, 400 MHz) δ 2.29-2.32 (m, 2H), 2.52-2.54 (m, 2H), 3.33 (br s, 1H), 
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4.96-5.06 (m, 2H), 5.77-5.84 (m, 1H), 7.49 (d, 1H, J = 7.2 Hz), 7.90 (d, 1H, J = 6.8 Hz) 
and 11.2 (s, 1H); 
13
C NMR (DMSO-d6, 100 MHz) δ 28.2, 35.4, 99.2, 115.4, 137.0, 147.2, 
158.7, 173.4 and 180.4. To a stirred suspension containing 209 mg (1.00 mmol) of 
compound 3.29 in 5 mL of DMSO was added 0.18 mL (183 mg, 1.20 mmol) of DBU. 
Within 15 min, a solution containing 220 mg (1.20 mmol) of N-(tert-Butoxycarbonyl)-L-
serine β-lactone in 5 mL of DMSO was added. The reaction mixture was stirred at room 
temperature for 2 h under argon, then diluted with 10 mL of 0.5 N HCl and extracted 
with two 20-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 5:1 ethyl acetate–methanol gave 3.30 as a 
colorless solid: yield 265 mg (63%); silica gel TLC Rf 0.15 (5:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 400 MHz)  1.39 (s, 9H), 2.42-2.44 (m, 2H), 2.55-2.58 (m, 2H), 3.74-
3.78 (m, 1H), 4.43-4.47 (m, 1H), 4.99-5.11 (m, 3H), 5.87-5.89 (m, 2H), 7.84 (s, 1H) and 
8.35 (s, 1H); 
13
C NMR(CDCl3, 100 MHz)  28.6, 28.8, 30.1, 34.2, 37.3, 55.7, 80.5, 
106.6, 116.1, 138.0, 158.0, 159.4, 159.5, 172.2and; mass spectrum (APCI), m/z 
397.1537 (M+H)
+
 (C17H25N4O5S requires m/z 397.1546).
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(S)-2-pent-4-enamido-3-(4-pent-4-enamido-2-thioxopyrimidin-1(2H)-yl)propionic 
acid (3.31). To a stirred solution containing 127 mg (0.31 mmol) of 3.30 in 2 mL of 
anhydrous CH2Cl2 was added 0.24 mL (353 mg, 3.10 mmol) of trifluoroacetic acid. The 
reaction mixture was stirred at room temperature for 2 h and then concentrated under 
diminished pressure. To a stirred solution containing Boc-deprotection product in 2 mL 
of 1:1 dioxane–water was added 129 mg (0.93 mmol) of K2CO3 followed by 61.1 mg 
(0.31 mmol) of pentenoyl-NHS ester. The reaction mixture was stirred at room 
temperature for 14 h under argon, then diluted with 20 mL of 0.5 N HCl and extracted 
with two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 5:1 ethyl acetate–methanol gave 3.31 as a 
light yellow solid: yield 49.8 mg (41% for two steps); silica gel TLC Rf 0.10 (5:1 ethyl 
acetate–methanol); 1H NMR (CDCl3, 400 MHz)  2.26-2.56 (m, 8H), 3.51-3.69 (m, 2H), 
4.94-5.11 (m, 5H), 5.69-5.85 (m, 5H), 7.40 (br s, 1H), 7.87 (d, 1H, J = 4.4 Hz), 8.34 (d, 
1H, J = 4.0 Hz) and 9.16 (br s, 1H); mass spectrum (APCI), m/z 379.1432 (M+H)
+
 
(C17H23N4O4S requires m/z 379.1440). 
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Cyanomethyl (S)-2-Pent-4-enamido-3-(4-pent-4-enamido-2-thioxopyrimidin-1(2H)-
yl)propionate (3.32). To a stirred solution containing 11.8 mg (0.03 mmol) of 3.31 in 1 
mL of anhydrous DMF was added 25.0 mg (0.30 mmol) of NaHCO3 followed by 4.0 µL 
(5.0 mg, 0.06 mmol) of chloroacetonitrile. The reaction mixture was stirred at 23 °C for 
overnight under argon, then diluted with 20 mL of brine and extracted with two 50-mL 
portions of EtOAc. The combined organic phase was dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 2 cm). Elution with ethyl acetate gave 3.32 as a yellow solid: yield 6.67 mg 
(53%); silica gel TLC Rf 0.60 (10:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 400 MHz) 
δ 2.30-2.34 (m, 4H), 2.48-2.55 (m, 4H), 2.80 (s, 1H), 3.48-3.56 (m, 2H), 4.78 (s, 1H), 
5.00-5.09 (m, 4H), 5.74-5.89 (m, 2H), 7.02 (d, 1H, J = 7.2 Hz), 7.88 (d, 1H, J = 6.0 Hz), 
8.40 (d, 1H, J = 5.6 Hz) and 8.62 (br s, 1H); 
13
C NMR(CDCl3, 100 MHz) δ 28.9, 29.4, 
32.5, 35.6, 36.9, 49.3, 52.5, 106.3, 114.0, 116.0, 116.3, 136.3, 136.6, 157.5, 158.7, 169.6, 
169.9, 172.2 and 172.5; mass spectrum (APCI), m/z 418.1550 (M+H)
+
 (C19H24N5O4S 
requires m/z 418.1549). 
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((S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(4-amino-2-
oxopyrimidin-1(2H)-yl)propionic Acid pdCpA Ester (3.5). To a solution containing 
5.20 mg (4.00 μmol) of pdCpA tetrabutylammonium salt in 100 µL of 9:1 anhydrous 
DMF–triethylamine was added 8.76 mg (21.0 μmol) of 3.32. The reaction mixture was 
sonicated for 5 h. The reaction mixture was purified by HPLC on a C18 reversed phase 
column (250 × 10 mm) using a linear gradient of 99:1 → 1:99 50 mM aq ammonium 
acetate, pH 4.5–acetonitrile. The retention time of the desired product was 22.3 min. The 
fractions containing the product were lyophilized to afford 3.5 as a colorless solid: yield 
2.50 mg (65%); mass spectrum (ESI), m/z 995.2278 (M-H)
-
 (C36H45N12O16P2 requires m/z 
995.2272). 
                    
N
NO2
CH2Br
 
 187 
 
5-(Bromomethyl)-2-nitropyridine (3.33). To a stirred solution containing 250 mg (1.81 
mmol) of 5-methyl-2-nitropyridine in tetrachloromethane was added 37.0 mg (0.2 mmol) 
of 2, 2’-azobisisobutyronitrile and 320 mg (1.8 mmol) of N-bromosuccinimide. The 
reaction mixture was heated at 80 °C for 4 h under argon. The cooled reaction mixture 
was concentrated under diminished pressure and the residue was purified by 
chromatography on a silica gel column (10 × 4 cm). Elution with 3:1 hexanes–ethyl 
acetate gave the desired product 3.33 as a colorless oil: yield 210 mg (54%); silica gel 
TLC Rf 0.70 (1:1 hexanes–ethyl acetate);
 1
H NMR (CDCl3, 500 MHz) δ 4.55(s, 2H), 8.08 
(d, 1H, J = 8.0 Hz), 8.24 (d, 1H, J = 8.5 Hz) and 8.64 (s, 1H); 
13
C NMR (CDCl3, 125 
MHz) δ 27.2, 118.3, 140.1, 140.5 and 149.0; mass spectrum (EI+), m/z 215.9525 (M)+ 
(C6H5BrN2O2 requires m/z 215.9534). 
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(2R,5S)-2-Isopropyl-3,6-dimethoxy-5-((6-nitropyridin-3-yl)methyl)-2,5-
dihydropyrazine (3.34). To a stirred solution containing 0.17 mL (182 mg, 0.99 mmol) 
of Schöllkopf’s reagent in 3 mL of anhydrous THF at _78 °C was added 0.13 mL (86.1 
mg, 1.34 mmol) of 2.5 M BuLi. The reaction mixture was stirred at 
_
78 °C for 30 min 
under argon and then a solution containing 210 mg (0.98 mmol) of 3.33 in 5 mL of 
anhydrous THF was added. The reaction mixture was stirred at 
_
78 °C for 5 min under 
argon, then diluted with 50 mL of satd aq NH4Cl and extracted with two 50-mL portions 
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of EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with 2:1 hexanes–ethyl acetate gave 3.34 as a yellow oil: yield 69.0 
mg (22%); silica gel TLC Rf 0.65 (1:1 hexanes–ethyl acetate); 
1
H NMR (CDCl3, 400 
MHz) δ 0.59 (d, 3H, J = 6.8 Hz), 0.91 (d, 3H, J = 6.8 Hz), 2.10-2.14 (m, 1H), 3.18-3.26 
(m, 2H), 3.56-3.57 (m, 1H), 3.62 (s, 3H), 3.68 (s, 3H), 4.26-4.30 (m, 1H), 7.78 (dd, 1H, J 
= 8.4 and 2.4 Hz), 8.11 (d, 1H, J = 8.4 Hz) and 8.40 (d, 1H, J = 2.0 Hz); 
13
C NMR 
(CDCl3, 100 MHz) δ 16.7, 18.9, 31.9, 36.8, 52.57, 52.63, 55.6, 60.9, 117.3, 140.5, 140.8, 
150.2, 155.5, 161.5 and 164.8; mass spectrum (APCI), m/z 321.1563 (M+H)
+
 
(C15H21N4O4 requires m/z 321.1563). 
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Methyl (S)-2-Amino-3-(6-nitropyridin-3-yl)propionate (3.35). To a stirred solution 
containing 66.0 mg (0.21 mmol) of 3.34 in 4 mL of THF at 0 °C was added 3 mL of 2 N 
aq HCl. The reaction mixture was stirred at room temperature for 2 h. The reaction 
mixture was then slowly poured into 50 mL of satd aq NaHCO3 and then extracted with 
two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 4:1 ethyl acetate–methanol gave 3.35 as a 
yellow oil: yield 39.0 mg (84%); silica gel TLC Rf 0.50 (4:1 ethyl acetate–methanol); 
1
H 
NMR (CDCl3, 400 MHz) δ 3.02-3.21 (m, 2H), 3.68 (s, 3H), 3.80 (t, 1H, J = 6.8 Hz), 4.80 
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(br s, 2H), 8.04 (dd, 1H, J = 8.4 and 2.0 Hz), 8.23 (d, 1H, J = 8.4 Hz) and 8.45 (d, 1H, J = 
2.4 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 38.2, 52.7, 56.2, 118.9, 142.1, 142.3, 142.4, 
150.6 and 175.7; mass spectrum (APCI), m/z 226.0833 (M+H)
+
 (C9H12N3O4 requires m/z 
226.0828). 
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(6-nitropyridin-
3-yl)propionate (3.36). To a stirred solution containing 30.0 mg (0.13 mmol) of 3.35 in 1 
mL of 1:1 dioxane–water was added 55.2 mg (0.39 mmol) of K2CO3 followed by 41.3 
mg (0.20 mmol) of NVOC-Cl. The reaction mixture was stirred at room temperature for 
12 h, then diluted with 50 mL of brine and extracted with two 50-mL portions of EtOAc. 
The combined organic phase was dried (MgSO4) and concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (10 × 2 
cm). Elution with ethyl acetate gave 3.36 as a yellow solid: yield 33.4 mg (54% for two 
steps); silica gel TLC Rf 0.65 (ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) δ 3.21-3.43 (m, 
2H), 3.78 (s, 3H), 3.96 (s, 3H), 3.98 (s, 3H), 4.69-4.73 (m, 1H), 5.48 (s, 2H), 6.95 (s, 1H), 
7.70 (s, 1H), 7.85 (d, 1H, J = 8.4 Hz), 8.20-8.22 (m, 1H) and 8.40 (s, 1H); 
13
C NMR 
(CDCl3, 100 MHz) δ 34.5, 49.5, 54.0, 56.7, 56.9, 63.8, 110.2, 113.6, 117.3, 126.6, 136.9, 
140.8, 148.6, 149.0, 153.7, 154.1, 154.3, 156.5 and 169.3; mass spectrum (APCI), m/z 
465.1261 (M + H)
+
 (C19H21N4O10 requires m/z 465.1258). 
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Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(6-
nitropyridin-3-yl)propionate (3.37). To a stirred solution containing 46.4 mg (0.10 
mmol) of 3.36 in 1 mL of 1:3:1 water–THF–methanol was added 300 µL (0.30 mmol) of 
1 N LiOH. The reaction mixture was stirred at room temperature for 2 h, and then 
concentrated under diminished pressure. The residue was dissolved in 1 mL of anhydrous 
DMF under argon and 50.0 mg (0.60 mmol) of NaHCO3 was added followed by 20.0 µL 
(25 mg, 0.30 mmol) of chloroacetonitrile. The reaction mixture was stirred at 23 °C for 
overnight under argon, then diluted with 20 mL of brine and extracted with two 50-mL 
portions of EtOAc. The combined organic phase was dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 2 cm). Elution with ethyl acetate gave 3.37 as a yellow solid: yield 29.0 mg 
(34%); silica gel TLC Rf 0.67 (ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) δ 3.27-3.43 
(m, 2H), 3.96 (s, 3H), 3.98 (s, 3H), 4.75-4.89 (m, 3H), 5.46-5.50 (m, 3H), 6.93 (s, 1H), 
7.69 (s, 1H), 7.90 (d, 1H, J = 8.4 Hz), 8.23 (d, 1H, J = 8.4 Hz) and 8.45 (s, 1H); 
13
C 
NMR (CDCl3, 100 MHz) δ 34.9, 49.6, 54.2, 56.6, 56.7, 64.8, 108.5, 111.2, 113.5, 118.3, 
126.5, 137.9, 140.8, 148.7, 149.5, 153.6, 154.4, 155.3, 156.2 and 169.5; mass spectrum 
(APCI), m/z 490.1206 (M + H)
+
 (C20H20N5O10 requires m/z 490.1210). 
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(S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(6-nitropyridin-3-
yl)propionic Acid pdCpA Ester (3.6). To a solution containing 5.2 mg (4.0 μmol) of 
pdCpA tetrabutylammonium salt in 100 L of 9:1 anhydrous DMF–triethylamine was 
added 10.3 mg (21 μmol) of 3.37. The reaction mixture was sonicated for 6 h. The 
reaction mixture was purified by HPLC on a C18 reversed phase column (250 × 10 mm) 
using a linear gradient of 99:1 → 1:99 50 mM aq ammonium acetate (pH 4.5) – 
acetonitrile. The retention time of the desired product was 24.1 min. The fractions 
containing the product were lyophilized to afford 3.6 as a colorless solid: yield 2.45 mg 
(60%); mass spectrum (ESI), m/z 1067.1948 (M-H)
-
 (C37H41N12O22P2 requires m/z 
1067.1934). 
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Methyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(6-aminopyridin-
3-yl)propionate (3.38). To a solution containing 39.0 mg (0.17 mmol) of 3.37 in 5 mL of 
MeOH was added catalytic amount of 10% Pd/C and the reaction was placed under 1 atm 
of H2 (g) overnight. The catalyst was removed by filtration through a pad of Celite 545
®
 
and the filtrate was concentrated under diminished pressure and the residue was 
redissolved into 1 mL of 1:1 dioxane–water and 62.0 mg (0.45 mmol) of K2CO3 was 
added followed by 55.0 mg (0.20 mmol) of NVOC-Cl. The reaction mixture was stirred 
at room temperature for overnight, then diluted with 50 mL of brine and extracted with 
two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 1:3 methanol–ethyl acetate gave 3.38 as a 
yellow solid: yield 18.1 mg (23% for two steps); silica gel TLC Rf 0.45 (3:1 methanol–
ethyl acetate); 
1
H NMR (CD3OD, 400 MHz) δ 2.78-3.05 (m, 2H), 3.71 (s, 3H), 3.89 (s, 
3H), 3.91 (s, 3H), 4.36-4.39 (m, 1H), 5.36-5.47 (m, 2H), 6.54 (d, 1H, J = 8.4 Hz), 7.09 (s, 
1H), 7.37 (d, 1H, J = 8.4 Hz ) and 7.72-7.74 (m, 2H);
 13
C NMR (CD3OD, 100 MHz) δ 
34.9, 37.1, 52.8, 56.8, 57.0, 64.6, 109.3, 110.4, 110.7, 122.6, 129.7, 140.4, 140.7, 147.8, 
149.5, 155.4, 158.1, 159.7 and 173.8; mass spectrum (APCI), m/z 435.1512 (M + H)
+
 
(C19H23N4O8 requires m/z 435.1516). 
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Cyanomethyl (S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(6-
aminopyridin-3-yl)propionate (3.39). To a stirred solution containing 21.8 mg (0.05 
mmol) of 3.38 in 1 mL of 1:3:1 water–THF–methanol was added 150 µL (0.15 mmol) of 
1 N LiOH. The reaction mixture was stirred at room temperature for 2 h, and then 
concentrated under diminished pressure. The residue was redissolved into 1 mL of 
anhydrous DMF and 25.0 mg (0.30 mmol) of NaHCO3 was added followed by 10.0 L 
(11.3 mg, 0.15 mmol) of chloroacetonitrile. The reaction mixture was stirred at 23 °C for 
overnight under argon, then diluted with 20 mL of brine and extracted with two 50-mL 
portions of EtOAc. The combined organic phase was dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 2 cm). Elution with 1:3 methanol–ethyl acetate gave the desired product 
3.39 as a yellow solid: yield 7.37 mg (32% for two steps); silica gel TLC Rf 0.51 (1:3 
methanol–ethyl acetate); 1H NMR (CD3OD, 400 MHz) δ 2.83-3.06 (m, 2H), 3.90 (s, 3H), 
3.92 (s, 3H), 4.46-4.50 (m, 1H), 4.92 (s, 2H), 5.36-5.48 (m, 2H), 6.57 (d, 1H, J = 8.4 Hz), 
7.08 (s, 1H), 7.43 (dd, 1H, J = 8.0 and 2.4 Hz), 7.72 (s, 1H), 7.77 (s, 1H) and 7.98 (s, 
1H); mass spectrum (APCI), m/z 460.1472 (M + H)
+
 (C19H23N4O8 requires m/z 
460.1468). 
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(S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(6-aminopyridin-3-
yl)propionic Acid pdCpA Ester (3.7). To a solution containing 5.20 mg (4.00 μmol) of 
pdCpA tetrabutylammonium salt in 100 µL of 9:1 anhydrous DMF–triethylamine was 
added 9.64 mg (21.0 μmol) of cyanomethyl (S)-2-((4,5-dimethoxy-2-
nitrobenzyloxy)carbonylamino)-3-(6-cyano-1-tosyl-1H-indol-3-yl)propionate (3.39). The 
reaction mixture was sonicated for 5 h. The reaction mixture was purified by HPLC on a 
C18 reversed phase column (250 × 10 mm) using a linear gradient of 99:1 → 1:99 50 mM 
aq ammonium acetate, pH 4.5–acetonitrile. The retention time of the desired product was 
21.3 min. The fractions containing the product were lyophilized to afford 3.7 as a 
colorless solid: yield 2.21 mg (54%); mass spectrum (ESI), m/z 1037.2203 (M-H)
-
 
(C37H43N12O20P2 requires m/z 1037.2192). 
                                                       
N
NO2
NHCBz
O
O
 
 195 
 
Methyl (S)-2-(Benzyloxycarbonylamino)-3-(6-nitropyridin-3-yl)propionate (3.40). 
To a stirred solution containing 42.8 mg (0.19 mmol) of 3.35 in 1 mL of 1:1 dioxane–
water was added 55.2 mg (0.39 mmol) of K2CO3 followed by 0.07 mL (32.4 mg, 0.19 
mmol) of ClCOOBn. The reaction mixture was stirred at room temperature for 12 h, then 
diluted with 50 mL of brine and extracted with two 50-mL portions of EtOAc. The 
combined organic phase was dried (MgSO4) and concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution 
with ethyl acetate gave 3.40 as a yellow solid: yield 53.3 mg (78%); silica gel TLC Rf  
0.83 (ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) δ 3.18-3.21 (m, 1H), 3.35-3.40 (m, 1H), 
3.76 (s, 3H), 4.70-4.72 (m, 1H), 5.08 (s, 2H), 5.39 (s, 1H), 7.33-7.37 (m, 5H), 7.77 (d, 
1H, J = 8.8 Hz), 8.14 (d, 1H, J = 8.4 Hz) and 8.38 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) 
δ 35.5, 53.1, 54.4, 67.5, 117.9, 128.4, 128.6, 128.8, 135.9, 138.7, 140.7, 149.6, 155.6, 
156.0 and 170.9; mass spectrum (APCI), m/z 360.1188 (M + H)
+
 (C17H18N3O6 requires 
m/z 360.1196). 
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Methyl (S)-2-((S)-2-(Benzyloxycarbonylamino)-3-(6-nitropyridin-3-
yl)propanamido)-3-(6-nitropyridin-3-yl)propionate (3.42). To a stirred solution 
containing 52.3 mg (0.15 mmol) of 3.40 in 2 mL of 1:3:1 water–THF–methanol was 
added 300 µL (0.30 mmol) of 1 N LiOH. The reaction mixture was stirred at room 
temperature for 2 h, and then concentrated under diminished pressure. The residue was 
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redissolved into 3 mL of anhydrous DMF at 0
 
°C, 57.2 mg (0.15 mmol) of HBTU was 
added and resulting solution was stirred at 0
 
°C for 15 min. To this solution were added 
33.8 mg (0.15 mmol) of compound 3.35 and 0.04 mL (30.4 mg, 0.30 mmol) of 
triethylamine in 1.5 mL of dry DMF. The reaction mixture was stirred at 25 °C for 5 h. 
The reaction mixture was concentrated under diminished pressure and the residue was 
diluted with 80 mL of ethyl acetate. The organic layer was washed with two 40-mL 
portions of 1 N aq HCl, 40 mL of water and 20 mL of brine, then dried over MgSO4 and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (10 × 2 cm). Elution with 1:10 methanol–ethyl 
acetate afforded 3.42 as a colorless oil: yield 42.6 mg (53%); silica gel TLC Rf 0.71 (5:1 
ethyl acetate–methanol); 1H NMR (CD3OD, 400 MHz) δ 3.02-3.33 (m, 4H), 3.72 (s, 3H), 
4.53-4.55 (m, 1H), 4.86-5.00 (m, 3H), 5.80-5.82 (m, 1H), 7.09-7.25 (m, 4H), 7.79-7.81 
(m, 2H), 8.02-8.12 (m, 2H) and 8.34 (s, 2H); 
13
C NMR (CD3OD, 100 MHz) δ 34.7, 35.1, 
52.7, 53.1, 55.3, 67.5, 118.0, 128.0, 128.1, 128.6, 128.7, 135.8, 138.9, 139.3, 140.8, 
149.4, 149.6, 155.67, 155.74, 155.8, 170.3, 170.5 and 170.7; mass spectrum (APCI), m/z 
553.1679 (M + H)
+
 (C25H25N6O9 requires m/z 553.1683). 
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Methyl (S)-2-((S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(6-
aminopyridin-3-yl)propanamido)-3-(6-aminopyridin-3-yl)propionate (3.43). To a 
solution containing 41.0 mg (0.07 mmol) of 3.42 in 5 mL of MeOH was added catalytic 
amount of 10% Pd/C and the reaction was placed under 1 atm of H2 (g) overnight. The 
catalyst was removed by filtration through a pad of Celite 545® and the filtrate was 
concentrated under diminished pressure and the residue was redissolved into 1 mL of 1:1 
dioxane–water and 20.7 mg (0.15 mmol) of K2CO3 was added followed by 19.3 mg (0.07 
mmol) of NVOC-Cl. The reaction mixture was stirred at room temperature for 12 h under 
argon, then diluted with 50 mL of brine and extracted with two 50-mL portions of 
EtOAc. The combined organic phase was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with 1:3 methanol–ethyl acetate gave 3.43 as a yellow solid: yield 
10.0 mg (21% for two steps); silica gel TLC Rf 0.50 (1:1 methanol–ethyl acetate);
 1
H 
NMR (CD3OD, 400 MHz) δ 2.84-2.97 (m, 4H), 3.69 (s, 3H), 3.90 (s, 6H), 4.30-4.32 (m, 
1H), 4.61 (br s, 1H), 5.41 (br s, 2H), 6.57-6.58 (m, 2H), 7.05-7.06 (m, 1H), 7.36-7.45 (m, 
2H) and 7.70-7.75 (m, 3H); mass spectrum (APCI), m/z 598.2253 (M + H)
+
 (C27H32N7O9 
requires m/z 598.2261). 
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Cyanomethyl (S)-2-((S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(6-
aminopyridin-3-yl)propanamido)-3-(6-aminopyridin-3-yl)propionate (3.44). To a 
stirred solution containing 10.2 mg (0.02 mmol) of 3.43 in 1 mL of 1:3:1 water–THF–
methanol was added 60 µL (0.06 mmol) of 1 N LiOH. The reaction mixture was stirred at 
room temperature for 2 h, and then concentrated under diminished pressure. The residue 
was dissolved in 1 mL of anhydrous DMF under argon and 8.33 mg (0.10 mmol) of 
NaHCO3 was added followed by 4.0 µL (5.0 mg, 0.06 mmol) of chloroacetonitrile. The 
reaction mixture was stirred at 23 °C for overnight under argon, then diluted with 20 mL 
of brine and extracted with two 50-mL portions of EtOAc. The combined organic phase 
was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 1 cm). Elution with 1:3 
methanol–ethyl acetate gave 3.44 as a yellow solid: yield 5.20 mg (49% for two steps); 
silica gel TLC Rf 0.51 (1:1 methanol–ethyl acetate);
 1
H NMR (CD3OD, 400 MHz) δ 2.64-
3.06 (m, 4H), 3.89 (s, 6H), 4.29-4.30 (m, 1H), 4.66-4.68 (m, 1H), 4.89 (s, 2H), 5.41 (s, 
2H), 6.56-6.61 (m, 2H), 7.08 (s, 1H), 7.36-7.48 (m, 2H), 7.73-7.76 (m, 2H) and 7.98 (s, 
1H); mass spectrum (APCI), m/z 623.2208 (M + H)
+
 (C28H31N8O9 requires m/z 
623.2214). 
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(S)-2-((4,5-Dimethoxy-2-nitrobenzyloxy)carbonylamino)-3-(6-aminopyridin-3-
yl)propionic Acid pdCpA Ester (3.8). To a solution containing 5.20 mg (4.00 μmol) of 
pdCpA tetrabutylammonium salt in 100 µL of 9:1 anhydrous DMF–triethylamine was 
added 13.1 mg (21.0 μmol) of 3.44. The reaction mixture was sonicated for 5 h. The 
reaction mixture was purified by HPLC on a C18 reversed phase column (250 × 10 mm) 
using a linear gradient of 99:1 → 1:99 50 mM aq ammonium acetate, pH 4.5–acetonitrile. 
The retention time of the desired product was 24.5 min. The fractions containing the 
product were lyophilized to afford 3.8 as a colorless solid: yield 2.52 mg (55%); mass 
spectrum (ESI), m/z 1200.2963 (M-H)
-
 (C45H52N15O21P2 requires m/z 1200.2937). 
                                           
OH
O
N
H
O
O
 
(S)-2-(Benzyloxycarbonylamino)-3-phenylpropionic acid (3.45). To a stirred solution 
containing 500 mg (2.96 mmol) of phenylalanine in 10 mL of 1:1 dioxane–water was 
 200 
 
added 510 mg (3.70 mmol) of K2CO3 followed by 0.53 mL (631 mg, 3.70 mmol) of 
ClCOOBn. The reaction mixture was stirred at room temperature for 12 h, then acidified 
with 10 mL of 1 N aq HCl and the aqueous layer was extracted with three 50-mL 
portions of ethyl acetate. The combined organic phase was dried over MgSO4 and 
concentrated under diminished pressure. The crude residue was purified by 
chromatography on a silica gel column (10 × 4 cm). Elution with 5:1 ethyl acetate–
methanol gave 3.45 as a colorless solid: yield 750 mg (83%); silica gel TLC Rf 0.33 (5:1 
ethyl acetate–methanol); 1H NMR (CDCl3, 400 MHz) δ 3.15-3.27 (m, 2H), 4.78-4.80 (m, 
1H), 5.15 (s, 2H), 5.58-5.60 (m, 1H), 7.21-7.38 (m, 10H) and 10.70 (s, 1H); 
13
C NMR 
(CDCl3, 100 MHz) δ 37.6, 54.7, 67.2, 127.1, 128.0, 128.2, 128.5, 128.6, 129.3, 135.7, 
136.0, 156.1 and 175.8; mass spectrum (APCI), m/z 300.1233 (M+H)
+
 (C17H18NO4 
requires m/z 300.1236). 
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Methyl (S)-2-((S)-2-(benzyloxycarbonylamino)-3-phenylpropanamido)-3-
phenylpropionate (3.46). To a stirred solution containing 993 mg (3.30 mmol) of 3.45 in 
5 mL of anhydrous DMF at 0
 
°C, 1.90 g (4.98 mmol) of HBTU was added and resulting 
solution was stirred for 15 min. To this solution were added 1.10 g (4.99 mmol) of L-
phenylalanine methyl ester and 1.40 mL (1.01 g, 9.98 mmol) of triethylamine in 5 mL of 
dry DMF. The reaction mixture was stirred at 25 °C for 5 h. The reaction mixture was 
concentrated under diminished pressure and the residue was diluted with 80 mL of ethyl 
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acetate. The organic layer was washed with two 40-mL portions of 1 N aq HCl and 20 
mL of brine, then dried over MgSO4 and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (10 × 4 cm). 
Elution with ethyl acetate gave 3.46 as a yellow solid: yield 947 mg (62%); silica gel 
TLC Rf 0.85 (ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) δ 2.99-3.11 (m, 4H), 3.63 (s, 
3H), 4.60-4.62 (m, 1H), 4.85-4.87 (m, 1H), 4.96-5.09 (m, 2H), 5.79 (d, 1H, J = 8.4 Hz), 
6.90 (br s, 1H), 5.58-5.60 (m, 1H) and 7.04-7.38 (m, 14H); 
13
C NMR (CDCl3, 100 MHz) 
δ 37.9, 38.4, 52.1, 53.3, 55.9, 66.8, 126.8, 126.9, 127.8, 128.0, 128.4, 129.2, 129.3, 135.7, 
136.4, 155.88, 155.90, 170.8 and 171.4; mass spectrum (APCI), m/z 461.2065 (M+H)
+
 
(C27H29N2O5 requires m/z 461.2076). 
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(S)-2-((S)-2-(Benzyloxycarbonylamino)-3-phenylpropanamido)-3-phenylpropionic 
acid (3.47). To a stirred solution containing 715 mg (1.55 mmol) of 3.46 in 5 mL of 1:3:1 
water–THF–methanol was added 111 mg (4.65 mmol) of LiOH in 3 mL of water. The 
reaction mixture was stirred at room temperature for 2 h, and then then acidified with 1 N 
aq HCl and the aqueous layer was extracted with three 50-mL portions of ethyl acetate. 
The combined organic extract was dried (MgSO4) and concentrated under diminished 
pressure to afford the crude product. The residue was purified by chromatography on a 
silica gel column (10 × 4 cm). Elution with 5:1 ethyl acetate–methanol gave 3.47 as a 
colorless solid: yield 590 mg (85%); silica gel TLC Rf 0.75 (1:1 ethyl acetate–methanol); 
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1
H NMR (CD3OD, 400 MHz) δ 2.68-3.17 (m, 4H), 4.45-4.71 (m, 2H), 4.87-5.10 (m, 4H) 
and 7.17-7.22 (m, 15H); 
13
C NMR (CD3OD, 100 MHz) δ 38.4, 38.9, 54.5, 57.5, 67.5, 
127.7, 128.5, 128.8, 129.3, 129.4, 130.2, 130.3, 130.4, 137.9, 138.4, 157.9, 173.8 and 
174.2; mass spectrum (APCI), m/z 447.1919 (M+H)
+
 (C27H27N2O5 requires m/z 
447.1920). 
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9-[3ʹ-Deoxy-3ʹ-((S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-3-
phenylpropanoyl)-β-D-ribofuranosyl]-6-(N, N-dimethylamino)purine (3.48). To a 
stirred solution containing 89.2 mg (0.20 mmol) of 3.47 and 35.0 mg (0.30 mmol) of N-
hydroxysuccinimide in 3 mL of anhydrous CH2Cl2 at 0
 
°C was added dropwise 61.0 mg 
(0.30 mmol) of DCC dissolved in 3 mL of anhydrous CH2Cl2. The reaction mixture was 
stirred at room temperature for 18 h, and then concentrated under diminished pressure 
and suspended in CH3CN to permit the removal of dicyclohexylurea. The suspension was 
filtered and the filtrate was concentrated under diminished pressure. The resulting solid 
was used in the next reaction without further purification. To a stirred solution containing 
130 mg (0.24 mmol) of this crude intermediate and 47.0 mg (0.16 mmol) of puromycin 
aminonucleoside in 1.5 mL of dry DMF was added 0.30 mL (24 mg, 0.24 mmol) of Et3N. 
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The reaction mixture was stirred at 25 °C for 3 h, and then concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel column (10 × 
2 cm). Elution with ethyl acetate gave 3.48 as a yellow solid: yield 36.0 mg (25%); silica 
gel TLC Rf  0.31 (5:1 ethyl acetate–methanol);
 1
H NMR (CDCl3, 400 MHz) δ 2.73-2.78 
(m, 2H), 2.96-3.10 (m, 4H), 3.45 (s, 6H), 3.46-3.47 (m, 1H), 3.80-3.82 (m, 2H), 3.99 (br 
s, 1H), 4.32-4.35 (m, 1H), 4.54-4.58 (m, 3H), 4.65-4.67 (m, 1H), 4.99-5.01 (m, 2H), 5.93 
(br s, 1H), 7.12-7.27 (m, 15H), 8.16 (br s, 1H) and 8.31 (br s, 1H); 
13
C NMR (CDCl3, 100 
MHz) δ 26.0, 26.7, 34.7, 38.9, 51.8, 56.0, 57.9, 62.1, 67.7, 75.0, 84.6, 91.9, 121.6, 127.7, 
128.6, 129.4, 129.5, 130.2, 130.4, 137.8, 138.0, 138.1, 139.0, 150.4, 152.8, 156.0, 173.3 
and 173.9; mass spectrum (APCI), m/z 723.3265 (M+H)
+
 (C38H43N8O7 requires m/z 
723.3255). 
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9-[3ʹ-Deoxy-3ʹ-((S)-2-((S)-2-amino-3-phenylpropanamido)-3-phenylpropanoyl)-β-D-
ribofuranosyl]-6-(N, N-dimethylamino)purine (3.9). To a solution containing 36.0 mg 
(0.05 mmol) of 3.48 in 3 mL of MeOH was added catalytic amount of 10% Pd/C and the 
reaction was placed under 1 atm of H2 (g) overnight. The catalyst was removed by 
filtration through a pad of Celite 545
®
 and the filtrate was concentrated under diminished 
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pressure and purified by chromatography on a silica gel column (10 × 2 cm). Elution with 
5:1 ethyl acetate–methanol gave 3.9 as a colorless solid: yield 98.0 mg (47%); silica gel 
TLC Rf 0.51 (1:1 ethyl acetate–methanol);
 1
H NMR (CDCl3, 400 MHz) δ 2.71-2.75 (m, 
2H), 2.99-3.07 (m, 4H), 3.48 (s, 6H), 3.52-3.55 (m, 2H), 3.67-3.70 (m, 2H), 3.77-3.81 
(m, 1H), 3.93-3.95 (m, 2H), 4.55-4.56 (m, 2H), 4.68-4.72 (m, 1H), 5.93 (br s, 1H), 7.17-
7.30 (m, 10H), 8.18 (br s, 1H) and 8.33 (br s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 39.3, 
41.3, 52.0, 56.1, 56.9, 62.3, 75.1, 84.8, 92.0, 121.6, 127.99, 128.00, 129.58, 129.62, 
129.65, 129.69, 129.71, 130.3, 130.38, 130.43, 130.5, 138.0, 138.1, 139.2, 150.6, 153.0, 
156.1, 173.5 and 173.9; mass spectrum (APCI), m/z 589.2898 (M+H)
+
 (C30H37N8O5 
requires m/z 589.2887). 
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CHAPTER 4 
SYNTHESIS OF N-HYDROXYPYRIDONES AS MULTIFUNCTIONAL RADICAL 
QUENCHERS 
4.1. Introduction  
            Coenzyme Q10 (CoQ10) is one of the electron carriers in the electron transport 
chain, mediating transport from Complexes I and II to ubiquinone-cytochrome c 
reductase (Complex III). Its reduced form, CoQ10H2 is one of the most potent lipophilic 
antioxidants in cell membranes as it inhibits lipid peroxidation in vitro by quenching lipid 
radicals and superoxide.
104-107,170-172 
The reduced state, CoQ10H2 can be converted back to 
CoQ10 by the respiratory chain via redox cycling (Figure 4.1).
170-172 
CoQ10  has been 
tested for the treatment of illnesses related to mitochondrial dysfunction like Friedreich’s 
ataxia but its low solubility (octanol-water partition coefficient > 10
20
)
 
 makes it poorly 
bioavailable so that it cannot easily gain access to the mitochondria. Without access to 
the mitochondrial inner membrane of mitochondria, exogenous CoQ10 is unable to restore 
normal respiration.
170,173 
 
O
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O
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coenzyme Q -semiquinone radical
.
 
Figure 4.1. General scheme showing redox cycling of coenzyme Qn where n is the 
number of isoprenoid Units. 
 
There has been growing interest in the development of CoQ10 analogues having 
modified side chains in order to impart good pharmacokinetic properties and 
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mitochondrial membrane absorption. Recently, idebenone was proposed as an analogue 
of CoQ10 capable of functioning as a neuroprotective agent. Idebenone has been shown to 
accept electrons from mitochondrial Complex I and to restore respiration in ubiquinone-
deficient mitochondria. Idebenone has a shorter aliphatic chain than CoQ10, which makes 
it less lipophilic, but it is still lipophilic enough to interact with lipid bilayers. The 
compound has been the subject of a number of clinical trials for the treatment of inherited 
disorders of the respiratory chain;
174-177
 however, a few studies have shown that 
idebenone fails to increase ATP levels in CoQ10 deficient fibroblasts at high doses and 
also inhibits Complex I in the respiratory chain.
178-180 
 
O
O
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n
coenzyme Q10 Idebenone  
Figure 4.2. Structures of natural and synthetic antioxidants CoQ10 and idebenone.   
 
 
            The natural electron carrier, α-tocopherol (α-TOH) is one of the best lipophilic 
antioxidants.
109,110
 The activity of phenolic antioxidants in quenching lipid radicals 
depends on their ability to transfer the phenolic hydrogen atom to a carbon or peroxyl 
radical, as well as on the stability of the formed phenoxyl radical. It has been found that 
an increase in ring electron density of phenolic antioxidants lowers the O-H bond 
dissociation energy (O-H BDE) by stabilizing the phenoxyl radical, thus their activity as 
antioxidants is enhanced. However, some antioxidants with strong electron-donating 
substituents are less stable to air oxidation.
181-183
 Air stability is correlated to the  
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ionization potential (IP) of molecules: with a lower IP value, it is easier for a molecule to 
lose electrons and be oxidized.
181-183
 An antioxidant having a very low IP, could transfer 
an electron to molecular oxygen, and may become a source of superoxide rather than 
acting as antioxidant. To improve the air stability of such molecules, a series of nitrogen 
heterocyclic α-TOH type analogues (Figure 4.3) having one nitrogen atom (3-position) or 
two nitrogen atoms (3- and 5- positions) in the phenolic ring have been studied.
181-183
 The 
incorporation of a nitrogen atom in the phenolic ring increased the ionization potential 
(IP) and thus improved the air stability. 
   
O
HO
-tocopherol
NN
OH
N
N
OH
N
(a) (b)  
Figure 4.3. Chemical structures of α-TOH type analogues having pyrimidine (a) and 
pyridine (b) redox cores. 
 
            The pyrimidinol and pyridinol analogues have been found to exhibit favorable 
antioxidant properties. They scavenge free radicals, inhibit lipid peroxidation and 
preserve mitochondrial function from oxidative stress in a number of cell lines. Some of 
the pyrimidinol analogues augment ATP production in cultured CoQ10 deficient 
lymphocytes and FRDA fibroblasts and lymphocytes.
184-187
 These compounds have been 
termed multifunctional radical quenchers (MRQs), having multiple functions in the cell 
such as accepting electrons from superoxide, quenching carbon-centered lipid radicals 
and restoring ATP production in ATP-deficient cells.
186,187
 These encouraging results 
prompted us to explore other aza analogues of α-TOH or idebenone that might lead to 
more potent and efficacious compounds. N-hydroxy-4-pyridones (Figure 4.4) bear 
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structural resemblance to the quinone moiety of CoQ10. Their particular structure should 
allow them to stabilize radicals more effectively than quinones. The presence of a 
nitrogen atom in the ring increases the ionization potential, which is expected to stabilize 
the presence of strong electron donating groups without affecting the bond dissociation 
energy between oxygen and hydrogen. Therefore, these molecules should behave as 
quenchers of reactive oxygen species and the presence of a more hydrophilic core should 
afford better solubility in aqueous environments. In order to test this thesis, a series of 
analogues containing a N-hydroxy-4-pyridone core has been prepared. To enable a study 
of their ability to reach mitochondria and their interaction with the electron transport 
chain, different lipophilic side chains were employed (Figure 4.4). A hypothetical 
catalytic cycle for the N-hydroxy-4-pyridones acting as lipid radical and superoxide 
quenchers is outlined in Figure 4.5. Quenching of lipid peroxidation by N-hydroxy-4-
pyridone would result in a radical that should be a strong electron acceptor. This species 
should be capable of reacting with superoxide, the form of ROS that is expected to be 
produced in partially dysfunctional mitochondria through the leakage of electrons from 
the electron transport chain onto oxygen.  
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Figure 4.4. N-Hydroxypyridone analogues synthesized and evaluated. 
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Figure 4.5. Proposed catalytic cycle for the N-hydroxypyridones acting as lipid radical 
and superoxide quencher (adapted from ref 184). 
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4.2. Results 
Synthesis of N-Hydroxy-4-pyridones 
            The aim of this study was to synthesize and evaluate as MRQs a library of N-
hydroxy-4-pyridones having long alkyl chains. The commercially available long chain 
methyl ketones, 2-decanone, 2-tridecanone and 2-nonadecanone, were treated with 
polyphosphoric acid (PPA) and acetic acid to produce trimethyl-γ-pyrones (4.13, 4.14 
and 4.15, respectively) in 45%-51% yields (Scheme 4.1).
188
 Treating these trimethyl-γ-
pyrones with hydroxylamine led to the formation of N-hydroxypyridones 4.1, 4.2 and 4.3, 
respectively, in 43%-50% yields. Compounds 4.1, 4.2 and 4.3 were brominated by 
treatment with Br2 in acetic acid to afford 4.4, 4.5 and 4.6, respectively, in 69%-73% 
yields (Scheme 4.2). Chlorination of the compounds 4.1 and 4.2 with N-
chlorosuccinamide (NCS) in acetic acid produced compounds 4.7 and 4.8 in 54% and 
64% yields, respectively (Scheme 4.2).
189 
Trimethyl-γ-pyrone 4.13 was treated with ammonium hydroxide to produce NH-
pyridone 4.16 in 51% yield (Scheme 4.3). Iodination of the pyridone 4.16 in presence of 
ceric ammonium nitrate (CAN) afforded the iodopyridone 4.17 in 68% yield.
190
 
Treatment of the iodopyridone with Boc anhydride produced the Boc-protected 
compound 4.18 in 75% yield.
191
 Compound 4.18 underwent 
tetrakis(triphenylphosphine)palladium-mediated Stille coupling with tributyl(vinyl)tin to 
produce compound 4.19 in 27% yield.
192
 N-oxidation using mCPBA converted the 
compound 4.19 to N-oxide 4.20.
191 
Boc deprotection of compound 4.20 using 10 M KOH 
afforded the desired vinyl-substituted N-hydroxypyridone 4.9 (Scheme 4.3).
191 
 211 
 
O
O
O
AcOH, PPA
130 oC, 8 h aq EtOH, 100 
oC, 3 days
NH2OH.HCl, NaOAc
2-decanone ( n = 7)
2-tridecanone ( n = 10 )
2-nonadecanone ( n = 16 )
4.13 ( n = 6 )
4.14 ( n = 9 )
4.15 ( n = 15 )
n
n
51%
45%
49%
50%
43%
49%
N
O
4.1 ( n = 6 )
4.2 ( n = 9 )
4.3 ( n = 15 )
n
OH
 
Scheme 4.1. Synthesis of N-Hydroxypyridone Analogues Having Linear Alkyl Side Chains. 
 
                 
Br2, HOAc
rt, 2 h
NCS, HOAc
100 oC, 8 h
N
O
4.1 ( n = 6 )
4.2 ( n = 9 )
4.3 ( n = 15 )
n
OH
N
O
n
OH
Cl
4.4 ( n = 6 )
4.5 ( n = 9 )
4.6 ( n = 15 )
4.7 ( n = 6 )
4.8 ( n = 9 )
N
O
n
OH
Br
64%
54%
69%
73%
71%
 
Scheme 4.2. Synthesis of Bromo- and Chloro-substituted N-Hydroxy-4-pyridones. 
 
             Iodo derivative 4.17 was treated with benzyl chloride (BnCl) and sodium hydride 
(NaH) to afford OBn-protected compound 4.21 in 80% yield (Scheme 4.4).
193
 Treatment 
of 4.21 with metallic sodium in methanol formed 4.22 in 71% yield.
189
 m-
Chloroperoxybenzoic acid (mCPBA) converted 4.22 to the N-oxide 4.23 in 87% yield.
191
 
Hydrogenolysis over 10% Pd/C produced the desired methoxy-substituted pyridone 4.10 
in 70% yield (Scheme 4.4).
194 
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Scheme 4.3. Synthesis of Vinyl-substituted N-Hydroxy-4-pyridone 4.9. 
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Scheme 4.4. Synthesis of Methboxy-substituted N-Hydroxy-4-pyridone 4.10. 
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NH-pyridone 4.16 (Scheme 4.5) was treated with a HNO3/H2SO4 mixture to 
produce nitro pyridone 4.24 in 68% yield.
195
 Treatment of nitropyridone 4.24 with Boc 
anhydride produced 4.25 in 53% yield. N-oxidation using mCPBA converted 4.25 to the 
N-oxide 4.26 in 72% yield. Boc deprotection of N-oxide 4.26 by trifluoroacetic acid 
(TFA) produced the nitro pyridone 4.27 which underwent reduction of the nitro group 
over Pd/C to form the desired amino-substituted N-hydroxy-4-pyridone 4.11 in 79% yield 
(Scheme 4.5). 
N
O
H
       80 oC, 3 h
HNO3, H2SO4 tBuOK, (Boc)2O, THF
60 oC, 8 h
N
OBoc
O2N
4.16
6 6
N
O
H
4.24
6O2N
4.25
N
O
OH
4.11
6H2N
N
OBoc
O2N 6
4.26
mCPBA, DCM, rt
           5 h
O
68% 53% 72%
79%
N
O
OH
6O2N
Pd/C, H2, EtOH
       30 minTFA, DCM, rt, 4 h
78%
4.27  
Scheme 4.5. Synthesis of Amino-substituted N-Hydroxy-4-pyridone 4.11. 
 
Trimethyl-γ-pyrone 4.15 was treated with ammonium hydroxide to produce NH- 
pyridone 4.28 in 50% yield (Scheme 4.6). NH-pyridone 4.28 was treated with a 
HNO3/H2SO4 mixture to produce the compound 4.29 in 64% yield. Treatment of 
nitropyridone 4.29 with Boc anhydride produced 4.30 in 44% yield. N-oxidation using 
mCPBA converted 4.30 to the respective N-oxide 4.31 in 70% yield. Boc deprotection of 
the compound 4.31 by TFA, followed by reduction of the nitro group afforded the desired  
amino-substituted N-hydroxy-4-pyridone 4.12 in 39% overall yield (Scheme 4.6). 
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Scheme 4.6. Synthesis of Amino-substituted N-Hydroxy-4-pyridone 4.12. 
 
Biological Evaluation of the N-Hydroxy-4-pyridones 
            In order to evaluate the structural effects of analogues 4.1-4.12, the compounds 
were tested for NADH oxidase activity, suppression of lipid peroxidation, ROS 
scavenging and in cell viability assays. 
 
Mitochondrial Electron Transport Chain Function (NADH Oxidase Activity) 
            Inhibition of any of the mitochondrial electron transport chain complexes can 
limit the potential therapeutic use of MRQ analogues. It is important to prepare 
compounds lacking any inhibitory effect on the respiratory chain. Any ETC inhibition 
will ultimately reduce mitochondrial ATP production. Since, ETC begins with the 
oxidation of NADH and channeling the derived electrons into the formation of reduced 
coenzymes, ETC function can be estimated through a change in the rate of NADH 
oxidation. The NADH oxidase assay evaluates the inhibitory effect of molecules on the 
ETC. Molecules having therapeutic potential should exhibit only limited inhibition of 
NADH oxidase activity even at higher concentrations.  
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            The inhibitory effects of N-hydroxy-4-pyridone analogues were evaluated using 
submitochondrial particles (SMP). The results (performed by Dr. Sriloy Dey) presented in 
Tables 4.1 and Table 4.2 show that compound 4.3 (Table 4.1), having a 16-carbon atom 
side chain was less inhibitory than the corresponding analogues having 10 or 7-carbon 
atom side chains. Compound 4.9, having a 7-carbon atom side chain and a vinyl group, 
and compound 4.12, having a 16 carbon atom side chain and an amino group, were the  
most inhibitory analogues (Table 4.2). 
 
Table 4.1. NADH Oxidase Activity of N-Hydroxypyridone Analogues (4.1-4.8) are 
Shown Relative to Untreated Control. Data are expressed as the mean ± SEM (n = 3). 
 
                                                         NADH oxidase (Complex I, III, IV) activity (%) 
 
 
 
 
 
 
 
 
Compound 0.5 M 1 M 
untreated control 100 100 
4.1 70 ± 2 67 ± 1 
4.3 85 ± 3 79 ± 2 
4.4 60 ± 3 55 ± 1 
4.5 44 ± 1 42 ± 1 
4.7 64 ± 1 61 ± 2 
4.8 79 ± 2 75 ± 1 
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Table 4.2. NADH Oxidase Activity of N-Hydroxypyridone Analogues (4.9-4.12) are 
Shown Relative to Untreated Control. Data are expressed as the mean ± SEM (n = 3). 
 
                                                   NADH oxidase (Complex I, III, IV) activity (%) 
    
Inhibition of Lipid Peroxidation 
            The ability of the synthesized analogues to quench lipid peroxidation was 
evaluated in cultured CEM leukemia lymphocytes. These cells were placed under 
oxidative stress by depleting them of glutathione (GSH) by treatment with diethyl 
maleate (DEM). The extent of lipid peroxidation was quantified using a hydrophobic 
fatty acid fluorophore C11-BODIPY
581/591
, which inserts preferentially in membranes. 
Upon oxidation of the polyunsaturated butadienyl portion of the fluorophore, the red 
emitting form of the dye (λem 595 nm) is converted into a green emitting form (λem 520 
nm). Increased C11-BODIPY
581/591
-green fluorescence, a measure of peroxyl radical 
production, was quantified by flow cytometric analysis, which is expressed as percent 
scavenging activity. 
            The results in Table 4.3 show that most of the analogues were inactive or poorly 
effective in suppressing lipid peroxidation. Compound 4.3 (Table 4.3) had some lipid 
peroxidation suppressing ability, whereas the corresponding analogues 4.1 and 4.2 were 
        Compound 1 M 5 M 10 M 
untreated control 100 100 100 
4.9 29.7 ± 3.8 20.7 ± 2.2 13.2 ± 1 
4.10 74.5 ± 6.9 44.5 ± 3.6 33.5 ± 2.2 
4.11 92.9 ± 10.9 76.7 ± 6.9 70.4 ± 5.5 
4.12 17.7 ± 1 12.7 ± 1.7 10.7 ± 1.3 
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inactive, suggesting that alkyl side chain length was important. Amino-substituted N-
hydroxypyridone analogue 4.12 was best analogue in suppressing lipid peroxidation at 5 
μM concentration (94% suppression of lipid peroxidation).  
 
Table 4.3. Suppression of Lipid Peroxidation by N-Hydroxypyridone Analogues (4.1- 
4.12) in Cultured CEM Lymphocytes Treated with DEM. The experiment was performed 
by Dr. Omar M. Khdour. 
 
                                                                               Scavenging activity (%) 
 
 
 
Compound 1 M 5 M 
untreated control
 100 100 
treated control
 0 0 
4.1 0 0 
4.2 0 0 
4.3 10 ± 4.3 20 ± 3.4 
4.4 0 0 
4.5 0 0 
4.6 7 ± 2.3 15 ± 3.3 
4.7 0 0 
4.8 0 0 
4.9 0 0 
4.10 11 ± 1.8 2.2 ± 2.3 
4.11 14 ± 4.1 9.6 ± 2.8 
4.12 18 ± 2.2 94 ± 0.2 
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Suppression of Reactive Oxygen Species 
            Some of the N-hydroxy-4-pyridone analogues 4.9-4.12 were assayed for 
suppression of reactive oxygen species (ROS) production in cultured CEM leukemia cells 
pretreated with DEM. The intracellular ROS level was measured based on the ROS-
induced formation of the highly fluorescent product 2′,7′-dichlorofluorescein (DCF) from 
the non-fluorescent dye 2′,7′- dichlorodihydrofluorescein diacetate (DCFH-DA). The 
results presented in Table 4.4 show 4.11 and 4.12 exhibited dose-dependent behaviors in 
suppressing ROS. Amino-substituted N-hydroxypyridone 4.12 having a 16-carbon atom 
substituent was the most effective in suppressing ROS, in agreement with the present 
lipid peroxidation results.   
 
Table 4.4. Suppression of ROS Production in Cultured CEM Leukemia Cells Pretreated 
with DEM. Results are Expressed as % Scavenging Activity. The experiment was 
performed by Dr. Ruth Goldschmidt. 
 
                                                                          ROS Scavenging activity (%) 
 
 
Compound 0.25 M 2.5 M 10 M 
untreated control
 100 100 100 
treated control
 0 0 0 
4.9 23.4 ± 1.6 22.2 ± 3.5 20.0 ± 4.4 
4.10          21.0 ± 5.5 26.4 ± 4.4 0 ± 10 
4.11 4.6 ± 5.4 42.2 ± 2.9 67.0 ± 5.9 
4.12 41.4 ± 14.9 81.8 ± 3.7 91.0 ± 1.5 
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Cytoprotection 
            The ability of the test compounds (4.1–4.12) to confer cytoprotection to cultured 
cells under DEM-induced oxidative stress was evaluated (Table 4.5). Cell viability was 
determined by trypan blue exclusion assay in an FRDA cell line. This technique was used 
to assess the cytoprotective effects of the compounds in cultured cells treated with diethyl  
 
Table 4.5. Cytoprotection of Cultured FRDA Lymphocytes from the Effects of DEM 
Induced Oxidative Stress. Results are Expressed as % Viability. The experiment was 
performed by Dr. Ruth Goldschmidt. 
 
                                                                                         % Viable Cells 
Compound 0.1 M     0.5 M        2.5 M        untreated            Treated 
4.1 27 ± 7 30 ± 13 24 ± 6           93 ± 7           21 ± 8           
 4.2 36 ± 6 14 ± 5 20 ± 3 97 ± 9 17 ± 2 
4.3 19 ± 6 15 ± 5 18 ± 2 97 ± 9 17 ± 2 
4.4 31 ± 12 28 ± 7 32 ± 5 97 ± 5 18 ± 3 
4.5 19 ± 6 20 ± 13 32 ± 8 97 ± 5 18 ± 3 
4.6 12 ± 5 6 ± 3  8 ± 3 96 ± 2 12 ± 3 
4.7 15 ± 6 29 ± 3 39 ± 3 97 ± 5 18 ± 3 
4.8 17 ± 3 14 ± 2 19 ± 5 97 ± 9 17 ± 2 
4.9 25 ± 6 42 ± 3 30 ± 6 93 ± 7 21 ± 8 
4.10 12 ± 6 17 ± 7 14 ± 3 96 ± 2 12 ± 3 
4.11 19 ± 6 19 ± 3 25 ± 5 96 ± 2 12 ± 3 
4.12 17 ± 5 21 ± 9 35 ± 9 96 ± 2 12 ± 3 
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maleate to induce cell death by depletion of cellular glutathione. The viability of DEM-
treated FRDA cells was determined by their ability to exclude the dye trypan blue. None 
of the compounds provided significant cytoprotection from DEM-induced stress. 
 
4.3. Discussion 
            There has been no study to date of the efficiency of N-hydroxy-4-pyridones 
analogues as radical quenchers. In this study, some analogues have been synthesized that 
can provide data relevant to the structural requirements for mitochondrial protection. 
Trimethyl-γ-pyrones (4.13, 4.14 and 4.15) were prepared from commercially available 
long chain methyl ketones.
188
 These trimethyl-γ-pyrones produced N-hydroxy-4-
pyridones (4.1, 4.2 and 4.3) under reflux condition (Scheme 4.1), whereas the synthesis 
of NH-pyridones (4.16 and 4.28) was performed in a high pressure tube (Schemes 4.3 
and 4.6). Both the syntheses of N-OH pyridones and N-H pyridones from pyrones were 
low yielding, needing longer reaction times. The reactivity of the pyrones decreased with 
an increasing number of carbon atoms in the side chains, making the ring more electron 
rich and less likely to be attacked by nucleophiles such as hydroxylamine or ammonia 
(Schemes 4.1, 4.2 and 4.6). N-hydroxy-4-pyridones (4.1, 4.2 and 4.3) underwent 
electrophilic bromination or chlorination to afford bromo-and chloro-substituted N-
hydroxy-4-pyridones (4.4-4.8).  
            Vinyl-, methoxy- and amino-substitued N-hydroxy-4-pyridones 4.9-4.12 
(Schemes 4.3, 4.4, 4.5 and 4.6) were synthesized anticipating that these substitutions 
would stabilize the pyridonoxyl radical more effectively. The synthesis of vinyl-
substitued pyridone 4.9 commenced with iodination of NH-pyridone 4.16. Boc protection 
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of NH-pyridone 4.17 at 60 
o
C afforded 4.18. Compound 4.18 underwent 
tetrakis(triphenylphosphine)palladium mediated Stille coupling with tributyl(vinyl)tin to 
afford 4.19. N-oxidation using mCPBA, followed by Boc deprotection using 10 M KOH, 
afforded the desired vinyl-substituted N-hydroxypyridone 4.9 (Scheme 4.3). 
            Benzylation of iodopyridone 4.17 was effected using benzyl chloride at 50 
o
C in 
order to obtain the thermodynamically stable O-benzylated product rather than the N-
benzylated product (Scheme 4.4). N-Oxidation using mCPBA in dichloromethane, and 
the removal of the benzyl protecting group by hydrogenolysis, afforded the desired N-OH 
pyridone 4.10 (Scheme 4.4). Nitration of the pyridones had to be done using a mixture of 
HNO3 and H2SO4 at high temperature. The Boc protection reaction of nitro pyridones 
(4.24 and 4.29) and the subsequent N-oxidation reactions to form 4.26 and 4.31 were 
low-yielding involving longer reaction times because of the presence of the electron 
withdrawing nitro group in the ring (Schemes 4.5 and 4.6). Boc deprotection of the N-
oxides by TFA followed by hydrogenation over Pd/C afforded 4.11 and 4.12. 
            Compounds 4.1-4.12 are inhibitors of mitochondrial electron transfer at all tested 
concentrations. Analogues with longer alkyl side chains were generally found to be less 
inhibitory than the corresponding analogues having shorter side chains (Table 4.1). 
However, 16 carbon chain compound 4.12 having a polar amine group on the redox core 
was a strong inhibitor even at lower concentrations (Table 4.2).   
            As shown in Table 4.3, all of the new N-hydroxy-4-pyridones were tested for their 
ability to quench lipid peroxidation in FRDA lymphocytes following oxidative challenge 
with diethyl maleate. Most of the analogues were inactive or poorly effective in 
suppressing lipid peroxidation. Increasing the side chain length (to 16 carbon atoms) 
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improved suppression of lipid peroxidation. The analogues were tested at two different 
(2.5 and 5 μM) concentrations and compound 4.12 having electron-donating amine group 
on the redox core was the best inhibitor of lipid peroxidation (94% suppression at 5 μM 
concentration). However, at a lower concentration, it did not show much suppression. 
Some of the compounds were also tested for suppression of ROS in CEM lymphocytes 
(Table 4.4), affording results that fairly closely paralleled those found for lipid 
peroxidation. The analogues were tested at three different (0.25, 2.5 and 10.0 μM) 
concentrations; the results indicated that amino-substituted analogues 4.11 and 4.12 
suppressed ROS reasonably potently at high (10 μM) concentration. The ability of the 
synthesized N-hydroxy-4-pyridones to protect cultured Friedreich’s ataxia lymphocytes 
from cell death by oxidative stress was measured (Table 4.5). None of the compounds 
provided significant cytoprotection from DEM-induced stress in FRDA lymphocytes. 
The biological results provide an understanding of the structure-activity 
relationships between the N-hydroxy-4-pyridone analogues and their binding to the 
mitochondrial complexes. Analogue 4.12 exhibited promising biological activity in 
inhibition of lipid peroxidation and ROS suppression. However, its inhibitory effect 
towards the respiratory chain as well as its inability to confer cytoprotection to cultured 
FRDA cells makes it a poor candidate for treating mitochondrial disorders. Therefore, 
further studies and modification of these N-hydroxy-4-pyridones will be required to  
identify a potential candidate for the treatment of Friedreich’s ataxia and other 
disorders of the mitochondrial respiratory chain. 
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4.4. Experimental Procedures 
            The chemicals used were purchased from Alfa Aesar, Aldrich Chemical Co. or 
Sigma Chemical Co. and were used without further purification. Tetrahydrofuran and 
dichloromethane were distilled from sodium/benzophenone and calcium hydride, 
respectively. All experiments requiring anhydrous conditions were conducted in flame-
dried glassware fitted with rubber septa under a positive pressure of dry nitrogen or 
argon. Reactions were performed at room temperature unless indicated otherwise. 
Analytical thin layer chromatography was performed using glass plates pre-coated with 
silica gel (0.25 mm, 60 Å pore size, 230-400 mesh, Silicycle) impregnated with a 
fluorescent indicator (254 nm). TLC chromatograms were visualized by exposure to 
ultraviolet light (UV). Flash column chromatography was performed employing silica gel 
(60 Å pore size, 40-63 μm, standard grade, Silicycle).  
1
H NMR and 
13
C NMR spectra were recorded on Varian INOVA 400 (400 MHz) 
or Varian INOVA 500 (500 MHz) spectrometers at 25 °C. Proton chemical shifts are 
expressed in parts per million (ppm, δ scale) and are referenced to residual protium in the 
NMR solvent (CDCl3 or CD3OD).  Splitting patterns are designated as follows: s, singlet; 
br s, broad singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet. 
High resolution mass spectra were obtained at the Arizona State University CLAS High 
Resolution Mass Spectrometry Facility or the Michigan State University Mass 
Spectrometry Facility.  
                            
O
O
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3-Heptyl-2,6-dimethyl-4H-pyran-4-one (4.13). To a mixture of 49.0 g of 
polyphosphoric acid and 30 mL of acetic acid was added 0.60 mL (0.50 g, 3.20 mmol) of 
2-decanone. The resulting solution was heated at 130 °C with vigorous stirring for 8 h. 
The resulting dark black solution was cooled to 0 °C, diluted with 200 mL of water and 
extracted with two 100-mL portions of EtOAc. The combined organic phase was washed 
with 10% aq KOH, dried over anhydrous MgSO4 and concentrated under diminished 
pressure to afford a crude residue. The residue was purified by chromatography on a 
silica gel column (20 × 4 cm). Elution with 1:1 hexane–ethyl acetate gave 3-heptyl-2,6-
dimethyl-4H-pyran-4-one (4.13) as a light yellow solid: yield 555 mg (51%); silica gel 
TLC Rf 0.45 (1:1 hexane–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) δ 0.45-0.50 (m, 
3H), 0.88-1.04 (m, 10H), 1.82 (s, 3H), 1.89 (s, 3H), 1.98 (t, 2H, J = 7.6 Hz) and 5.62 (s, 
1H); 
13
C NMR (CDCl3, 100 MHz) δ 13.3, 16.6, 18.9, 21.9, 23.6, 27.8, 28.5, 28.9, 31.1, 
112.1, 124.0, 160.6, 163.5 and 178.4; mass spectrum (APCI), m/z 223.1696 (M + H)
+
 
(C14H23O2 requires m/z 223.1698). 
                           
O
O
 
3-Decyl-2,6-dimethyl-4H-pyran-4-one (4.14). To a mixture of 50.0 g of polyphosphoric 
acid and 30 mL of acetic acid was added 0.61 mL (0.50 g, 2.52 mmol) of 2-tridecanone. 
The resulting solution was heated at 130 °C with vigorous stirring for 8 h. The resulting 
dark black solution was cooled to 0 °C, diluted with 200 mL of water and extracted with 
two 100-mL portions of EtOAc. The combined organic phase was washed with 10% aq 
KOH, dried over anhydrous MgSO4 and concentrated under diminished pressure to afford 
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a crude residue. The residue was purified by chromatography on a silica gel column (20 × 
4 cm). Elution with 1:1 hexane–ethyl acetate gave 3-decyl-2,6-dimethyl-4H-pyran-4-one 
(4.14) as a light yellow solid: yield 331 mg (49%); silica gel TLC Rf 0.52 (1:1 hexane–
ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) δ 0.80-0.83 (m, 3H), 1.12-1.37 (m, 16H), 
2.14 (s, 3H), 2.21 (s, 3H), 2.30-2.34 (t, 2H, J = 8.0 Hz) and 6.00 (s, 1H); 
13
C NMR 
(CDCl3, 100 MHz) δ 14.2, 17.4, 19.7, 22.7, 24.5, 28.6, 29.4, 29.6, 29.7, 29.8, 32.0, 113.0, 
124.9, 161.5, 164.3 and 179.6; mass spectrum (APCI), m/z 265.2163 (M + H)
+
 (C17H29O2 
requires m/z 265.2168). 
                     
O
O
 
3-Hexadecyl-2,6-dimethyl-4H-pyran-4-one (4.15). To a mixture of 49.5 g of 
polyphosphoric acid and 30 mL of acetic acid was added 0.50 g (1.77 mmol) of 2-
nonadecanone. The resulting solution was heated at 130 
o
C with vigorous stirring for 8 h. 
The resulting dark black solution was cooled to 0 
o
C, diluted with 200 mL of water and 
extracted with two 100-mL portions of EtOAc. The combined organic phase was washed 
with 10% aq KOH, dried over anhydrous MgSO4 and concentrated under diminished 
pressure to afford a crude residue. The residue was purified by chromatography on a 
silica gel column (20 × 4 cm). Elution with 2:1 hexane–ethyl acetate gave 3-hexadecyl-2, 
6-dimethyl-4H-pyran-4-one (4.15) as a light yellow solid: yield 331 mg (45%); silica gel 
TLC Rf 0.60 (1:1 hexane–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) δ 0.78-0.82 (m, 
3H), 1.18-1.24 (m, 28H), 2.14 (s, 3H), 2.21 (s, 3H), 2.30 (t, 2H, J = 8.4 Hz) and 6.06 (s, 
1H);
 13
C NMR (CDCl3, 100 MHz) δ 14.3, 17.5, 19.8, 22.8, 24.5, 28.7, 29.5, 29.7, 29.78, 
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29.81, 29.83, 32.1, 113.1, 125.1, 161.6, 164.4 and 179.7; mass spectrum (APCI), m/z 
349.3106 (M + H)
+
 (C23H41O2 requires m/z 349.3107). 
                                     
N
O
OH
 
 
 3-Heptyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.1). A mixture containing 113 
mg (0.51 mmol) of trimethyl pyrone 4.13, 707 mg (10.2 mmol) of hydroxylamine 
hydrochloride, 835 mg (10.2 mmol) of sodium acetate, 1.0 mL of water and 2.0 mL of 
EtOH was heated at reflux for 18 h. The cooled reaction mixture filtered, and the filtrate 
was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 4 cm). Elution with 5:1 ethyl acetate–
methanol gave 3-heptyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.1) as a brown 
solid: yield 62.9 mg (50%); silica gel TLC Rf 0.35 (3:1 ethyl acetate–methanol); 
1
H NMR 
(CD3OD, 400 MHz) δ 0.84-0.87 (m, 3H), 1.26-1.45 (m, 10H), 2.42 (s, 3H), 2.48 (s, 3H), 
2.59-2.63 (t, 2H, J = 8.4 Hz), 5.21 (br s, 1H) and 6.73 (s, 1H); 
13
C NMR (CD3OD, 100 
MHz) δ 14.6, 14.8, 18.5, 23.7, 27.1, 29.9, 30.3, 30.6, 33.0, 111.6, 126.4, 148.9, 150.3 and 
160.1; mass spectrum (APCI), m/z 238.1808 (M + H)
+
 (C14H24NO2 requires m/z 
238.1807). 
                                  
N
O
OH
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3-Decyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.2). A mixture containing 200 mg 
(0.75 mmol) of trimethyl pyrone 4.14, 1.05 g (15.2 mmol) of hydroxylamine 
hydrochloride, 1.24 g (15.2 mmol) of sodium acetate, 1.0 mL of water and 2.0 mL of 
EtOH was heated at reflux for 3 days. The cooled reaction mixture was concentrated 
under dimished pressure to afford a brown residue. The residue was purified by 
chromatography on a silica gel column (10 × 4 cm). Elution with 5:1 ethyl acetate–
methanol gave 3-decyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.2) as a brown oil: 
yield 90.1 mg (49%); silica gel TLC Rf 0.41 (3:1 ethyl acetate–methanol);
 1
H NMR 
(CD3OD, 400 MHz) δ 0.85-0.88 (m, 3H), 1.26-1.46 (m, 16H), 2.42 (s, 3H), 2.49 (s, 3H), 
2.61-2.65 (t, 2H, J = 8.0 Hz) and 6.74 (s, 1H); 
13
C NMR (CD3OD, 100 MHz) δ 14.5, 
14.8, 18.5, 23.8, 27.1, 29.9, 30.0, 30.5, 30.56, 30.61, 30.8, 33.1, 111.5, 126.4, 149.1, 
150.5 and 160.0; mass spectrum (APCI), m/z 280.2282 (M + H)
+
 (C17H30NO2 requires 
m/z 280.2277). 
                   
N
O
OH
  
3-Hexadecyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.3). A mixture containing 
200 mg (0.57 mmol) of trimethyl pyrone 4.15, 399 mg (5.70 mmol) of hydroxylamine 
hydrochloride, 471 mg (5.70 mmol) of sodium acetate, 1.0 mL of water and 2.0 mL of 
EtOH was heated at reflux for 3 days. The cooled reaction mixture was concentrated 
under diminished pressure to afford a brown oil. The residue was purified by 
chromatography on a silica gel column (10 × 4 cm). Elution with 5:1 ethyl acetate–
methanol gave 3-hexadecyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.3) as a brown 
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solid: yield 89.2 mg (43%); silica gel TLC Rf 0.45 (3:1 ethyl acetate–methanol);
 1
H NMR 
(CD3OD, 400 MHz) δ 0.83-0.85 (m, 3H), 1.22-1.27 (m, 28H), 2.32 (s, 3H), 2.46 (s, 3H), 
2.55 (t, 2H, J = 8.4 Hz) and 6.70 (s, 1H);
 13
C NMR (CD3OD, 100 MHz) δ 14.1, 16.8, 
18.8, 22.5, 22.6, 25.3, 28.9, 29.3, 29.6, 29.7, 30.0, 31.9, 113.4, 126.1, 145.1, 146.8 and 
178.4; mass spectrum (APCI), m/z 364.3212 (M + H)
+
 (C23H41O2 requires m/z 364.3216). 
                                             
N
O
OH
Br
 
3-Bromo-5-heptyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.4). To a stirred 
solution containing 63.0 mg (0.27 mmol) of 4.1 in 2.0 mL acetic acid was added 
dropwise a solution containing 0.04 mL (0.27 mmol) of bromine in 1.0 mL of acetic acid 
at room temperature. After 2 h a few drops of a saturated aq sodium sulfite was added to 
discharge excess bromine. The reaction mixture was diluted with 20 mL of water and 
extracted with two 20-mL portions of EtOAc. The combined organic phase was dried 
over anhydrous MgSO4 and concentrated under diminished pressure to afford a crude 
residue. The residue was purified by chromatography on a silica gel column (10 × 2 cm). 
Elution with 10:1 ethyl acetate–methanol gave compound 3-bromo-5-heptyl-1-hydroxy-
2,6-dimethylpyridin-4(1H)-one (4.4) as a yellow oil: yield 57.4 mg (69%); silica gel TLC 
Rf 0.68 (5:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 400 MHz) δ 0.84-0.87 (m, 3H), 
1.26-1.41 (m, 10H), 2.41 (s, 3H), 2.57-2.61 (m, 2H), 2.63 (s, 3H) and 4.86 (br s, 1H); 
13
C 
NMR (CDCl3, 100 MHz) δ 14.4, 14.7, 18.8, 23.2, 27.7, 29.3, 29.8, 30.3, 32.4, 111.5, 
126.2, 147.0, 147.6 and 166.7; mass spectrum (APCI), m/z 316.0911 (M + H)
+
 
(C14H23NO2Br requires m/z 316.0912). 
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N
O
OH
Br
 
 
3-Bromo-5-decyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.5). To a stirred 
solution containing 40.0 mg (0.14 mmol) of 4.2 in acetic acid (2.0 mL) was added 
dropwise a solution containing 0.02 mL (0.14 mmol) of bromine in 1.0 mL of acetic acid 
at room temperature. After 2 h a few drops of a saturated aq sodium sulfite was added to 
discharge excess bromine. The reaction mixture was diluted with 20 mL of water and 
extracted with two 20-mL portions of EtOAc. The combined organic phase was dried 
over anhydrous MgSO4 and concentrated under diminished pressure to afford a crude 
residue. The residue was purified by chromatography on a silica gel column (10 × 2 cm). 
Elution with 10:1 ethyl acetate–methanol gave compound 3-bromo-5-decyl-1-hydroxy-2, 
6-dimethylpyridin-4(1H)-one (4.5) as a brown oil: yield 37.0 mg (73%); silica gel TLC Rf 
0.75 (5:1 ethyl acetate–methanol); 1H NMR (CDCl3, 400 MHz) δ 0.88-0.91 (m, 3H), 
1.29-1.46 (m, 16H), 2.44 (s, 3H) and 2.66 (s, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 14.3, 
14.9, 19.0, 22.8, 28.9, 29.5, 29.7, 29.79, 29.82, 32.1, 111.7, 126.0, 146.8, 147.6 and 
168.9; mass spectrum (APCI), m/z 358.1381 (M + H)
+
 (C17H29NO2Br requires m/z 
358.1382). 
 
               
N
O
OH
Br
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3-Bromo-5-hexadecyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.6). To a stirred 
solution containing 44.0 mg (0.12 mmol) of 4.3 in 2.0 mL acetic acid was added 
dropwise a solution containing 0.01 mL (0.12 mmol) of bromine in 1.0 mL of acetic acid 
at 10-15
 o
C. After 1.5 h a few drops of a saturated aq sodium sulfite was added to 
discharge excess bromine. The reaction mixture was diluted with 20 mL of water and 
extracted with two 20-mL portions of EtOAc. The combined organic phase was dried 
over anhydrous MgSO4 and concentrated under diminished pressure to afford a crude 
residue. The residue was purified by chromatography on a silica gel column (10 × 2 cm). 
Elution with 10:1 ethyl acetate–methanol gave compound 3-bromo-5-hexadecyl-1-
hydroxy-2,6-dimethylpyridin-4(1H)-one (4.6) as a brown solid: yield 38.9 mg (71%); 
silica gel TLC Rf 0.80 (5:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 400MHz) δ 0.87-
0.89 (m, 3H), 1.25-1.51 (m, 28H) and 2.41-2.58 (m, 8H); 
13
C NMR (CD3OD, 100 MHz) 
δ 14.2, 15.9, 18.8, 22.3, 22.6, 25.3, 27.9, 29.3, 29.2, 29.7, 30.0, 30.9, 113.4, 127.1, 145.2, 
147.8 and 177.1; mass spectrum (APCI), m/z 442.2325 (M + H)
+
 (C23H41NO2Br requires 
m/z 442.2321). 
                                       
N
O
OH
Cl
 
 
3-Chloro-5-heptyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.7). To a stirred 
solution containing 11.0 mg (0.05 mmol) of 4.1 in 1.0 mL of acetic acid was added 6.70 
mg (0.05 mmol) of N-chlorosuccinimide. The reaction mixture was heated at 100 °C for 
8 h and cooled to room temperature, diluted with 20 mL of water and extracted with two 
20-mL portions of EtOAc. The combined organic phase was dried over anhydrous 
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MgSO4 and concentrated under diminished pressure to afford a crude residue. The 
residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution with 
10:1 ethyl acetate–methanol gave compound 3-chloro-5-heptyl-1-hydroxy-2,6-
dimethylpyridin-4(1H)-one (4.7) as a brown solid: yield 7.10 mg (54%); silica gel TLC 
Rf 0.66 (5:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 400 MHz) δ 0.88-0.91 (m, 3H), 
1.26-1.45 (m, 10H), 2.34 (s, 3H), 2.43 (s, 3H) and 2.48-2.55 (m, 2H); 
13
C NMR (CDCl3, 
100 MHz) δ 14.4, 14.7, 18.8, 23.2, 27.7, 29.3, 29.8, 30.3, 32.4, 111.5, 126.2, 147.0, 147.6 
and 166.7; mass spectrum (APCI), m/z 272.1422 (M + H)
+
 (C14H23NO2Cl requires m/z 
272.1417). 
 
                             
N
O
OH
Cl
 
 
3-Chloro-5-decyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.8). To a stirred 
solution containing 40.0 mg (0.14 mmol) of 4.2 in 2.0 mL of acetic acid was added 19.1 
mg (0.14 mmol) of N-chlorosuccinimide. The reaction mixture was heated at 100 °C for 
8 h and cooled to room temperature, diluted with 20 mL of water and extracted with two 
20-mL portions of EtOAc. The combined organic phase was dried over anhydrous 
MgSO4 and concentrated under diminished pressure to afford a crude residue. The 
residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution with 
10:1 ethyl acetate–methanol gave 3-chloro-5-decyl-1-hydroxy-2,6-dimethylpyridin-
4(1H)-one (4.8) as a brown solid: yield 28.3 mg (64%); silica gel TLC Rf 0.7 (7:1 ethyl 
acetate–methanol); 1H NMR (CD3OD, 400 MHz) δ 0.73-0.78 (m, 3H), 1.15-1.20 (m, 
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16H), 2.25 (s, 3H), 2.30 (s, 3H) and 2.37-2.40 (m, 2H);
 13
C NMR (CD3OD, 100 MHz) δ 
14.5, 14.8, 18.5, 23.8, 27.1, 29.9, 30.0, 30.5, 30.56, 30.61, 30.8, 33.1, 111.5, 126.4, 149.1, 
150.5 and 160.0; mass spectrum (APCI), m/z 314.1877 (M + H)
+
 (C17H29NO2Cl requires 
m/z 314.1887). 
                                                 
N
O
H
 
3-Heptyl-2,6-dimethylpyridin-4(1H)-one (4.16). Trimethyl-γ-pyrone 4.13 (0.01 g, 30.6 
mmol) was heated at 100 °C with 2 mL of aqueous ammonia in a high pressure tube for 
18 h. The cooled reaction mixture was concentrated under diminished pressure to afford a 
brown oil. The crude residue was purified by chromatography on a silica gel column (10 
× 2 cm). Elution with 10:1 ethyl acetate–methanol gave 3-heptyl-2, 6-dimethylpyridin-
4(1H)-one (4.16) as a brown solid: yield 50.7 mg (51%); silica gel TLC Rf 0.25 (3:1 ethyl 
acetate–methanol); 1H NMR (CD3OD, 400 MHz) δ 0.88-0.90 (m, 3H), 1.29-1.46 (m, 
10H), 2.30 (s, 3H), 2.36 (s, 3H), 2.48-2.52 (m, 2H), 4.97 (br s, 1H) and 6.25 (s, 1H);
 13
C 
NMR (CD3OD, 100 MHz) δ 14.5, 17.1, 18.8, 23.8, 26.0, 29.8, 30.5, 30.9, 33.1, 114.4, 
127.2, 147.0, 148.6 and 179.6; mass spectrum (APCI), m/z 222.1850 (M + H)
+
 
(C14H24NO requires m/z 222.1858). 
                                                  
N
O
H
I
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3-Heptyl-5-iodo-2,6-dimethylpyridin-4(1H)-one (4.17). To a stirred solution containing 
100 mg (0.45 mmol) of compound 4.16 in acetonitrile (2.5 mL) was added 25.0 mg (45.0 
µmol) of ceric ammonium nitrate followed by 126 mg (50 µmol) of iodine. The reaction 
mixture was heated at 70 
o
C under nitrogen for 7 h. The resulting dark brown solution 
was cooled to room temperature, diluted with 200 mL of water and extracted with two 
100-mL portions of EtOAc. The combined organic phase was dried over anhydrous 
MgSO4 and concentrated under diminished pressure to afford a crude residue. The 
residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution with 
1:1 hexane–ethyl acetate gave 3-heptyl-5-iodo-2,6-dimethylpyridin-4(1H)-one (4.17) as a 
light yellow solid: yield 110 mg (68%); silica gel TLC Rf 0.45 (1:1 hexane–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) δ 0.88-0.91 (m, 3H), 1.29-1.46 (m, 10H), 2.34 (s, 3H) and 
2.53-2.56 (m, 5H);
 13
C NMR (CDCl3, 100 MHz) δ 13.3, 16.6, 18.9, 21.9, 23.6, 27.8, 28.5, 
28.9, 31.1, 112.1, 124.0, 160.6, 163.5 and 178.4; mass spectrum (APCI), m/z 348.0835 
(M + H)
+
 (C14H23INO requires m/z 348.0825). 
                                                      
N
OBoc
I
 
tert-Butyl-3-heptyl-5-iodo-2,6-dimethylpyridin-4-yl carbonate (4.18). To a stirred 
solution containing 60.0 mg (0.73 mmol) of iodo derivative 4.17 in anhydrous THF (3 
mL) was added 102 mg (0.91 mmol) of t-BuOK and the reaction mixture was stirred at 
room temperature for 1 h. Then 175 mg (0.80 mmol) of Boc anhydride was added and the 
reaction mixtre was heated at 60 °C for 1 h. The cooled reaction mixture was 
concentrated under diminished pressure to afford a yellow oil. The residue was purified 
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by chromatography on a silica gel column (10 × 2 cm). Elution with 3:1 hexane–ethyl 
acetate gave 4.18 as a light yellow oil: yield 60.1 mg (75%); silica gel TLC Rf 0.71 (1:1 
hexane–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 0.82-0.86 (m, 3H), 1.22-1.33 (m, 
10H), 1.51 (s, 9H) and 2.51-2.54 (m, 8H);
 
mass spectrum (APCI), m/z 448.1355 (M + H)
+
 
(C19H31INO3 requires m/z 448.1349). 
                                                
N
OBoc
 
tert-Butyl 3-heptyl-2,6-dimethyl-5-vinylpyridin-4-yl carbonate (4.19). To a stirred 
solution containing 60.0 mg (0.864 mmol) of 4.18 in 1,4-dioxane (4 mL) were added 73.2 
mg (1.73 mmol) of lithium chloride, 99.8 mg (10 mol%) of 
tetrakis(triphenylphosphine)palladium and 0.33 mL (355 mg, 1.12 mmol) of 
tributyl(vinyl)tin. The reaction mixture was heated at reflux for 8 h and cooled to room 
temperature, diluted with 20 mL of water and extracted with two 20-mL portions of 
EtOAc. The combined organic phase was dried over anhydrous MgSO4 and concentrated 
under diminished pressure to afford a crude residue. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 10:1 ethyl acetate–
methanol gave compound 4.19 as a light yellow oil: yield 12.5 mg (25%); silica gel TLC 
Rf 0.25 (1:1 hexane–ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) δ 0.81-0.85 (m, 3H), 
1.24-1.42 (m, 10H), 1.47 (s, 9H), 2.44 (s, 3H), 2.45-2.47 (m, 5H), 5.48 (dd, 2H, J = 18 
and 11.2 Hz) and 6.51 (dd, 1H, J = 17.8 and 11.6 Hz);
 13
C NMR (CDCl3, 100 MHz) δ 
14.1, 22.2, 22.7, 23.0, 26.6, 27.7, 29.08, 29.10, 29.9, 31.8, 83.7, 120.7, 123.9, 126.4, 
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129.7, 150.5, 153.8, 154.4 and 156.5; mass spectrum (APCI), m/z 348.2536 (M + H)
+
 
(C21H34NO3 requires m/z 348.2539). 
                                                 
N+
OBoc
O-
 
tert-Butyl 3-heptyl-2,6-dimethyl-5-vinylpyridin-4-yl carbonate-N-oxide (4.20). To a 
stirred solution containing 30.0 mg (0.66 mmol) of compound 4.19 in 2 mL of anhydrous 
CH2Cl2, 125 mg (0.72 mmol) of mCPBA was added. The reaction mixture was stirred at 
0 °C for 1 h under argon atmosphere, and then concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution 
with 10:1 ethyl acetate–methanol gave tert-butyl-3-heptyl-2,6-dimethyl-5-vinylpyridin-4-
yl-carbonate-N-oxide (4.20) as a light yellow oil: yield 23.4 mg (76%); silica gel TLC Rf 
0.25 (ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) δ 0.80-0.84 (m, 3H), 1.22-1.28 (m, 
10H), 1.45 (s, 9H), 2.46 (s, 3H), 2.47-2.49 (m, 5H), 5.48 (d, 1H, J = 17.6 Hz), 5.56 (d, 
1H, J = 11.6 Hz) and 6.51 (dd, 1H, J = 17.8 and 11.6 Hz);
 13
C NMR (CDCl3, 100 MHz) δ 
14.1, 14.9, 15.6, 22.7, 27.2, 27.6, 29.0, 29.2, 29.6, 31.8, 84.3, 122.9, 127.0, 128.4, 129.3, 
143.7, 146.3, 148.1 and 150.5; mass spectrum (APCI), m/z 364.2480 (M + H)
+
 
(C21H34NO4 requires m/z 364.2488). 
                         
N
O
OH
 
3-Heptyl-1-hydroxy-2, 6-dimethyl-5-vinylpyridin-4(1H)-one (4.9). To a stirred 
solution containing 138 mg (0.54 mmol) of compound 4.20 in 1.5 mL of EtOH, aqueous 
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10 M KOH was added. The reaction mixture was stirred at room temperature for 1 h, 3 
mL of water was added and pH was brought to 1-2 using conc. HCl, extracted with two 
20-mL portions of EtOAc. The combined organic phase was dried over anhydrous 
MgSO4 and concentrated under diminished pressure to afford a crude residue. The 
residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution with 
10:1 ethyl acetate–methanol gave 3-heptyl-1-hydroxy-2,6-dimethyl-5-vinylpyridin-
4(1H)-one (4.9) as a light yellow oil: yield 12.7 mg (72%); silica gel TLC Rf 0.35 (1:1 
ethyl acetate–methanol); 1H NMR (CDCl3, 400 MHz) δ 0.87-0.91 (m, 3H), 1.29-1.50 (m, 
10H), 2.49 (s, 3H), 2.50 (s, 3H), 2.65-2.69 (m, 2H), 5.57 (d, 1H, J = 17.6 Hz), 5.68 (d, 
1H, J = 11.6 Hz) and 6.64 (dd, 1H, J = 17.8 and 11.6 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 
14.5, 14.8, 15.8, 23.7, 27.3, 30.1, 30.3, 30.7, 33.0, 123.4, 123.6, 126.6, 130.4, 147.1 and 
148.4; mass spectrum (APCI), m/z 264.1956 (M + H)
+
 (C16H26NO2  requires m/z 
264.1964). 
                                         
N
OBn
I
 
 4-(Benzyloxy)-3-heptyl-5-iodo-2,6-dimethylpyridine (4.21). To a stirred suspension of 
oil-free NaH (5.0 mg, 0.11 mmol) in 5 mL of DMF was added 38.0 mg (0.11 mmol) of 
compound 4.17. When evolution of hydrogen ceased, 14.0 mg (0.11 mmol) of benzyl 
chloride was added and the reaction mixture was heated at 50 °C for 4 h. The cooled 
reaction mixture was diluted with 10 mL of water and extracted with two 20-mL portions 
of EtOAc. The combined organic phase was dried over anhydrous MgSO4 and 
concentrated under diminished pressure to afford a crude residue. The residue was 
 237 
 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with 1:1 hexane–
ethyl acetate gave 4-(benzyloxy)-3-heptyl-5-iodo-2,6-dimethylpyridine (4.21) as a light 
yellow oil: yield 38.0 mg (80%); silica gel TLC Rf 0.7 (1:1 hexane–ethyl acetate); 
1
H 
NMR (CDCl3, 400 MHz) δ 0.85-0.88 (m, 3H), 1.26-1.33 (m, 8H), 1.48-1.51 (m, 2H), 
2.50 (s, 3H), 2.60-2.64 (m, 2H) 2.74 (s, 3H), 4.95 (s, 2H), 7.37-7.43 (m, 4H) and 7.55-
7.57 (m, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 14.2, 21.9, 22.7, 27.4, 29.1, 29.4, 29.8, 
30.0, 31.9, 75.1, 91.7, 128.0, 128.7, 136.5, 158.0, 159.0 and 163.7; mass spectrum 
(APCI), m/z 438.1303(M + H)
+
 (C21H29NOI  requires m/z 438.1294). 
                                  
N
OBn
MeO
 
4-(Benzyloxy)-3-heptyl-5-methoxy-2,6-dimethylpyridine (4.22). To a stirred solution 
containing sodium methoxide prepared from 5.10 mg (0.23 mmol) of sodium and 1 mL 
of MeOH were added 27.0 mg (0.06 mmol) of the iodo derivative 4.21 and 1.66 mg (0.01 
mmol) of CuI. The reaction mixture was heated at 110 °C for 18 h. The cooled reaction 
mixture was diluted with 1 M aqueous NH4Cl and extracted with two 20-mL portions of 
EtOAc. The combined organic phase was dried over anhydrous MgSO4 and concentrated 
under diminished pressure to afford a crude residue. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with ethyl acetate gave 4-
(benzyloxy)-3-heptyl-5-methoxy-2,6-dimethylpyridine (4.22) as a light yellow oil: yield 
19.0 mg (71%); silica gel TLC Rf 0.3 (1:1 hexane–ethyl acetate); 
1
H NMR (CDCl3, 400 
MHz) δ 0.85-0.87 (m, 3H), 1.23-1.38 (m, 10H), 2.41 (s, 3H), 2.43 (s, 3H), 2.48-2.52 (m, 
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2H), 3.76 (s, 3H), 5.11 (s, 2H) and 7.33-7.43 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 
14.2, 18.7, 22.0, 22.7, 26.6, 29.1, 29.7, 30.0, 31.9, 60.3, 64.8, 74.5, 127.0, 128.0, 128.5, 
137.4, 145.4, 150.0, 152.4 and 148.4; mass spectrum (APCI), m/z 342.2431 (M + H)
+
 
 (C22H32NO2  requires m/z 342.2433). 
                                                  
N
OBn
MeO
O
 
4-(Benzyloxy)-3-heptyl-5-methoxy-2,6-dimethylpyridine-N-oxide (4.23). To a stirred 
solution containing 19.0 mg (0.06 mmol) of compound 4.22 in 2 mL of anhydrous 
CH2Cl2 was added 12.5 mg (0.07 mmol) of mCPBA. The reaction mixture was stirred at 
0 °C for 1 h under argon atmosphere, and then concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution 
with 10:1 ethyl acetate–methanol gave 4-(benzyloxy)-3-heptyl-5-methoxy-2,6-
dimethylpyridine-N-oxide (4.23) as a light yellow oil: yield 17.3 mg (87%); silica gel 
TLC Rf 0.25 (10:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 500 MHz) δ 0.84-0.86 (m, 
3H), 1.23-1.36 (m, 10H), 2.47 (s, 3H), 2.50 (s, 3H), 2.53-2.56 (m, 2H), 3.81 (s, 3H), 5.08 
(s, 2H) and 7.34-7.40 (m, 5H); 
13
C NMR (CDCl3, 125 MHz) δ 11.9, 14.2, 14.7, 22.7, 
26.8, 29.1, 31.9, 61.1, 75.3, 128.3, 128.7, 129.9, 136.8, 143.3, 145.3, 146.7 and 148.3; 
mass spectrum (APCI), m/z 358.2385 (M + H)
+
 (C22H32NO3  requires m/z 358.2382). 
                              
N
O
H3CO
OH
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3-Heptyl-1-hydroxy-5-methoxy-2,6-dimethylpyridin-4(1H)-one (4.10). To a solution 
containing 18.0 mg (0.05 mmol) of 4.23 in 5 mL of EtOH was added catalytic amount of 
10% Pd/C and the reaction was placed under 1 atm of H2 (g) overnight. The catalyst was 
removed by filtration through a pad of Celite 545
®
 and the filtrate was concentrated under 
diminished pressure and purified by chromatography on a silica gel column (10 × 1 cm). 
Elution with 5:1 ethyl acetate–methanol gave 4.10 as a colorless solid: yield 9.91 mg 
(70%); silica gel TLC Rf 0.21 (5:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 400 MHz) 
δ 0.89-0.91 (m, 3H), 1.31-1.51 (m, 10H), 2.46 (s, 3H), 2.48 (s, 3H), 2.69-2.72 (m, 2H) 
and 3.75 (s, 3H); 
13
C NMR (CDCl3, 125 MHz) δ 12.0, 14.4, 14.6, 23.7, 27.0, 30.0, 30.3, 
30.6, 33.0, 61.9, 111.4, 126.0, 143.5, 143.9 and 146.7; mass spectrum (EI), m/z 267.1838 
(M)
+
 (C15H25NO3  requires m/z 267.1834). 
                                                 
N
O
H
O2N
 
3-Heptyl-2,6-dimethyl-5-nitropyridin-4(1H)-one (4.24). To a stirred solution 
containing 94.0 mg (0.41) of compound 4.16 in 1 mL of sulfuric acid (d 1.64, 0.5 g) at 5-
10 °C was added a mixture of 0.10 mL (155 mg, 2.46 mmol) of nitric acid and 0.05 mL  
(80.3 mg, 0.82 mmol) of sulfuric acid. The reaction mixture was heated at 80 °C for 3 h. 
The cooled reaction mixture was added to 100 mL of ice water. Saturated aqueous 
sodium carbonate was added until effervescence ceased. The reaction mixture was 
extracted with two 20-mL portions of EtOAc. The combined organic phase was dried 
over anhydrous MgSO4 and concentrated under diminished pressure to afford a crude 
residue. The residue was purified by chromatography on a silica gel column (10 × 2 cm). 
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Elution with ethyl acetate gave 3-heptyl-2,6-dimethyl-5-nitropyridin-4(1H)-one (4.24) as 
a yellow oil: yield 76.1 mg (68%); silica gel TLC Rf 0.45 (1:1 hexane–ethyl acetate); 
1
H 
NMR (CDCl3, 400 MHz) δ 0.84-0.88 (m, 3H), 1.25-1.32 (m, 8H), 1.42-1.44 (m, 2H), 
2.35 (s, 3H), 2.42 (s, 3H) and 2.49-2.52 (m, 2H); 
13
C NMR (CDCl3, 100 MHz) δ 14.2, 
16.1, 17.1, 22.8, 25.8, 28.6, 29.3, 30.0, 31.9, 129.9, 140.2, 143.3, 145.8 and 160.1; mass 
spectrum (APCI), m/z 267.1708 (M+H)
+
 (C15H23NO3  requires m/z 267.1709). 
                                                    
N
OBoc
O2N
 
tert-Butyl-3-heptyl-2,6-dimethyl-5-nitropyridin-4-yl carbonate (4.25). To a stirred 
solution containing 76.0 mg (0.29 mmol) of nitro derivative 4.24 in 3 mL of anhydrous 
THF was added 40.1 mg (0.36 mmol) of t-BuOK. The reaction mixture was stirred at 
room temperature for 1 h. Then 63.0 mg (0.32 mmol) of Boc2O was added and the 
reaction mixture was heated at 60 °C for 5 h. The cooled reaction mixture was 
concentrated under diminished pressure to afford a yellow oil. The crude residue was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with 3:1 hexane–
ethyl acetate gave tert-butyl 3-heptyl-2,6-dimethyl-5-nitropyridin-4-yl carbonate (4.25) 
as a light yellow oil: yield 54.1 mg (53%); silica gel TLC Rf 0.7 (1:1 hexane–ethyl acetate 
); 
1
H NMR (CDCl3, 400 MHz) δ 0.85-0.88 (m, 3H), 1.24-1.32 (m, 10H), 1.54 (s, 9H) and 
2.54-2.57 (m, 8H); 
13
C NMR (CDCl3, 100 MHz) δ 14.2, 21.5, 22.7, 23.0, 26.7, 27.6, 28.7, 
29.0, 29.8, 31.8, 85.8, 128.9, 139.3, 148.1, 149.5, 149.6 and 161.4; mass spectrum 
(APCI), m/z 367.2230 (M+H)
+
 (C19H31N2O5  requires m/z 367.2233). 
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N
OBoc
O2N
O
 
tert-Butyl 3-heptyl-2,6-dimethyl-5-nitropyridin-N-oxide-4-yl carbonate (4.26). To a 
stirred solution containing 28.0 mg (0.08 mmol) of compound 4.25 in 2 mL of anhydrous 
CH2Cl2 was added 15.0 mg (0.09 mmol) of mCPBA. The reaction mixture was stirred at 
0 °C for 1 h under argon atmosphere, then concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution with 
10:1 ethyl acetate–methanol gave tert-butyl 3-heptyl-2,6-dimethyl-5-nitropyridin-N-oxide 
-4-yl-carbonate (4.26) as a light brown solid: yield 21.3 mg (72%); silica gel TLC Rf 0.40 
(ethyl acetate); 
1
H NMR (CDCl3, 400 MHz) δ 0.82-0.85 (m, 3H), 1.24-1.34 (m, 8H), 
1.45-1.46 (m, 2H), 1.47 (s, 9H), 2.50 (s, 3H), 2.54 (s, 3H) and 2.56-2.58 (m, 2H); 
13
C 
NMR (CDCl3, 100 MHz) δ 14.1, 14.5, 15.5, 22.7, 27.4, 27.5, 28.8, 28.9, 29.6, 31.7, 
128.9, 131.4, 137.0, 141.1, 142.6, 149.7 and 152.8; mass spectrum (APCI), m/z 383.2178 
(M+H)
+
 (C19H31N2O6  requires m/z 383.2182). 
                                                     
N
O
O2N
OH
 
3-Heptyl-1-hydroxy-2,6-dimethyl-5-nitropyridin-4(1H)-one (4.27). To a stirred 
solution containing 115 mg (0.30 mmol) of 3.16 in 2 mL of anhydrous CH2Cl2 was added 
0.23 mL (342 mg, 3.00 mmol) of trifluoroacetic acid. The reaction mixture was stirred at 
room temperature for 4 h, then diluted with 50 mL of satd aq NaHCO3 and extracted with 
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two 50-mL portions of EtOAc. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 10:1 ethyl acetate–methanol gave 3-Heptyl-
1-hydroxy-2,6-dimethyl-5-nitropyridin-4(1H)-one (4.27) as a light brown solid: yield 
66.1 mg (78%); silica gel TLC Rf 0.30 (10:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 
400 MHz) δ 0.85-0.89 (m, 3H), 1.27-1.33 (m, 8H), 1.43-1.45 (m, 2H), 2.54 (s, 3H), 2.55 
(s, 3H) and 2.61-2.64 (m, 2H); 
13
C NMR (CDCl3, 100 MHz) δ 14.2, 14.5, 15.1, 22.8, 
26.8, 28.6, 29.2, 29.8, 31.9, 129.8, 138.0, 145.3, 151.2 and 162.8; mass spectrum (APCI), 
m/z 283.1661 (M+H)
+
 (C14H23N2O4  requires m/z 283.1658).               
                       
N
O
H2N
OH
 
3-Amino-5-heptyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.11). To a solution 
containing 64.0 mg (0.23 mmol) of 4.27 in 2.5 mL of EtOH was added catalytic amount 
of 10% Pd/C and the reaction was placed under 1 atm of H2 (g) for 30 min. The catalyst 
was removed by filtration through a pad of Celite 545
®
 and the filtrate was concentrated 
under diminished pressure and purified by chromatography on a silica gel column(10 × 2 
cm). Elution with 5:1 ethyl acetate–methanol gave 3-amino-5-heptyl-1-hydroxy-2,6-
dimethylpyridin-4(1H)-one (4.11) as a light yellow oil: yield 45.1 mg (79%); silica gel 
TLC Rf 0.25 (3:1 ethyl acetate–methanol); 
1
H NMR (CD3OD, 400 MHz) δ 0.86-0.88 (m, 
3H), 1.27-1.43 (m, 10H), 2.41 (s, 6H) and 2.61-2.63 (m, 2H); 
13
C NMR (CD3OD, 100 
MHz) δ 12.3, 14.2, 14.4, 23.4, 27.1, 30.0, 30.1, 30.4, 32.7, 111.0, 123.7, 132.6, 133.5 and 
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162.8; mass spectrum (APCI), m/z 253.1908 (M+H)
+
 (C14H25N2O2  requires m/z 
253.1916).               
                           
N
O
H
 
3-Hexadecyl-2,6-dimethylpyridin-4(1H)-one (4.28). Trimethyl-γ-pyrone 4.15 (0.02 g, 
30.6 mmol) was heated at 100 °C with 2 mL of aqueous ammonia in a high pressure tube 
for 18 h. The cooled reaction mixture was concentrated under diminished pressure. The 
crude residue was purified by chromatography on a silica gel column (10 × 2 cm). Elution 
with 5:1 ethyl acetate–methanol gave 3-hexadecyl-2, 6-dimethylpyridin-4(1H)-one (4.28) 
as a brown solid: yield 39.8 mg (40%); silica gel TLC Rf 0.25 (3:1 ethyl acetate–
methanol); 
1
H NMR (CDCl3, 400 MHz) δ 0.81-0.84 (m, 3H), 1.21-1.40 (m, 28H), 2.24 (s, 
3H),  2.34 (s, 3H), 2.45-2.52 (m, 2H) and 6.07 (s, 1H); 
13
C NMR (CD3OD, 100 MHz) δ 
14.2, 16.8, 18.8, 22.7, 25.4, 28.9, 29.4, 29.7, 29.8, 30.1, 32.0, 113.5, 126.2, 145.2, 146.8 
and 178.5; mass spectrum (APCI), m/z 348.3271 (M+H)
+
 (C14H25N2O2  requires m/z 
348.3266).               
                                        
N
O
H
O2N
 
3-Hexadecyl-2,6-dimethyl-5-nitropyridin-4(1H)-one (4.29). To a stirred solution 
containing 69.6 mg (0.20) of compound 4.28 in 1 mL of sulfuric acid at 5-10 °C, a 
mixture of 0.10 mL of nitric acid (155 mg, 2.46 mmol) and 0.05 mL (80.3 mg, 0.82 
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mmol) of sulfuric acid was added. The reaction mixture was heated at 80°C for 3 h. The 
cooled reaction mixture was added to ice. Saturated aqueous sodium carbonate was added 
until effervescence ceased. The reaction mixture was extracted with two 20-mL portions 
of EtOAc. The combined organic phase was dried over anhydrous MgSO4 and 
concentrated under diminished pressure to afford a crude residue. The residue was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with ethyl acetate 
gave 3-hexadecyl-2,6-dimethyl-5-nitropyridin-4(1H)-one (4.29) as a yellow oil: yield 50 
mg (64%); silica gel TLC Rf 0.60 (1:1 hexane–ethyl acetate); 
1
H NMR (CDCl3, 400 
MHz) δ 0.82-0.85 (m, 3H), 1.21-1.29 (m, 28H), 2.33 (s, 3H), 2.39 (s, 3H) and 2.46-2.52 
(m, 2H); 
13
C NMR (CDCl3, 100 MHz) δ 14.3, 16.0, 17.1, 22.8, 25.8, 28.6, 29.5, 29.75, 
29.82, 29.9, 30.1, 32.1, 129.9, 140.3, 143.3, 145.8 and 169.1; mass spectrum (APCI), m/z 
393.3111 (M+H)
+
 (C23H41N2O2  requires m/z 393.3117).               
                                            
N
OBoc
O2N
  
tert-Butyl 3-Hexadecyl-2,6-dimethyl-5-nitropyridin-4-yl carbonate (4.30). To a stirred 
solution containing 31.4 mg (0.08 mmol) of nitro derivative 4.29 in 3 mL of anhydrous 
THF was added 13.1 mg (0.113 mmol) of t-BuOK and the reaction mixture was stirred at 
room temperature for 1 h. Then 20.0 mg (0.09 mmol) of Boc2O was added and the 
reaction mixtre was heated at 60 °C for 5 h. The cooled reaction mixture was 
concentrated under diminished pressure to afford a yellow oil. The residue was purified 
by chromatography on a silica gel column (10 × 2 cm). Elution with 3:1 hexane–ethyl 
acetate gave tert-butyl 3-hexadecyl-2,6-dimethyl-5-nitropyridin-4-yl carbonate (4.30) as 
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a light yellow oil: yield 17.0 mg (44%); silica gel TLC Rf 0.85 (1:1 hexane–ethyl 
acetate); 
1
H NMR (CDCl3, 400 MHz) δ 0.85-0.89 (m, 3H), 1.25-1.51 (m, 28H), 1.55 (s, 
9H) and 2.54-2.58 (s, 8H); 
13
C NMR (CDCl3, 100 MHz) δ 14.2, 21.5, 22.8, 23.0, 26.7, 
27.6, 28.7, 29.4, 29.5, 29.7, 29.77, 29.80, 29.83, 29.9, 32.1, 85.8, 128.9, 139.4, 148.2, 
149.5, 149.6 and 161.5; mass spectrum (APCI), m/z 493.3652 (M+H)
+
 (C28H49N2O5  
requires m/z 493.3641).               
                                 
N
OBoc
O2N
O
 
tert-Butyl 3-Hexadecyl-2,6-dimethyl-5-nitropyridin-N-oxide-4-yl carbonate (4.31). 
To a stirred solution containing 27.0 mg (0.05 mmol) of compound 4.30 in 2 mL of 
anhydrous CH2Cl2 was added 10.1 mg (0.06 mmol) of mCPBA. The reaction mixture 
was stirred at room temperature for 5 h under argon atmosphere, then concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 2 cm). Elution with 10:1 ethyl acetate–methanol gave tert-butyl 3-hexadecyl-2,6-
dimethyl-5-nitropyridin-N-oxide-4-yl carbonate (4.31) as a light brown solid: yield 18.6 
mg (70%); silica gel TLC Rf 0.50 (10:1 ethyl acetate–methanol); 
1
H NMR (CDCl3, 400 
MHz) δ 0.83-0.86 (m, 3H), 1.22-1.49 (m, 28H), 1.52 (s, 9H), 2.54 (s, 3H), 2.57 (s, 3H) 
and 2.60-2.61 (m, 2H); 
13
C NMR (CDCl3, 100 MHz) δ 14.8, 22.5, 22.9, 23.5, 27.7, 27.9, 
28.6, 29.2, 29.4, 29.5, 29.6, 29.7, 29.8, 29.9, 32.2, 86.8, 129.9, 139.8, 148.8, 149.7, 149.9 
and 164.5; mass spectrum (APCI), m/z 509.3580 (M+H)
+
 (C28H49N2O6  requires m/z 
509.3585).               
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N
O
OH
H2N
 
3-Amino-5-hexadecyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.12). To a stirred 
solution containing 20.0 mg (0.03 mmol) of 4.31 in 2 mL of anhydrous CH2Cl2 was 
added 0.23 mL (342 mg, 3.00 mmol) of trifluoroacetic acid. The reaction mixture was 
stirred at room temperature for 2 h and then concentrated under diminished pressure. To a 
solution containing Boc-deprotection product in 2.5 mL of EtOH was added catalytic 
amount of 10% Pd/C and the reaction was placed under 1 atm of H2 (g) overnight. The 
catalyst was removed by filtration through a pad of Celite 545
®
 and the filtrate was 
concentrated under diminished pressure and purified by chromatography on a silica gel 
column (10 × 1 cm). Elution with 10:1 ethyl acetate–methanol gave 3-amino-5-
hexadecyl-1-hydroxy-2,6-dimethylpyridin-4(1H)-one (4.12) as a light yellow oil: yield 
6.0 mg (39% in two steps); silica gel TLC Rf 0.35 (1:1 ethyl acetate–methanol); 
1
H NMR 
(CDCl3, 400 MHz) δ 0.86-0.89 (m, 3H), 1.25-1.45 (m, 28H), 2.30 (s, 3H), 2.50 (s, 3H) 
and 2.54-2.57 (m, 2H);
 13
C NMR (CDCl3, 100 MHz) δ 14.2, 15.9, 18.8, 22.3, 22.6, 25.3, 
27.9, 29.3, 29.2, 29.7, 30.0, 30.9, 113.4, 127.1, 145.2, 147.8 and 165.1; mass spectrum 
(APCI), m/z 379.3318 (M+H)
+
 (C23H43N2O2  requires m/z 379.3325).               
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